Tuesday, November 19, 2024
Print Entire 2024 Program:
|
|
SESSION 2 SCHEDULE | |
Tuesday
SESSION 2:
PROGRESS IN THE TREATMENT OF AORTIC ARCH LESIONS AND AORTIC DISSECTIONS
|
|
x | |
7:50 AM - 7:55 AM | Primary And Redo Open Aortic Arch Repair: When Will They And Will They Not Be Replaced By Endo And Hybrid Techniques |
Presenter(s):Anthony L. Estrera, MD | |
7:56 AM - 8:01 AM | Current Status Of Hybrid Repair Of Aortic Arch And Thoracic Aortic Aneurysms Using ThoraFlex (Hybrid) And Relay Devices For Frozen Elephant Trunk (FET) And TEVAR: Indications And Results |
Presenter(s):Joseph S. Coselli, MD | |
8:02 AM - 8:07 AM | Endovascular Arch Repair With Cook 2 Or 3 Branched Devices For Lesions Involving The Whole Aortic Arch: When Are They Indicated; When Contradicted And Tips For Making Them Work |
Presenter(s):Mark A. Farber, MD | |
8:08 AM - 8:13 AM | Comparative Late Results With 2-Branched Endograft (Relay – Terumo) And A Single Branched Device (Nexus – Endospan) Versus Debranching For Treatment Of Zone 0 Arch Lesions |
Presenter(s):Toru Kuratani, MD, PhD | |
8:14 AM - 8:19 AM | Current Status And Results Of The Terumo Relay Branched Endograft Device For Aortic Arch Lesion Repairs: Unique Features And When Will It Be available In The US |
Presenter(s):Vicente Riambau, MD, PhD / Ciro Ferrer, MD, PhD / Martin Czerny, MD | |
8:20 AM - 8:25 AM | Update On Total And Partial Aortic Arch Lesion Repairs With The Gore TAG Single Branch Endograft: An Off-The-Shelf (OTS) Device For Revascularizing Arch Branches: Experience To Date, Advantages And Limitations |
Presenter(s):Michael D. Dake, MD / Himanshu Patel, MD / Joseph E. Bavaria, MD | |
8:26 AM - 8:31 AM | Physician Modified Endografts (PMEGs) For Treating Aortic Arch Lesions: When Are They Superior Options And Technical Tips |
Presenter(s):Sukgu Han, MD | |
8:32 AM - 8:37 AM | How Best To Treat Aortic Dissections (Type A Or Type B) Extending Into The Arch, Its Branches Or Ascending Aorta; When Open, When Endo, When Hybrid: More Updated Meta-Analysis Comparison Between Medical, Surgical And Endovascular Treatment In 2024 |
Presenter(s):I-Hui Wu, MD, PhD | |
8:38 AM - 8:43 AM | How Best To Treat Aortic Arch Lesions: Is There Still Ever An Indication For Chimney Endografting With OTS Devices For Aortic Arch Lesions, And How To Make Them Work Without Gutter Endoleaks: What Are Other Options For Emergent Patients |
Presenter(s):Nicola Mangialardi, MD | |
8:44 AM - 8:49 AM | Comparison Of Indication And Results For Treatment Of Aortic Arch Lesions With Branched Endografts, Fenestrated Endografts, Parallel Stent Grafts, Hybrid Repairs, Or Open Repairs |
Presenter(s):Chang Shu, MD | |
8:50 AM - 8:55 AM | Techniques For Cerebral Protection During Ascending Aortic Arch Repairs – Endo And Open: The Value Of CO2 Device Flushing |
Presenter(s):Tilo Koelbel, MD, PhD | |
8:56 AM - 9:02 AM | Panel Discussion |
END OF SESSION 2 | |
SESSION 3 SCHEDULE | |
Tuesday
SESSION 3:
PROGRESS IN THE ENDOVASCULAR TREATMENT OF THE ASCENDING AORTA, AORTIC ARCH, AORTIC DISSECTIONS, REPORTING STANDARDS AND CLASSIFICATION SYSTEMS, STABILISE, GUIDELINES AND MORE
|
|
x | |
9:02 AM - 9:07 AM | Current Status of The Relay Ascending Aortic Endograft From Terumo: What Makes It Different |
Presenter(s):Adam Beck, MD | |
9:08 AM - 9:13 AM | How And Why The Aortic Arch Is An Unhospitable Location For Endovascular Graft Treatments |
Presenter(s):Piotr M. Kasprzak, MD | |
9:14 AM - 9:19 AM | The SVS-STS Aortic Dissection Reporting Standards And Classification System: What Is It; What Are Its Advantages; How Widely Is It Being Adopted |
Presenter(s):Joseph V. Lombardi, MD, MBA | |
9:20 AM - 9:25 AM | What Is The STABILISE Concept For Treating Acute And Chronic TBADs By Disrupting The Intimal Flap By Overdilating The Distal Bare Stent: Current Results, And When Should It Be The Treatment Of Choice |
Presenter(s):Jean-Marc Alsac, MD, PhD | |
9:26 AM - 9:31 AM | New Developments With The STABILISE Technique For Acute And Subacute TBADs: How Is The STABILISE Registry Helping: Technical Tips, And Precautions (First Author Germano C.G. Melissano, MD) |
Presenter(s):Andrea Kahlberg, MD / Germano C.G. Melissano, MD / Roberto L.V. Chiesa, MD | |
9:32 AM - 9:37 AM | Dual Lumen Interventions To Promote False Lumen Thrombosis In Chronic Aortic Dissections: The FLIRT Procedure: What Is It; When Is It Useful; How To Do It |
Presenter(s):Christoph A. Nienaber, MD, PhD | |
9:38 AM - 9:43 AM | When Is Open Repair For Post-Dissection TAAAs The Best Treatment Option Especially For Preventing SCI: Will There Be Surgeons Trained To Do It |
Presenter(s):Hazim J. Safi, MD | |
9:44 AM - 9:49 AM | Advances In Endograft Repair Of The Ascending Aorta Without And With Involvement Of The Aortic Valve (Endo-Bentall): What Lesions Are Or Will Be Suitable: World Clinical Experience With Endo-Bentall To Date |
Presenter(s):Ali B. Khoynezhad, MD, PhD / Shahab Toursavadkohi, MD | |
9:50 AM - 9:55 AM | Distal Stent-Graft Induced New Entry Tears (SINEs): Do They Prevent Aortic Remodeling After TBAD Treatment: How To Prevent And Treat Them |
Presenter(s):Chun Che Shih, MD, PhD | |
9:56 AM - 10:01 AM | High Risk Features Of TEVAR For TBAD: Did The AHA Guidelines Get Them Right: TEVAR Outcomes For TBAD Are Worse Than For Degenerative Aneurysms |
Presenter(s):James H... Black, III, MD | |
10:02 AM - 10:07 AM | Multicenter International Study Shows That There Is A Role For Endovascular Treatment Of Complex Aortic Diseases From Marfans, Loeys-Dietz And Ehlers-Danlos Syndromes: What Is This Role |
Presenter(s):Anders Wanhainen, MD, PhD | |
10:08 AM - 10:14 AM | Panel Discussion |
10:14 AM - 10:24 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 3 | |
SESSION 4 SCHEDULE | |
Tuesday
SESSION 4:
MORE NEW DEVELOPMENTS IN THE TREATMENT OF TBADs, THORACIC AORTIC DISEASE AND THORACOABDOMINAL ANEURYSMS (TAAAs)
|
|
x | |
10:24 AM - 10:29 AM | When Should Hybrid Treatment (Endograft Proximal + Open Distal) Be The Preferred Treatment For TAAA Repair: Advantages And Technical Tips |
Presenter(s):Gilbert R. Upchurch, MD | |
10:30 AM - 10:35 AM | New Strategies And Indications For Open TAAA Repair Including Failed EVAR And F/B/EVAR: Technical Tips And Results |
Presenter(s):Andrea Kahlberg, MD / Germano C.G. Melissano, MD / Roberto L.V. Chiesa, MD | |
10:36 AM - 10:41 AM | Open Repair Of TAAAs Following TEVAR Treatment Of TBAD: Technical Tips: Will This Procedure Survive The Endovascular Revolution |
Presenter(s):Michael J. Jacobs, MD | |
10:42 AM - 10:47 AM | Retrograde Inner Branched Devices (From Cook) To Treat Aortic Arch Lesions: Indications, Value, Technical Tips And Initial Experience |
Presenter(s):Marcelo Ferreira, MD | |
10:48 AM - 10:53 AM | Endovascular Treatment Of Ascending Aortic Diseases; What Can Be Done Currently: What Cannot And What Does The Future Hold: From A Systematic Review |
Presenter(s):Santi Trimarchi, MD, PhD | |
10:54 AM - 10:59 AM | Update On F/B/EVAR For Degenerative And Post TBAD TAAAs: The Value Of Inner Branched Devices: Value Of The BeBack Catheter (Bentley) To Cross The Dissection Flap And For Other Purposes |
Presenter(s):Eric L.G. Verhoeven, MD, PhD / Athanasios Katsargyris, MD | |
11:00 AM - 11:05 AM | The Present Status Of Endovascular Treatment For Lesions Of The Aortic Arch: What Can Be Done, What Can't Be Done: What Has Changed In The Last Decade |
Presenter(s):Gustavo S. Oderich, MD, FACS | |
11:06 AM - 11:12 AM | Panel Discussion |
11:12 AM - 11:17 AM | Endovascular Procedures After Open Surgical Type A Aortic Dissection (TAAD) Repair Are Essential For Long-Term Success: Why And What Procedures Are Necessary |
Presenter(s):Götz M. Richter, MD, PhD | |
11:18 AM - 11:23 AM | The Anatomical And Hemodynamic Bases Of Obstruction In Branch Arteries And The True Lumen With Aortic Dissections: How They Can Be Treated Before And After Closure Of The Primary Tear: What Is The Value Of Fenestration Or Septotomy |
Presenter(s):David M. Williams, MD | |
11:24 AM - 11:29 AM | Endovascular Thermal Septotomy Of The Dissection Flap With An Electrocautery Activated Guidewire To Treat Chronic TBADs: When And How Does It Work: Complications And When It Should Be Avoided: Technical Tips And How To Avoid Pitfalls |
Presenter(s):Carlos H. Timaran, MD / Gustavo S. Oderich, MD, FACS | |
11:30 AM - 11:35 AM | Update On The Current Status Of A Catheter Aortic Septotomy Device For Treating Aortic Dissections By Cutting The Septum From Below: Yes, There Is A Downside To Other Septotomies That Cut The Septum From Above |
Presenter(s):Ramon Berguer, MD, PhD | |
11:36 AM - 11:41 AM | In Situ Fenestration (Septotomy) Versus Multiple Chimneys For Urgent Endovascular Treatment Of Aortic Arch Pathologies: Technical Tips |
Presenter(s):Ivo Petrov, MD, PhD | |
11:42 AM - 11:47 AM | Update On Laser Fenestrated Endografts For Aortic Emergencies: Technical Tips And Long-Term Results |
Presenter(s):Jean M. Panneton, MD | |
11:48 AM - 11:53 AM | The Endopatch: A Promising Solution For Endovascular Repairs For Aortic Dissections: What Is It And How Does It Work: Clinical Experience |
Presenter(s):Wei Guo, MD | |
11:54 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 4 | |
SESSION 5 SCHEDULE | |
Tuesday
SESSION 5:
NEW DEVELOPMENTS IN ABDOMINAL AORTIC ANEURYSM (AAA) ETIOLOGY, DETECTION, TREATMENT AND EVAR
|
|
x | |
1:00 PM - 1:05 PM | Unexpected Small Bowel Necrosis When Performing EVAR In Patients With Visceral Artery (SMA) Occlusive Disease: How To Predict It And How To Avoid It |
Presenter(s):Karan Garg, MD / Neal S. Cayne, MD / Carlos H. Timaran, MD / Frank J. Veith, MD | |
1:06 PM - 1:11 PM | New Medical Therapies For AAA Disease And An Update On The Metformin Trials For Slowing Aneurysm Growth |
Presenter(s):Ronald L. Dalman, MD | |
1:12 PM - 1:17 PM | DEBATE: The Safe-AAA Study Emphasizes The Importance Of Ongoing Surveillance And Continuing EVAR Device Risk: Some EVAR Endografts Have Been Found To Have More Late Risks Than Others |
Presenter(s):Philip P. Goodney, MD, MS / Eric A. Secemsky, MD, MSc | |
1:18 PM - 1:23 PM | DEBATE: Patient Survival After EVAR Was NOT Improved By Compliance With Surveillance Protocols: The EVAR Surveillance Paradox: From A Systematic Meta-Analysis: What Is The Explanation |
Presenter(s):George A. Antoniou, MD, PhD, MSc, FEBVS | |
1:24 PM - 1:29 PM | Computer Analysis Of CT Factors Determining AAA Wall Weakness/Strength Of Areas In AAAs Predicts Rupture Risk Independent Of Size And Post EVAR Neck Behavior: The ViTAA System |
Presenter(s):Randy D. Moore, MD | |
1:30 PM - 1:35 PM | Value Of Properly Performed Ch/EVAR For Juxtarenal AAAs: Results From A Single Center With The Longest Available Follow-Up Confirm Long-Term Safety And Effectiveness: Technique Is Vital |
Presenter(s):Joost van Herwaarden, MD, PhD | |
1:36 PM - 1:41 PM | Panel Discussion |
1:42 PM - 1:47 PM | Update On An Interesting New Endovascular Technology (Nectero – Intra-Sac Drug After AAA Balloon Isolation) To Slow AAA Growth: Updated Clinical Results Of The First-In-Human Trial |
Presenter(s):Andrew Holden, MBChB / Daniel G. Clair, MD / Venkatesh G. Ramaiah, MD | |
1:48 PM - 1:53 PM | Short And Long-Term Results For Endovascular Therapy For Infected Aortic Aneurysms At Various Levels: An 18-Year, >163-Case Experience: EVAR Can Work |
Presenter(s):Boonprasit Kritpracha, MD | |
1:54 PM - 1:59 PM | Size Thresholds For Repair Of AAAs Are Wrong On The Low Side: Data From Medicare And The VQI Indicate That Rupture Risk Only Increases With AAAs Over 6-6.9 cm |
Presenter(s):David H. Stone, MD / Sal Scali, MD / Bjoern D. Suckow, MD | |
2:00 PM - 2:05 PM | Update On Long-Term Results From The Dream RCT Comparing EVAR With Open Repair For AAAs Suitable For Both: Adverse Neck Anatomy (Short, Wide, Angulated) Was Associated With Increased Reintervention And Mortality Rates Equally After Open And Endo Repairs: Neck Dilatation Only Occurs After Open Repair And In EVARs With Self-Expanding Endografts: How Should This Influence Today’s Treatment |
Presenter(s):Jan D. Blankensteijn, MD | |
2:06 PM - 2:11 PM | DEBATE: Mortality 30 Days And 3-5 Years After Endo Repair Of Juxtarenal And Complex AAAs In The UK Compass Trial (Real World) Is Double That Of Open Repairs: Why Is This So And Why Is This Different Than Results From US Single Centers And The ARC Registry |
Presenter(s):S. Rao Vallabhaneni, MD, FRCS / Michael P. Jenkins, MBBS, BSc, MS, FRCS, FEBVS | |
2:12 PM - 2:17 PM | DEBATE: Mortality Early And 3-5 Years After Endo Repair Of Juxtarenal And Complex AAAs In The US Aortic Research Consortium (ARC) Registry Is Less Than That Reported For Comparable Open Repairs |
Presenter(s):Andres Schanzer, MD | |
2:18 PM - 2:23 PM | Why EVAR Should Be Preferred Over Open Repair In Young Patients With Suitable Anatomy: From A Meta-Analysis Of >50,000 Patients |
Presenter(s):George A. Antoniou, MD, PhD, MSc, FEBVS | |
2:24 PM - 2:30 PM | Panel Discussion |
2:30 PM - 2:40 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 5 | |
SESSION 6 SCHEDULE | |
Tuesday
SESSION 6:
MORE ABOUT TBADs, AAAs AND EVAR, STANDARD AND COMPLEX: UPDATES ON PHYSICIAN MODIFIED ENDOGRAFTS (PMEGs) AND GUIDELINES
|
|
x | |
2:40 PM - 2:45 PM | Initial Experience With A Uniquely Designed Device (The Chinese Fabulous Stent) Designed To Treat TBADs: What Makes It Different And How Does It Work |
Presenter(s):Weiguo Fu, MD | |
2:46 PM - 2:51 PM | Why The NICE AAA Guidelines Favoring Open Repair Over EVAR Are The Way They Are: Bias Has Played A Role As It Does In Many Things: Randomized Controlled Trials (RCTs) Can Be Misleading |
Presenter(s):Frans L. Moll, MD, PhD | |
2:52 PM - 2:57 PM | Cancer Is Associated With AAAs: It’s A Chicken And Egg Paradox; Which Came First, The Aneurysm Or The Cancer: Is It Related To Diagnostic And Therapeutic Radiation |
Presenter(s):Natzi Sakalihasan, MD, PhD | |
2:58 PM - 3:03 PM | The Link Between Elevated Cancer Risk And EVARs: Evidence From Biological Studies And A Large Population Based Data Analysis |
Presenter(s):Bijan Modarai, PhD, FRCS | |
3:04 PM - 3:09 PM | What Do The New ESVS Guidelines For Elective And Emergent AAA Treatment Add To Vascular Practice In 2024: Big Changes Are Coming |
Presenter(s):Ian Loftus, MD | |
3:10 PM - 3:15 PM | The SVS/ESVS/NICE/ACC/AHA Guidelines On AAA: Agreements, Conflicting Recommendations, And Omissions |
Presenter(s):Peter Gloviczki, MD | |
3:16 PM - 3:21 PM | Evolving Role For Physician Modified Endografts (PMEGs) For Complex AAA Repair: Why Are Poor Results Underreported And When Are They Justified |
Presenter(s):Javairiah Fatima, MD | |
3:22 PM - 3:27 PM | Hospitals Without Investigational Device Exemptions Have Worse Outcomes After PMEGs: These Are Often Unreported |
Presenter(s):Caitlin W. Hicks, MD, MS | |
3:28 PM - 3:33 PM | PMEGs For Juxta-And Para-Renal Aneurysms Come Out Of The Shadows And Are Now Mainstream: When Should They NOT Be Done |
Presenter(s):Benjamin W. Starnes, MD | |
3:34 PM - 3:39 PM | DEBATE: Population Screening With Ultrasound For Early Detection Of AAA Is Recommended For Women Age >65 Years, With A History Of Smoking Or A Family History Of AAA, And For Women Age >75 Years, With A History Of Smoking If They Are Otherwise In Good Health |
Presenter(s):Marc L. Schermerhorn, MD | |
3:40 PM - 3:45 PM | DEBATE: Population Screening With Ultrasound For Early Detection Of AAA Is NOT Recommended For Women Age >65 Years, Even If They Are Former Or Current Smokers Or Have Cardiovascular Disease |
Presenter(s):Janet T. Powell, MD, PhD | |
3:46 PM - 3:56 PM | Panel Discussion |
END OF SESSION 6 | |
SESSION 7 SCHEDULE | |
Tuesday
SESSION 7:
MORE NEW DEVELOPMENTS IN THE TREATMENT OF THORACIC AORTIC PATHOLOGY
|
|
x | |
3:56 PM - 4:01 PM | Use Of TEVARs For TBAD In Patients With Connective Tissue Disease: When Should They Be Done: How Durable Are They And When Are Open Repairs Better |
Presenter(s):Martin R. Back, MD | |
4:02 PM - 4:07 PM | How To Treat Aortic Dissections With Entry Tears In The Aortic Arch: Can They Be Treated Endovascularly: Technical Tips |
Presenter(s):Santi Trimarchi, MD, PhD | |
4:08 PM - 4:13 PM | With Aortic Dissections, How Can Pressures In The True And False Lumens Be Measured And How Should They Influence Treatment Decisions |
Presenter(s):David M. Williams, MD | |
4:14 PM - 4:19 PM | Chronic False Lumen Expansion In Aortic Dissection Requires Complete Flow And Pressure Exclusion: How To Do It With CT Guided Interventions Including Embolization With Polymer Plugs (From Shape Memory) Or Other Methods |
Presenter(s):Götz M. Richter, MD, PhD | |
4:20 PM - 4:25 PM | How To Classify Acute Aortic Intramural Hematomas (IMHs): How And When To Treat Them Safely By TEVAR: When And Why Are They So Dangerous |
Presenter(s):Jean M. Panneton, MD | |
4:26 PM - 4:31 PM | Causes And Management Of Retrograde Aortic Dissection After TEVAR For TBAD |
Presenter(s):Boonprasit Kritpracha, MD | |
4:32 PM - 4:37 PM | A Novel Off-The-Shelf (OTS) Endograft For All Aortic Arch Pathologies: What Makes It Unique And Promising: Early Clinical Results |
Presenter(s):Wayne W. Zhang, MD | |
4:38 PM - 4:43 PM | Long-Term (>5 Years) Good Results Of The Medtronic Valiant Captiva Endografts For TEVAR In TBAD Patients: Advantages And Disadvantages |
Presenter(s):Joseph E. Bavaria, MD / Nimesh D. Desai, MD, PhD | |
4:44 PM - 4:49 PM | Motor Evoked Potentials (MEPs) Provide Highly Reliable Information On Spinal Cord Function During Open Thoracoabdominal Aortic Aneurysm (TAAA) Repair: Advantages, Requirements And Why It Hasn't Worked For Some Groups |
Presenter(s):Michael J. Jacobs, MD | |
4:50 PM - 4:56 PM | Panel Discussion |
END OF SESSION 7 | |
SESSION 8 SCHEDULE | |
Tuesday
SESSION 8:
MORE NEW DEVELOPMENTS REGARDING TBADs AND TEVAR: NEED FOR AND TIMING OF TEVAR FOR ACUTE UNCOMPLICATED TYPE B AORTIC DISSECTION (uTBADs) (FOR IMPORTANT RELATED TALKS SEE SESSION 8 IN OUR 2023 PROGRAM ON OUR WEBSITE VEITHsymposium.org)
|
|
x | |
4:56 PM - 5:01 PM | DEBATE ROUND 2: With Uncomplicated TBADs, The Case For Early TEVAR With Extensive Aortic Coverage In Most Patients: New Data |
Presenter(s):William D. Jordan Jr., MD | |
5:02 PM - 5:07 PM | DEBATE ROUND 2: With Uncomplicated Acute TBADs, The Case For Waiting 2-6 Weeks From Onset For TEVAR And Then Limiting Aortic Coverage: New Data |
Presenter(s):Mark A. Farber, MD | |
DO WE NEED AN RCT COMPARING TEVAR VERSUS MEDICAL TREATMENT FOR uTBADs | |
5:08 PM - 5:13 PM | Fate Of Medically Managed Acute TBADs: A Plea For Early Repair In Most Patients-Including Those Who Appear Uncomplicated |
Presenter(s):Fabio Verzini, MD, PhD, FEBVS | |
5:14 PM - 5:19 PM | TEVAR For Acute TBAD Significantly Reduces All-Cause Mortality At 3-Years Compared To Best Medical Management: New Data On Outcomes Of All Dissections In England: We Really Don't Need A Randomized Trial |
Presenter(s):Jonathan R. Boyle, MD, MA (Cantab) FRCS | |
5:20 PM - 5:25 PM | TEVAR To Treat Uncomplicated Acute/Subacute Type B Aortic Dissections (uTBADs) Must Still Be Justified By An RCT: Is An Appropriate One Possible Or Not |
Presenter(s):Colin D. Bicknell, MD, FRCS | |
5:26 PM - 5:31 PM | Scandinavian (SUNDAY) RCT Comparing TEVAR Versus Medical Therapy In uTBAD: Justification, Rationale And Current Status |
Presenter(s):Jacob Budtz-Lilly, MD, PhD | |
5:32 PM - 5:37 PM | Status Of The Multicenter RCT (IMPROVE-AD) To Evaluate The Value Of TEVAR Versus Medical Therapy In Acute And Subacute uTBADs: Rationale And Recruitment To Date |
Presenter(s):Firas F. Mussa, MD / Panos Kougias, MD, MSc | |
5:38 PM - 5:43 PM | Advances In The Endovascular Repair Of Complex Aortic Dissections: Timing Of Interventions, Adjunctive Techniques And Outcomes |
Presenter(s):Rami Tadros, MD | |
5:44 PM - 5:49 PM | What Does Endovascular Aortic Repair Do To Cardiac And Coronary Artery Function: Does The Position Of The Graft In The Aorta Make A Difference: Do We Need A Compliant Endograft |
Presenter(s):Rachel E. Clough, PhD, FRCS | |
5:50 PM - 5:55 PM | Re-Entry Specific Endovascular Therapy (RESET), i.e. TEVAR Plus Dealing With Re-Entry Tears: It Promotes False Lumen Thrombosis, Aortic Remodeling And Improves Outcomes: How To Do It |
Presenter(s):Jean M. Panneton, MD | |
5:56 PM - 6:02 PM | Panel Discussion End of Program A |
END OF SESSION 8 | |
SESSION 9 SCHEDULE | |
Tuesday
SESSION 9:
PROGRESS IN WEARABLE VASCULAR ROBOTICS, LAPAROSCOPY, GUIDANCE SYSTEMS AND SIMULATION
|
|
x | |
6:47 AM - 6:50 AM | Opening Remarks |
Presenter(s):Enrico Ascher, MD | |
WEARABLE REMOTE VASCULAR MONITORING SYSTEMS | |
6:50 AM - 6:55 AM | Vascular Research And Innovation Priorities In The UK Should Be Applied Everywhere: They Include Wearable Sensors, And Telehealth Systems |
Presenter(s):Celia Riga, MD, FRCS | |
6:56 AM - 7:01 AM | Remote Measurement Of Blood Flow In Any Artery Or Graft Using An Implantable Ultrasonic Sensor With Transmission To The Internet (From IntelVasc): How Does It Work, And Experimental Data |
Presenter(s):Jean Bismuth, MD | |
7:02 AM - 7:07 AM | Inside Out: Next Generation Technology That Transmits Physical Intelligence And Parameters Continuously From Within The Patient: How Will It Help In Vascular Treatment |
Presenter(s):Barry T. Katzen, MD | |
7:08 AM - 7:13 AM | Integrating Robotic Systems Back Into Vascular Surgery: Do Not Abandon Them Yet: We Must Be Involved |
Presenter(s):Alan B. Lumsden, MD, FACS | |
7:14 AM - 7:19 AM | Robotic And Laparoscopic Vascular Surgery: Where Do They Stand And Why Bother Continuing To Consider Them |
Presenter(s):Willem Wisselink, MD | |
RADIATION REDUCING IMAGING GUIDANCE TECHNIQUES | |
7:20 AM - 7:25 AM | Updated Experience With The Fiberoptic RealShape (FORS From Philips) System: Results From The Completed Multicenter LEARN Registry: What Are Its Limitations And Can FORS Work With Very Complex Anatomy |
Presenter(s):Joost van Herwaarden, MD, PhD | |
7:26 AM - 7:31 AM | Improved Fiberoptic Based Imaging With The FORS Lumiguide System (Philips): Fiberoptic Sensors Within A Guidewire And A Special 3D Hub Allow Imaging Guidance With Any Catheter: How Does It Work And Experience |
Presenter(s):Carlos H. Timaran, MD | |
7:32 AM - 7:37 AM | Update On The 3D Radiation Free Electromagnetic Intraoperative Positioning System (IOPS) From Centerline For Endovascular Guidance: Advantages And Limitations |
Presenter(s):Matthew J. Eagleton, MD / Francis Caputo, MD | |
7:38 AM - 7:43 AM | Cydar Technology And Its AI Modifications Enhance The Accuracy Of Fusion For F/B/EVAR For Complex AAA Treatment: How Does It Work And Reduce Radiation: Advantages And Limitations |
Presenter(s):Murray L. Shames, MD / Ross Milner, MD | |
7:44 AM - 7:50 AM | Panel Discussion |
END OF SESSION 9 | |
SESSION 10 SCHEDULE | |
Tuesday
SESSION 10:
NEW DEVELOPMENTS IN CAROTID DISEASE AND ITS TREATMENT; DIFFERING VIEWS ON TREATMENT OF ASYMPTOMATIC CAROTID STENOSIS (ACS) AND CAROTID SCREENING
|
|
x | |
7:50 AM - 7:55 AM | A Data-Driven Look At Interventions For Carotid Disease: Do They Represent Exuberant Enthusiasm, Financial Opportunity For Industry, Doctors And Institutions, Or A Path To Excessive Risk |
Presenter(s):Colin P. Derdeyn, MD | |
CORONARY DISEASE IN CAROTID STENOSIS (CS) PATIENTS | |
7:56 AM - 8:01 AM | Ten-Year Results Of A Multicenter RCT Showing The Long-Term Benefit In CS Patients Of Pre CEA Coronary Angiography And Treatment In Preventing Late MIs And Death |
Presenter(s):Jean-Baptiste Ricco, MD, PhD | |
8:02 AM - 8:07 AM | Asymptomatic Coronary Artery Disease Is Deadly In Patients With Carotid Stenosis (CS) Whether The CS Is Treated Invasively Or Not: An RCT Shows How The Coronary Artery Disease Can Be Quantified And Treated To Reduce Myocardial Infarction And Improve Long-Term Survival |
Presenter(s):Dainis K. Krievins, MD / Christopher K. Zarins, MD | |
8:08 AM - 8:13 AM | Practice Patterns (CAS, CEA, Medical Treatment, TCAR) For Treatment Of CS Are Changing Dramatically From Those In Previous RCTs: Evidence From A Population Based Analysis |
Presenter(s):Christian A. Behrendt, MD | |
VALUE OF CAROTID SCREENING | |
8:14 AM - 8:19 AM Power Point Presentation with Synched Audio |
The Case Against Screening For ACS (Like Lifeline): Who Profits: It May Lead To Unnecessary And Possibly Harmful Invasive Treatments |
Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
8:20 AM - 8:25 AM | Screening For ACS: Its Main Value Is In Guiding Lipid Treatment: How Low Should LDL-Cholesterol (LDL-C) Be Pushed And What Will It Do To Carotid Plaques |
Presenter(s):Stavros K. Kakkos, MD, PhD / Andrew N. Nicolaides, MS, FRCS | |
8:26 AM - 8:32 AM | Panel Discussion |
DIFFERING VIEWS ON TREATMENT OF ACS AND REIMBURSEMENT POLICY | |
8:32 AM - 8:37 AM | Plaque Progression In Asymptomatic Carotid Stenosis (ACS) Patients On Best Medical Therapy (BMT): Does It Mandate Invasive Therapy Or Continued BMT |
Presenter(s):Gianluca Faggioli, MD | |
8:38 AM - 8:43 AM Power Point Presentation with Synched Audio |
DEBATE: All ACS Patients Are Best Treated Medically: Invasive Treatment Causes More Harm Than Good And Should Not Have Been Widely Reimbursed By CMS |
Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
8:44 AM - 8:49 AM | DEBATE: Not So: About 25% Of ACS Patients Can Benefit From CEA Or CAS And Should Be So Treated And Reimbursed Accordingly |
Presenter(s):Bruce A. Perler, MD, MBA | |
8:50 AM - 8:55 AM | DEBATE: Both Views Are Wrong: Severe ACS Has Declined As A Cause Of Ischemic Stroke To <1% Per Year: So Only <5% Of ACS Patients Should Be Treated Invasively And Reimbursed Accordingly: Can Computer Analysis Of Plaque CT Imaging Help |
Presenter(s):Robert W. Chang, MD | |
8:56 AM - 9:01 AM | CMS Expansion Of Reimbursement For CAS For Asymptomatic Disease: An Expensive And Potentially Harmful Decision: How Could CMS Disregard The Evidence, And Why Couldn't They Wait For CREST 2 Results |
Presenter(s):Joseph L. Mills, MD | |
9:02 AM - 9:07 AM | Is Transfemoral CAS Being Overused One Year After CMS Increased Reimbursement For Treating Asymptomatic Carotid Stenosis |
Presenter(s):Sean P. Lyden, MD | |
9:08 AM - 9:14 AM | Panel Discussion |
9:15 AM - 9:30 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 10 | |
SESSION 11 SCHEDULE | |
Tuesday
SESSION 11:
MORE ABOUT CAROTID DISEASE: UPDATE ON INVASIVE TREATMENT FOR ACUTE STROKES
Moderators:Klaus D. Mathias, MD / Allan L. Brook, MD
|
|
x | |
9:28 AM - 9:33 AM | A System For Performing TCAR Percutaneously: How Does It Achieve Flor Reversal And How Can It Be Done Safely |
Presenter(s):Wayne W. Zhang, MD | |
9:34 AM - 9:39 AM | Acute Stroke Management: How Can A Vascular Surgeon Lead A Team That Provides Optimal Care And What Are Its Advanced Features |
Presenter(s):Laura Capoccia, MD | |
9:40 AM - 9:45 AM | The Current Status Of Intracranial Stroke Thrombectomy: What’s New With Devices And Indications: Technical Tips |
Presenter(s):Allan L. Brook, MD | |
9:46 AM - 9:51 AM | With Acute Strokes, What Is New With Endovascular Intracranial Techniques And Indications For Arterial Clot Removal: How Can Improved Imaging, A Dedicated System With Artificial Intelligence (AI) And Intraarterial Thrombolysis With Alteplase (Genentech) Help: The Importance Of Keeping Stroke Patients Flat |
Presenter(s):Adnan H. Siddiqui, MD, PhD / L. Nelson Hopkins, MD | |
9:52 AM - 9:57 AM | Current Optimal Treatment When Carotid Stenosis In The Neck Coexists With Intracranial Disease Or Clot |
Presenter(s):Klaus D. Mathias, MD | |
9:58 AM - 10:03 AM | How Best To Treat An ICA Occlusion With Distal Embolization: Sequence And Timing Of Treatment: Site Of Treatment (OR Versus Angio Suite Versus Hybrid Room): Technical Tips |
Presenter(s):Adnan H. Siddiqui, MD, PhD / L. Nelson Hopkins, MD | |
10:04 AM - 10:09 AM | With Tandem Carotid Lesions In The Neck And Supra-Aortic Trunks, How Should Acutely Symptomatic Patients Be Managed: What About Asymptomatic Patients With Such Lesions |
Presenter(s):Francesco Speziale, MD / W. Darrin Clouse, MD | |
10:10 AM - 10:15 AM | Current Optimal Treatment Of Carotid Artery Dissections: When Anticoagulation And Antiplatelet Drugs; When CAS And When Open Surgery: Technical Tips |
Presenter(s):Klaus D. Mathias, MD | |
10:16 AM - 10:21 AM | How Should Acute Stroke Severity (NIHSS) Influence Timing To Therapeutic Intervention: For TPA Use; For CEA And CAS; For Intracranial Arterial Clot Removal: It Matters To Neurologic Outcomes |
Presenter(s):Hernan A. Bazan, MD, DFSVS, FACS | |
10:22 AM - 10:30 AM | Panel Discussion |
END OF SESSION 11 | |
SESSION 12 SCHEDULE | |
Tuesday
SESSION 12:
PROGRESS IN THE TREATMENT OF AORTIC AND AORTOILIAC OCCLUSIVE DISEASE;HYPOGASTRIC REVASCULARIZATION
|
|
x | |
10:30 AM - 10:35 AM | The VORTEC Technique For Aortofemoral Bypass: What Is It And How To Do It: Why Is It Especially Valuable For Heavily Calcified And Scarred Aortas |
Presenter(s):Mario L. Lachat, MD | |
10:36 AM - 10:41 AM | What Is New In The Treatment Of External Iliac Artery Endofibrosis In Committed Cyclists: Is There A Role For Endovascular Treatment |
Presenter(s):Margaret Tracci, MD, JD | |
10:42 AM - 10:47 AM | Iliac Endofibrosis In Elite Cyclists: What Are Its Symptoms Despite Normal Pulses: Diagnosis Is Difficult: Diagnostic Workup: Surgical Treatment And Prognosis |
Presenter(s):Jason T. Lee, MD | |
10:48 AM - 10:53 AM | DEBATE: How To Treat Chronic Flush Juxtarenal Aortic Occlusions Endovascularly With Safety: Endo Is The Way To Go: How To Do It And What Is The Role Of Lysis |
Presenter(s):David J. Minion, MD | |
10:54 AM - 10:59 AM | DEBATE: Not So: Open Or Hybrid Repairs Are Best For Complex Juxtarenal Aortoiliac Occlusive Disease: Technical Tips |
Presenter(s):Yamume Tshomba, MD | |
11:00 AM - 11:05 AM | Value Of Shockwave Intravascular Lithotripsy (IVL) For Calcified Aortoiliac Occlusive Disease Treatment And For Facilitating Large Bore Access With Narrowed Calcified Iliac Arteries |
Presenter(s):Daniel G. Clair, MD | |
11:06 AM - 11:12 AM | Panel Discussion |
COVERED ENDOVASCULAR RECONSTRUCTION OF THE AORTIC BIFURCATION (CERAB) PROCEDURE | |
11:12 AM - 11:17 AM | Long-Term Outcomes Of The CERAB Technique In Patients With Aortoiliac Occlusive Disease: Advantages, Limitations, And Stent-Graft Choice: How Can CERAB Be Used To Treat Juxtarenal Occlusions |
Presenter(s):Michel Reijnen, MD, PhD / Peter C.J. Goverde, MD | |
11:18 AM - 11:23 AM | The CERAB Technique: From A Niche Procedure To A Better General Solution For Complex AortoIliac Occlusive Disease Based On The Updated Results Of The Physician Initiated Multicenter BeGlory Registry: Technical Tips And Precautions |
Presenter(s):Maria A. Ruffino, MD, EBIR, FCIRSE | |
11:24 AM - 11:29 AM | Impact Of Female Gender And Smaller Arteries On Outcomes Of Endovascular Treatment Of Aortoiliac Occlusive Disease: When Is Open Repair Indicated |
Presenter(s):Franco Grego, MD | |
11:30 AM - 11:35 AM | Treatment Of Isolated Infrarenal And Pararenal Aortic Stenosis: Why Results Are Worse In Women: When Stents; When Stent-Grafts; When Open Bypasses |
Presenter(s):Sigrid Nikol, MD | |
11:36 AM - 11:41 AM | Radiation Free CERAB Procedures Are Possible Using FORS Technology (Philips) With Its 3-D Hub: How Is It Done And Technical Tips: Clinical Experience In Over 20 Patients |
Presenter(s):Barend M.E. Mees, MD, PhD, FEBVS | |
11:42 AM - 11:47 AM | Can Mesh Covered Stents Replace Stent-Grafts For The Treatment Of Complex Iliac Occlusive Lesions: Advantages And Disadvantages |
Presenter(s):Piotr Myrcha, MD | |
11:48 AM - 11:53 AM | How Can The VORTEC Technique Be Used To Simplify Hypogastric Revascularization With Open Repair Of Difficult Iliac Aneurysms: How To Do It |
Presenter(s):Zoran Rancic, MD, PhD, EMBA HSG | |
11:54 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 12 | |
SESSION 13 SCHEDULE | |
Tuesday
SESSION 13:
NEW CONCEPTS; MACHINE LEARNING AND ARTIFICIAL INTELLIGENCE (AI); TO DECREASE RADIATION (SEE ALSO SESSIONS 9 AND 90)
Moderators:Kak Khee Yeung, MD, PhD / Barry T. Katzen, MD
|
|
x | |
1:00 PM - 1:05 PM | Revolutionizing Vascular Surgery: Navigating The AI And Multiomics Frontiers For Precision Care: Advantages And Limitations |
Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC, PhD, FACS | |
1:06 PM - 1:11 PM | Why RCTs In Vascular Surgery In The Era Of AI Are Unnecessary, Useless And Possibly Unethical |
Presenter(s):Willem Wisselink, MD | |
1:12 PM - 1:17 PM | What Is The VASCUL-AID Platform Which Uses AI To Predict Cardiovascular Disease Progression In AAA And Lower Extremity Lesion Patients (PAD): Interesting Findings To Date |
Presenter(s):Kak Khee Yeung, MD, PhD | |
1:18 PM - 1:23 PM Power Point Presentation with Synched Audio |
Focus On Radiation Protection During Simulation-Based Training Improves Both Correct Behavior And Procedural Performance: Proven By A Randomized Comparison |
Presenter(s):Lars B. Lonn, MD, PhD | |
1:24 PM - 1:29 PM | How Can AI Markedly Reduce Radiation, Contrast Usage And Complications For Complex TAAA Repair With PMEGs |
Presenter(s):Mahmoud B. Malas, MD, MHS | |
1:30 PM - 1:35 PM | Use Of Virtual Reality 3-D Visualization With A Headset For Preoperative Optimization For Treatment Of Visceral Artery Aneurysms |
Presenter(s):Dominique Fabre, MD, PhD | |
1:36 PM - 1:41 PM | Benefit Of AI And AAA Volume Measurements After EVAR And F/B/EVAR: How Do They Improve Care |
Presenter(s):Stephan Haulon, MD | |
1:42 PM - 1:47 PM | Is Image Fusion Advanced Guidance For Complex And Simple Aortic Procedures Really Worthwhile And Cost Effective: Why Is It A Question And Do We Need A Trial |
Presenter(s):Rachel E. Clough, PhD, FRCS | |
1:48 PM - 1:53 PM | Update On Siemens I-Flow: A New Intelligent Technology To Improve The Endo Treatment Of Lower Extremity Occlusive Disease And Predicting Stroke Risk With Carotid Disease; How Does It Work And How Reliable Is It |
Presenter(s):Ravi K. Veeraswamy, MD | |
1:54 PM - 1:59 PM | Update On How An AI Based Prediction Of Rupture Risk Is Better Than Size Based Predictions |
Presenter(s):Jes S. Lindholt, MD | |
2:00 PM - 2:05 PM | How Can AI Help In The Treatment Of Aortoiliac Occlusive Disease |
Presenter(s):Peter C.J. Goverde, MD | |
2:06 PM - 2:12 PM | Panel Discussion |
END OF SESSION 13 | |
SESSION 14 SCHEDULE | |
Tuesday
SESSION 14:
ISSUES IMPORTANT TO VASCULAR SURGERY’S INDEPENDENCE, IDENTITY AND TRAINING; SHOULD WE GET A COVID-19 VACCINATION
|
|
x | |
2:12 PM - 2:17 PM | Why Vascular Surgery Needs To Have An Independent Board And What Is The SVS Doing To Pursue This Goal |
Presenter(s):Joseph L. Mills, MD | |
2:18 PM - 2:23 PM | What Is The ABVS Doing To Pursue An Independent Board And Why Hasn't It Done More |
Presenter(s):Timur P. Sarac, MD / Jeffrey H. Hsu, MD / Sean P. Lyden, MD / Alan M. Dietzek, MD, RPVI, DFSVS | |
2:24 PM - 2:29 PM | Why An Independent Board Of Vascular Surgery Was So Helpful In France To Patients And To Vascular Surgeons After It Was Created In 1974: What Organizations Resisted It And How Was The Resistance Overcome |
Presenter(s):Jean Pierre Becquemin, MD, FRCS | |
2:30 PM - 2:35 PM | Five Issues Affecting Vascular Surgeons' Bargaining Power: Would An Independent Vascular Board Help |
Presenter(s):Margaret Tracci, MD, JD | |
2:36 PM - 2:41 PM | Status Of Cardiology’s Independent Board For Cardiovascular Medicine: What Will Be Its Impact On Vascular Surgery And How Would An Independent Vascular Surgery Board Counteract This |
Presenter(s):Alan M. Dietzek, MD, RPVI, DFSVS | |
2:42 PM - 2:47 PM | The SVS Public Marketing Initiative: Why It Will Help Overcome Vascular Surgery’s Clouded Identity: In View Of Cardiology’s Initiative To Obtain An Independent Board, Shouldn’t Vascular Surgery Get One Too |
Presenter(s):Matthew J. Eagleton, MD / Keith D. Calligaro, MD / Joseph L. Mills, MD | |
2:48 PM - 2:53 PM | The Importance Of Mentorship In Vascular Surgery: How Best To Achieve It |
Presenter(s):Malachi Sheahan, MD | |
2:54 PM - 2:59 PM | How To Handle Bad Clinical Outcomes And Other Professional And Personal Adversity: It Really Matters For A Vascular Surgeon/Specialist |
Presenter(s):John F. Eidt, MD | |
3:00 PM - 3:05 PM | Evolution And Current Status Of Integrated Vascular Surgery Residency (0+5) Training: Advantages And Limitations: A View From One Of The First Such Trainees |
Presenter(s):Daniel K. Han, MD | |
3:06 PM - 3:11 PM | Important Developments In Vascular Surgery Training Programs: Changes In Numbers And Quality Of 0+5 And 5+2 Trainees; Why We Need More Qualified Vascular Surgeons And How Are We Going To Get Them |
Presenter(s):Dawn M. Coleman, MD, FACS | |
3:12 PM - 3:17 PM | How Safe And Effective Are Current COVID-19 Drugs For Vaccination: When And How Often Should Vascular Surgeons/Specialists Get Them If They Are <50, >50, >65 Or >75 |
Presenter(s):Clayton J. Brinster, MD | |
3:18 PM - 3:24 PM | Panel Discussion |
3:25 PM - 3:36 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 14 | |
SESSION 15 SCHEDULE | |
Tuesday
SESSION 15:
PROGRESS IN THE TREATMENT OF VISCERAL AND RENAL ARTERY DISEASE (FOR IMPORTANT RELATED TALKS SEE SESSION 15 IN OUR 2023 PROGRAM ON OUR WEBSITE VEITHsymposium.org)
|
|
x | |
3:36 PM - 3:41 PM | Natural History Of Untreated Visceral And Renal Artery Aneurysms (Renal, Splenic, Celiac, Etc.): From Large Series With Mid-To Long-Term Follow Up |
Presenter(s):Caron B. Rockman, MD | |
3:42 PM - 3:47 PM | Multidisciplinary Consensus Statement On The Management Of Pediatric Renovascular Hypertension, Renal Artery Stenosis And Midaortic Syndrome: Optimal Conduits, Techniques And Results |
Presenter(s):Dawn M. Coleman, MD, FACS / James C. Stanley, MD | |
3:48 PM - 3:53 PM | Treatment Of Visceral And Renal Artery Aneurysms: Technical Tips And When To Use Coils, Covered Stents Or Uncovered Stents: How To Maintain Critical Arterial Flow |
Presenter(s):Paulo E. Ocke Reis, MD, PhD | |
3:54 PM - 3:59 PM | Why Is Open Repair Always Indicated To Treat Long Complex SMA Occlusions: Technical Tips |
Presenter(s):Armando Mansilha, MD, PhD, FEBVS | |
4:00 PM - 4:05 PM | Endovascular Mesenteric Artery Revascularization: Has It Improved Outcomes Of Acute Mesenteric Ischemia: Stents Versus Covered Stents |
Presenter(s):Manju Kalra, MBBS | |
4:06 PM - 4:11 PM | When Should SMA Endovascular Embolectomy Be The Standard Of Care: How To Do It |
Presenter(s):Loay S. Kabbani, MD, MHSA | |
4:12 PM - 4:17 PM | Visceral Artery Aneurysms: When To Treat Invasively, At What Size: When Endo, When Open |
Presenter(s):Rabih A. Chaer, MD | |
4:18 PM - 4:23 PM | Open Versus Endovascular Treatment For Visceral Artery Aneurysms And Acute Mesenteric Ischemia: When Is Open Surgery Mandatory |
Presenter(s):Timur P. Sarac, MD | |
4:24 PM - 4:29 PM | Gastroduodenal Aneurysms Associated With Celiac Artery Occlusion – Patterns, Treatment (Endo Versus Open); Technical Tips To Maintain Flow Through The Gastroduodenal And Results |
Presenter(s):Keith D. Calligaro, MD / Samy S. Nitecki, MD | |
4:30 PM - 4:36 PM | Panel Discussion |
END OF SESSION 15 | |
SESSION 16 SCHEDULE | |
Tuesday
SESSION 16:
UPDATE ON OPEN VASCULAR SURGICAL PROCEDURES; PROGRESS IN THE TREATMENT OF AORTIC COARCTATIONS (FOR IMPORTANT RELATED TALKS SEE SESSION 16 IN OUR 2023 PROGRAM ON OUR WEBSITE VEITHsymposium.org)
|
|
x | |
OPEN VASCULAR SURGERY | |
4:36 PM - 4:41 PM | What Are The Symptoms And What Is Current Open Surgical Treatment For Arterial Nutcracker Syndrome (Compression Of The Duodenum By The SMA) |
Presenter(s):Keith D. Calligaro, MD | |
4:42 PM - 4:47 PM | What Is ERAS (Early Recovery After [Open Aortic] Surgery): How To Do It With AAAs And What Are Its Advantages And Limitations |
Presenter(s):W. Anthony Lee, MD | |
4:48 PM - 4:53 PM | Strategies And Technical Challenges In The Open Treatment Of Large TAAAs In Patients With Connective Tissue Disorders |
Presenter(s):James H... Black, III, MD | |
4:54 PM - 4:59 PM | How To Perform All Vascular Operations Through Small Incisions: Technical Tips, Why Is It Advantageous And Results: When Is It Contraindicated |
Presenter(s):Robert M. Proczka, MD, PhD | |
5:00 PM - 5:05 PM | The Role Of Open AAA Repair In The Era Of F/EVAR And EVAR: Technical Tips |
Presenter(s):Francis Caputo, MD | |
5:06 PM - 5:11 PM | The Right Retroperitoneal Approach For Open AAA Repair: When To Do It, Advantages And Technical Tips |
Presenter(s):Ashraf Mansour, MD | |
5:12 PM - 5:17 PM | Update On Renal Consequences Of Left Renal Vein Division During Open AAA Repair: It Is Not Always Benign |
Presenter(s):Kimihiro Komori, MD | |
5:18 PM - 5:24 PM | Panel Discussion |
UPDATE ON COARCTATION TREATMENT | |
5:24 PM - 5:29 PM | Endovascular Repair Of Aortic Coarctation: Balloon Angioplasty Versus Bare Stents Versus Covered Stents And When Is Open Repair Necessary |
Presenter(s):Tilo Koelbel, MD, PhD | |
5:30 PM - 5:35 PM | Open And Endovascular Treatment Of Aortic Arch Aneurysms Following Aortic Coarctation Repairs - (First Author Germano C.G. Melissano, MD) |
Presenter(s):Andrea Kahlberg, MD / Germano C.G. Melissano, MD / Roberto L.V. Chiesa, MD | |
5:36 PM - 5:41 PM | Axillo-Unifemoral And Axillo-Bifemoral Bypasses Have Equal Patency For More Than A Year: Why The Bilateral Procedure Should Only Be Used When Bilateral Ischemia Exists |
Presenter(s):Jeffrey J. Siracuse, MD, MBA, FACS | |
5:42 PM - 5:47 PM | Technical Tips And Lessons Learned To Make In Situ Vein Bypasses More Effective And Better |
Presenter(s):R. Clement Darling III, MD | |
5:48 PM - 5:53 PM | Anterior Lumbar Spine Exposure: Technical Tips And How To Avoid Pitfalls |
Presenter(s):Timothy K. Liem, MD, MBA | |
5:54 PM - 5:59 PM | Panel Discussion End of Program B |
END OF SESSION 16 | |
SESSION 17 SCHEDULE | |
Tuesday
SESSION 17:
MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH – PART 1
Moderators:Michael R. Jaff, DO
|
|
x | |
7:00 AM - 7:05 AM | Introduction To The Symposium |
Presenter(s):Frank J. Veith, MD | |
7:05 AM - 7:15 AM | Welcome And Introduction |
Presenter(s):Michael R. Jaff, DO | |
7:15 AM - 7:25 AM | The Basics Of Pulmonary Embolism Diagnosis: What Is The Role Of The History, Exam, Biomarkers |
Presenter(s):Raghu Kolluri, MD | |
7:25 AM - 7:35 AM | Echocardiography Is All You Need To Manage Acute Submassive PE |
Presenter(s):David M. Dudzinski, MD | |
7:35 AM - 7:45 AM | CTA Is All You Need To Manage Acute Submassive PE |
Presenter(s):Brian B. Ghoshhajra, MD, MBA | |
7:45 AM - 7:55 AM | Testing For Cancer And Other Hypercoagulable States In PE: Why, When, And What Tests |
Presenter(s):Aditya Sharma, MD | |
7:55 AM - 8:10 AM | Medical Treatment Of PE: When, Why, For How Long, And How Can I Remember |
Presenter(s):Geno J. Merli, MD, MACP, FHM, FSVM | |
8:10 AM - 8:25 AM | An Overview Of Clinical Trials For PE: Will Any Of Them Move The Needle? |
Presenter(s):Rachel Rosovsky, MD, MPH | |
8:25 AM - 8:35 AM | Intravenous Thrombolytic Therapy For PE: Why, When, And At What Dose? |
Presenter(s):Jay Giri, MD, MPH | |
8:35 AM - 8:45 AM | Ultrasound-Assisted Pharmacomechanical Thrombolysis: Emerging Data To Define Use In PE |
Presenter(s):Asaaf Graif, MD | |
8:45 AM - 8:55 AM | Pharmacomechanical Thrombolysis With The Bashear Catheter: Unique And Differentiated Approach |
Presenter(s):Eric A. Secemsky, MD, MSc | |
8:55 AM - 9:05 AM | Percutaneous Mechanical Thrombectomy Without Lytics: The FlowTriever System |
Presenter(s):Mitchell D. Weinberg, MD | |
9:05 AM - 9:15 AM | Percutaneous Mechanical Thrombectomy Without Lytics: The Indigo System |
Presenter(s):Robert A. Lookstein, MD, MHCDL, FSIR, FAHA | |
9:15 AM - 9:25 AM | Large Bore Aspiration Thrombectomy—Tips, Tricks And Pearls |
Presenter(s):Gary M. Ansel, MD | |
Moderator(s): Michael R. Jaff, DO | |
9:25 AM - 9:40 AM | Panel Discussion |
Panelist(s): Gary M. Ansel, MD / Brian B. Ghoshhajra, MD, MBA / Jay Giri, MD, MPH / Asaaf Graif, MD / Raghu Kolluri, MD / Robert A. Lookstein, MD, MHCDL, FSIR, FAHA / Geno J. Merli, MD, MACP, FHM, FSVM / Rachel Rosovsky, MD, MPH / Eric A. Secemsky, MD, MSc / Aditya Sharma, MD / Mitchell D. Weinberg, MD | |
9:40 AM - 10:10 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 17 | |
SESSION 18 SCHEDULE | |
Tuesday
SESSION 18:
MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH – PART 2
Moderators:Michael R. Jaff, DO
|
|
x | |
10:10 AM - 10:20 AM | The AngioVac Strategy For The Treatment Of PE |
Presenter(s):Christopher J. Kwolek, MD, MBA | |
10:20 AM - 10:30 AM | ECMO-Assisted Pulmonary Embolectomy In Massive PE: Can It Replace Open Surgical Thrombo-Embolectomy |
Presenter(s):Animesh Rathore, MD | |
10:30 AM - 10:40 AM | Do Statins Matter In The Treatment Of Patients With PE |
Presenter(s):Anthony J. Comerota, MD, FACS, FACC | |
10:40 AM - 10:55 AM | Your Referring Docs Think Heparin Is All They Need To Offer For PE – How To Tell The Intervention Story |
Presenter(s):Patrick Troy, MD | |
10:55 AM - 11:10 AM | Pulmonary Denervation: A New Frontier In The Treatment Of Pulmonary Hypertension |
Presenter(s):Mark G. Davies, MD | |
11:10 AM - 11:25 AM | Balloon Pulmonary Angioplasty For Chronic Thromboembolic Pulmonary Hypertension: Has This Become Mainstream |
Presenter(s):Kenneth Rosenfield, MD | |
11:25 AM - 11:35 AM | The Team Approach To PE Management: The National PERT Consortium |
Presenter(s):Rachel Rosovsky, MD, MPH | |
Moderator(s): Michael R. Jaff, DO | |
11:35 AM - 12:00 PM | Challenging The Experts: Interactive Q&A |
Panelist(s): Anthony J. Comerota, MD, FACS, FACC / Mark G. Davies, MD / Christopher J. Kwolek, MD, MBA / Robert A. Lookstein, MD, MHCDL, FSIR, FAHA / Animesh Rathore, MD / Kenneth Rosenfield, MD / Rachel Rosovsky, MD, MPH / Eric A. Secemsky, MD, MSc / Patrick Troy, MD | |
12:00 PM - 1:00 PM | Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors)End of Program C-1 |
END OF SESSION 18 | |
SESSION 19 SCHEDULE | |
Tuesday
SESSION 19:
HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENTS - MEDICAL AND NATURAL HISTORY ISSUES
Moderators:William D. Jordan Jr., MD / Vincent L. Rowe, MD
|
|
x | |
1:00 PM - 1:05 PM | Personalized Anticoagulation For Lower Extremity Revascularization Using The Distinctive Utilization Of Antiplatelets Protocol To Decrease Thrombosis (Failure) Rates: How To Do It |
Presenter(s):Anahita Dua, MD, MS, MBA | |
1:06 PM - 1:11 PM | Why Are Patients Who Undergo Lower Extremity Revascularization At Risk For Major Bleeding: How To Estimate That Risk And What Should Be Done To Decrease It |
Presenter(s):Christian A. Behrendt, MD | |
1:12 PM - 1:17 PM | Frailty With CLTI: How Best To Measure It And Can It Improve With Revascularization |
Presenter(s):Mark G. Davies, MD | |
1:18 PM - 1:23 PM | How Atherosclerosis In Peripheral Arteries Differs From That In The Coronary Arteries: What Are The Therapeutic Implications |
Presenter(s):Janet T. Powell, MD, PhD | |
1:24 PM - 1:29 PM | Premature Peripheral Artery Disease: What Factors Predispose To It: How Should Its Treatment Differ: How Does It Influence Treatment Outcomes |
Presenter(s):Olamide Alabi, MD | |
1:30 PM - 1:35 PM | Open And Endo Revascularization In Young Patients With PAD: What Works, What Doesn’t, And How Should Treatment Be Modified |
Presenter(s):William P. Robinson, MD | |
1:36 PM - 1:41 PM | 'Low-Flow State' Induced Limb Ischemia: What’s The Etiology: Is The Incidence Increasing In The Era Of ECMO, IMPELLA, LVADs And Heart Transplantation: How Should It Be Treated |
Presenter(s):Sateesh C. Babu, MD | |
1:42 PM - 1:47 PM | Renal Failure In CLTI Patients Should Not Be A Contraindication To Limb Salvage Attempts |
Presenter(s):Vincent L. Rowe, MD | |
1:48 PM - 2:04 PM | Panel Discussion |
END OF SESSION 19 | |
SESSION 20 SCHEDULE | |
Tuesday
SESSION 20:
MORE HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT – EVALUATING ARTERIAL ANATOMY AND TREATMENT OUTCOMES WITH CLTI
Moderators:Marianne Brodmann, MD / Caron B. Rockman, MD
|
|
x | |
2:04 PM - 2:09 PM | How To Accurately Evaluate Availability And Nonavailability Of Ipsilateral Or Contralateral Great Saphenous Vein For Use For Potential Bypasses In Patients Being Treated For Severe CLTI: How Can One Determine Optimal Treatment |
Presenter(s):Caron B. Rockman, MD | |
2:10 PM - 2:15 PM | Value Of Optical Coherence Tomography (OCT) In Treating BTK Arterial Lesions: How Does It Work And Indications |
Presenter(s):Lee Bouwman, Dr | |
2:16 PM - 2:21 PM | The Value Of Distal Angiography, Selective And Subselective, In The Treatment Of Lesions Causing CLTI |
Presenter(s):Jos C. van den Berg, MD, PhD | |
2:22 PM - 2:27 PM Power Point Presentation with Synched Audio |
The Japanese SPINACH Registry Confirms That Open Bypasses Are Superior To Endovascular Treatments In CLTI Patients When Ischemia And Infection Are Advanced |
Presenter(s):Nobuyoshi Azuma, MD | |
2:28 PM - 2:33 PM | What Is The Role Of IVUS In Peripheral Arterial Endovascular Procedures: When Is It Better Than Contrast Arteriography And When Can It Replace It |
Presenter(s):Hany M. Zayed, MD | |
2:34 PM - 2:39 PM | What Are The Best Ways To Evaluate CLTI Treatment Outcomes: Physiology (ABIs And PVRs), Wound Healing, Anatomy (Angiography Or Ultrasound), MACE Or MALE: Why It Matters |
Presenter(s):Mitchell D. Weinberg, MD / Ido Weinberg, MD, MSc | |
2:40 PM - 2:45 PM | How Should We Define Success For CLTI Treatment: What Criteria Are Best: The UK Perspective: Why Is It Different |
Presenter(s):Jonathan R. Boyle, MD, MA (Cantab) FRCS | |
2:46 PM - 2:52 PM | Panel Discussion |
2:52 PM - 3:00 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 20 | |
SESSION 21 SCHEDULE | |
Tuesday
SESSION 21:
HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENTS
Moderators:Neal S. Cayne, MD / Gary M. Ansel, MD
|
|
x | |
3:00 PM - 3:05 PM | Technical Tips For Vessel Prep For DCBs Or DESs: It Is Different And Not Simple: How To Do It And How Important Is It |
Presenter(s):Erwin Blessing, MD | |
3:06 PM - 3:11 PM | Current Comparative Value Of Paclitaxel Coated DCBs Versus Uncoated Balloons In Below The Knee (BTK) Arteries: The SAMBA Trial Shows That DESs Can Work In This Location |
Presenter(s):Gunnar Tepe, MD | |
3:12 PM - 3:17 PM | When Are Polymer Based Paclitaxel Eluting Stents (Eluvia, Boston Scientific) Superior To Other Endo Treatments For Lower Extremity Lesions |
Presenter(s):Yann Gouëffic, MD, PhD | |
3:18 PM - 3:23 PM | Update On The Advantages Of The Chocolate Wire Constrained Uncoated Balloon (From Medtronic) For Treating Popliteal And BTK Lesions |
Presenter(s):Gunnar Tepe, MD | |
3:24 PM - 3:29 PM | Tips For Treating Difficult BTK/BTA Lesions: How To Get A Guidewire Across A Long Calcified Occlusion, Getting A Resistant Balloon To Go Over The Wire And Tips For Retrograde Access |
Presenter(s):Marco G. Manzi, MD | |
3:30 PM - 3:35 PM | Propensity Matched Comparison Of Uncoated And Paclitaxel-Coated Balloon Angioplasty For Isolated Popliteal Lesions Excluding Bail-Out Stenting: The DCBs Are Better |
Presenter(s):Fabrizio Fanelli, MD, EBIR / Thomas Zeller, MD | |
3:36 PM - 3:42 PM | Panel Discussion |
3:42 PM - 3:47 PM | Outcomes Following Profunda Revascularization Using Atherectomy And DCB Angioplasty: Technical Tips And Comparison With Open Surgery |
Presenter(s):Giovanni B. Torsello, MD | |
3:48 PM - 3:53 PM | First-In-Human Experience With The Efemoral Bioresorbable Scaffold And New Sirolimus DCB (Provision DCB From BD) In FemPop Disease |
Presenter(s):Andrew Holden, MBChB | |
3:54 PM - 3:59 PM | Why The Zilver PTX DES (Cook) Is A Durable Effective Treatment For Long FemPop Lesions: Based On Worldwide Trials And Experience |
Presenter(s):Charles J. Bailey, MD | |
4:00 PM - 4:05 PM | Non-Aspiration Based Mechanical Thrombo-Embolectomy With The Pounce (From Surmodics) Or Rotarex (From BD) Devices: How Do They Work And How They May Lead To More Concrete Procedural End Points And Improved Value Analysis |
Presenter(s):Gary M. Ansel, MD | |
4:06 PM - 4:11 PM | Local Anesthetic Injection Into A Lesion Site Facilitates Angioplasty (PTA) And Stent Placement: How To Do It |
Presenter(s):Andrej Schmidt, MD | |
4:12 PM - 4:17 PM | Technical Tips For A Successful BTK Intervention In Patients With CLTI Including How To Perform An Antegrade Femoral Artery Puncture And Pass The Guidewire Easily Into The SFA And Not The Profunda |
Presenter(s):Ali Amin, MD, RVT, FACS, FACC | |
4:18 PM - 4:23 PM | Panel Discussion |
END OF SESSION 21 | |
SESSION 22 SCHEDULE | |
Tuesday
SESSION 22:
MORE HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE, CLTI AND ITS TREATMENTS
Moderators:Brian G. DeRubertis, MD / Caitlin W. Hicks, MD, MS
|
|
x | |
4:24 PM - 4:29 PM | How To Evaluate The Need For Below The Ankle (BTA) Recanalization In CLTI Patients: When Is It Important To Achieve Foot Healing: Technical Tips To Do It And How Durable Is Its Patency |
Presenter(s):Lorenzo Patrone, MD | |
4:30 PM - 4:35 PM | Lymphatic Embolization For Postoperative Groin Wound Leaks: How To Do It And How Effective Is It |
Presenter(s):Lindsay Machan, MD | |
4:36 PM - 4:41 PM | When Is Endovascular Treatment For CLTI Justified And Better For Patients Classified As “Bypass Preferred” In The Global Vascular Guidelines: What Are The Guidelines Missing |
Presenter(s):Kimihiro Komori, MD | |
4:42 PM - 4:47 PM | A Radiologist's View Of Open Bypass vs Endovascular As First Treatment For CLTI: Bypasses Still Have An Important Role |
Presenter(s):Konstantinos Katsanos, MSc, MD, PhD, EBIR | |
4:48 PM - 4:53 PM | How To Size Lower Extremity Target Arteries For Endo Treatments Accurately Using Intravascular Ultrasound (IVUS): How Does It Help |
Presenter(s):Jos C. van den Berg, MD, PhD | |
4:54 PM - 4:59 PM | Do Diabetic Patients With CLTI And Extensive Foot Necrosis Have Time For An Endovascular First Strategy: Primary Open Bypass Is Better Treatment In This Setting |
Presenter(s):Katariina M. Noronen, MD | |
5:00 PM - 5:05 PM | Does Intravascular Lithotripsy (IVL) (Shockwave) Eliminate The Need For Other Vessel Prep |
Presenter(s):Lawrence A. Garcia, MD | |
5:06 PM - 5:11 PM | Panel Discussion |
5:12 PM - 5:17 PM | Experience With >1500 Retrograde Recanalization For Chronic Total Occlusions (CTOs); What Predicts Technical Success And What Predicts Periprocedural Complications: Are Re-Entry Devices Ever Helpful |
Presenter(s):Erwin Blessing, MD | |
5:18 PM - 5:23 PM Power Point Presentation with Synched Audio |
Guillotine TMA After Arterial Revascularization: When And Why Is It Helpful With CLTI And How Should It Be Done |
Presenter(s):Miguel F. Montero-Baker, MD | |
5:24 PM - 5:29 PM | Value Of Redo Tibial Bypasses: Technical Tips For Facilitating - Some Old And Some New Tricks |
Presenter(s):Ramesh K. Tripathi, MD, FRCS, FRACS | |
5:30 PM - 5:35 PM | A New Technology (From AOTI) Combining Local Oxygen Therapy With Cycled Compression And Humidification Enhances Healing Of Diabetic Wounds And Ischemic Ulcers After Revascularization |
Presenter(s):Anil P. Hingorani, MD / Enrico Ascher, MD | |
5:36 PM - 5:41 PM | When Lower Extremity Interventions Are Required In Patients With Prior EVAR Or Kissing Iliac Stents, How Can Contralateral Femoral Access Be Used: Technical Tips |
Presenter(s):Dipankar Mukherjee, MD | |
5:42 PM - 5:47 PM | Alternate Anatomic Approaches To Lower Extremity Arteries When Standard Approaches Are Prevented By Scarring Or Infection |
Presenter(s):Neal S. Cayne, MD / Enrico Ascher, MD / Frank J. Veith, MD | |
5:48 PM - 5:53 PM | Effects Of Atherectomy On Immediate Luminal Gain In Patients With In-Stent Restenosis/Thrombosis: Which Atherectomy Device Is Best |
Presenter(s):Joseph J. Ricotta II, MD, MS, DFSVS, FACS | |
5:54 PM - 5:59 PM | How To Do Bypass Surgery To Heavily Non-Compressible Calcified Target Arteries |
Presenter(s):Enrico Ascher, MD / Frank J. Veith, MD | |
6:00 PM - 6:06 PM | Panel Discussion End of Program C-2 |
END OF SESSION 22 | |
Wednesday, November 20, 2024
Print Entire 2024 Program:
|
|
SESSION 23 SCHEDULE | |
Wednesday
SESSION 23:
GENERALITIES IN THE ENDOVASCULAR AND OPEN TREATMENT OF LOWER EXTREMITY OCCLUSIVE DISEASE AND CLTI
|
|
x | |
6:40 AM - 6:45 AM | How Do Prior Endovascular Interventions Affect Future Lower Extremity Bypass Outcomes For CLTI: Why Do The Results Of The BEST-CLI Trial Make This More Important |
Presenter(s):Ramesh K. Tripathi, MD, FRCS, FRACS | |
6:46 AM - 6:51 AM | The Effect Of Optimal Medical Therapy On Outcomes In Patients With CLTI In The BEST-CLI Trial: What Should This Therapy Be And How Should It Be Monitored |
Presenter(s):Vik S. Kashyap, MD | |
6:52 AM - 6:57 AM | Five-Year Mortality In Medicare Patients Undergoing Interventions For CLTI And IC Is Worse Than We Thought: 67% For CLTI And 33% For IC |
Presenter(s):Jeffrey J. Siracuse, MD, MBA, FACS | |
6:58 AM - 7:03 AM | DEBATE: An Endo First Approach Is Best For Treating CLTI In Almost All Patients: The Role For Open Bypasses Is Very Limited (What Percent): Why BEST-CLI And BASIL 2 Have Not Changed My Practice |
Presenter(s):Christopher J. Abularrage, MD | |
7:04 AM - 7:09 AM | DEBATE: Open Bypass Should Be The First Treatment For Many CLTI Patients: When Is This So And In What Percent Of CLTI Patients |
Presenter(s):Michael S. Conte, MD | |
7:10 AM - 7:15 AM | Is The Open Surgery First Or Endovascular First Approach Controversy Still Alive For CLTI: What Percentage Of An Interventionalist's Patients Should Be Treated First By Open Surgery |
Presenter(s):Marianne Brodmann, MD | |
7:16 AM - 7:21 AM | What Causes Small Foot Arteries To Have Decreased Blood Flow Resulting In CLTI: Medial Arterial Calcification (MAC) Causes Increased Vascular Stiffness And Decreased Blood Flow; Atheromatous And Non Atheromatous Lesions Further Obstruct Blood As Shown Pathologically: Can Any Of These Be Treated |
Presenter(s):Roberto Ferraresi, MD | |
7:22 AM - 7:27 AM | What Are The Best Current Techniques For Revascularizing BTK And Below-The-Ankle (BTA) Lesions Causing CLTI: Is Open Bypass Ever The Best |
Presenter(s):Stefan Mueller-Huelsbeck, MD | |
7:28 AM - 7:33 AM | Microembolization During Complex Endovascular Procedures Is Causing More Damage Than We Think To The Already Compromised Pedal Runoff: Is Paclitaxel A Causal Agent |
Presenter(s):Peter A. Schneider, MD | |
7:34 AM - 7:39 AM | Is Preop CT Fractional Flow Reserve (FFRCT) Guided Coronary Revascularization Beneficial In Patients Requiring Invasive Treatment For Lower Extremity (LE) Lesions: An RCT Comparing Standard Care Versus Such Revascularization Is Showing The Benefit Of The Latter: What Is The Best Time For The Coronary Procedure—Before Or After The LE Treatment |
Presenter(s):Christopher K. Zarins, MD / Dainis K. Krievins, MD | |
7:40 AM - 7:45 AM | Radial-to-Peripheral Interventions For Lower Extremity Arterial Lesions (PAD): An Update On Available Tools And Techniques And Precautions: What's Possible And What's Not |
Presenter(s):Craig M. Walker, MD | |
7:46 AM - 7:53 AM | Panel Discussion |
END OF SESSION 23 | |
SESSION 24 SCHEDULE | |
Wednesday
SESSION 24:
NEW DEVELOPMENTS IN ATHERECTOMY, STENTS (UNCOATED, COATED AND BIORESORBABLE)
|
|
x | |
PROGRESS IN ATHERECTOMY | |
7:53 AM - 7:58 AM | Which Vascular Specialists Are Performing Tibial Atherectomies And Angioplasties For Intermittent Claudication And Are There Suboptimal Outcomes: Is Atherectomy Usage Overall Being Abused |
Presenter(s):Caitlin W. Hicks, MD, MS | |
7:59 AM - 8:04 AM | Update On Atherectomy Devices: Do They Still Have A Role In 2024: Which One Or Ones Are Best: Has Their Benefit Been Proven |
Presenter(s):Todd R. Vogel, MD, MPH | |
8:05 AM - 8:10 AM | Atherectomy In Patients With CLTI, In Stent Restenosis (ISR) And Diabetes: When Is It Helpful; How Durable Is It: Which Devices Are The Best |
Presenter(s):Ignacio Escotto, MD | |
8:11 AM - 8:16 AM | The Objective Benefits Of Directional Atherectomy In Treating Lower Extremity Occlusive Lesions Are Real: When And How Should It Be Used And When Should It Not |
Presenter(s):Dierk Scheinert, MD / Thomas Zeller, MD | |
8:17 AM - 8:22 AM | What Is The Evidence That Atherectomy Is Effective In Femoropopliteal Interventions |
Presenter(s):Eric A. Secemsky, MD, MSc | |
8:23 AM - 8:28 AM | 3-Year Experience With The Rotarex Atherectomy And Thrombectomy System (From BD) For Arterial Occlusive Disease And ISR: How Does It Work And Advantages |
Presenter(s):Michael K.W. Lichtenberg, MD | |
DRUG ELUTING STENTS (DESs) FOR BTK LESIONS | |
8:29 AM - 8:34 AM | Update And 2-Year Results Of The LIFE-BTK Randomized Controlled Comparison Of Abbott’s Esprit Drug-Eluting Resorbable Stent (DERS) With Plain Old Balloon Angioplasty (POBA): When Will DERSs Make A Difference |
Presenter(s):Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed (ClinEpi) / Sahil A. Parikh, MD / Brian G. DeRubertis, MD | |
8:35 AM - 8:40 AM | Update On Bioresorbable Everolimus DESs To Treat BTK Lesions Causing CLTI: Promising Results Up To 5 Years: From The DISAPEAR Registry And A Meta-Analysis Of Other Bioresorbable BTK Stent Results |
Presenter(s):Steven Kum, MD | |
8:41 AM - 8:46 AM | Updated Experience With Everolimus And Other Nonabsorbable DESs To Treat Infrapopliteal BTK Lesions – Long And Short – Causing CLTI: What Are The Stents And When Do They Help: Why Will The DERSs Be Better |
Presenter(s):Robert A. Lookstein, MD, MHCDL, FSIR, FAHA | |
8:47 AM - 8:52 AM | Late-Breaking Final Patency And Wound Healing Results With A 3-French Compatible Microstent (From Micro Medical) Versus POBA For Antegrade Or Retrograde Insertion To Treat Tibial Artery Lesions: From The STAND RCT |
Presenter(s):Robert E. Beasley, MD, FSIR, FSCAI / Marco G. Manzi, MD | |
8:53 AM - 9:00 AM | Panel Discussion |
END OF SESSION 24 | |
SESSION 25 SCHEDULE | |
Wednesday
SESSION 25:
LOWER EXTREMITY TOPICS RELATED TO DRUG COATED BALLOONS (DCBs), AND DRUG ELUTING STENTS (DESs) AND OTHER INTERWOVEN (SUPERA) STENTS
|
|
x | |
9:00 AM - 9:05 AM | One View On The Final Result Of The Scare And Concern That Paclitaxel Coated Devices For Lower Extremity Treatments Increased Mortality And Amputation Rates: The Case Is Closed: What Were Its Costs |
Presenter(s):Peter A. Schneider, MD | |
9:06 AM - 9:11 AM | Another View On The Final Word: Is There Still Any Validity To The Increased Amputation And Mortality Rate Signals After Use Of Paclitaxel Coated Devices In The Lower Extremity: How Can We Explain These Signals In Older Studies And Their Disappearance In More Recent Data: The Case Is Not Yet Fully Closed |
Presenter(s):Konstantinos Katsanos, MSc, MD, PhD, EBIR | |
9:12 AM - 9:17 AM | Update On DCBs For BTK Angioplasty: RCT Comparing A Paclitaxel DCB (Litos From Acotec) Versus A Sirolimus DCB (Magic Touch From Concept Medical): Update On Enrollment And Data In The DEBATE BTK DUELL RCT And The XTOSI Study |
Presenter(s):Francesco Liistro, MD / Edward T. Choke, MBBS, PhD | |
9:18 AM - 9:23 AM | Progress With A Sustained Release Sirolimus DCB For FemPop Lesions: 1-Year Results With The Magic Touch DCB Compared To A Paclitaxel DCB: From The SIRONA Study |
Presenter(s):Andrej Schmidt, MD / Thomas Zeller, MD / Dierk Scheinert, MD / Marianne Brodmann, MD | |
9:24 AM - 9:29 AM | Adventitial Drug Delivery With The BullFrog Device (From Mercator Medical) And The Spur Device (From ReFlow): How Do They Work And How Will We Know They Improve Results |
Presenter(s):William A. Gray, MD | |
9:30 AM - 9:35 AM | To Reduce Injury In Post Balloon PTA Dissections: The Value Of Stents, Tacks, Etc. |
Presenter(s):Michael K.W. Lichtenberg, MD | |
9:36 AM - 9:41 AM | Late Breaking Information Shows That Higher Dose Of Statins Greatly Lessens The Risk Of SFA Stent Restenosis: Is It True With DESs |
Presenter(s):Timothy W.I. Clark, MD | |
9:42 AM - 9:47 AM Power Point Presentation with Synched Audio |
The Light And Darkness Of Fluoropolymer-Based Limus DESs In The Treatment Of Femoropopliteal Lesions |
Presenter(s):Osamu Iida, MD, PhD | |
9:48 AM - 9:53 AM | Updated And Long-Term Follow-Up Results With The Vasculomimetic Interwoven Supera Stent In Angulated And Tortuous Lower Extremity Anatomies |
Presenter(s):Rajiv Parakh, MBBS, MS, FRCS | |
9:54 AM - 9:59 AM Power Point Presentation with Synched Audio |
Are DESs Ever Associated With Aneurysmal Degeneration: Is It Related To The Drug (Paclitaxel Or Limus) Or To The Fluoropolymer Excipient To Which The Drug Is Attached |
Presenter(s):Osamu Iida, MD, PhD | |
10:00 AM - 10:08 AM | Panel Discussion |
10:08 AM - 10:18 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 25 | |
SESSION 26 SCHEDULE | |
Wednesday
SESSION 26:
NEW DEVELOPMENTS IN DRUG COATED BALLOONS (DCBs) AND DRUG ELUTING STENTS (DESs): UPDATES ON RANDOMIZED CONTROLLED TRIALS (RCTs) AND BTK LESION TREATMENTS WITH DCBs AND DESs
|
|
x | |
NEW INFORMATION ON DCBs AND DESs FOR FEMPOP LESIONS: UPDATES ON RCTs | |
10:18 AM - 10:23 AM | How Should We Move Forward With Limus Coated Devices After FDA Has Cleared Paclitaxel Coated Devices: Are There Promising Results Currently With Limus Coated DCBs |
Presenter(s):Marianne Brodmann, MD | |
10:24 AM - 10:29 AM | 4-Year Results Of An RCT Comparing Surveil DCBs (Surmodics) With In.Pact DCBs (Medtronic) For Treating FemPop Lesions: From The TRANSCEND Trial |
Presenter(s):Peter A. Schneider, MD | |
10:30 AM - 10:35 AM | 2-3-Year Results Of The EMINENT RCT Show The Superiority Of DESs (Eluvia-Boston Scientific) Over Bare Metal Stents For Long Complex FemPop Lesions |
Presenter(s):Yann Gouëffic, MD, PhD | |
10:36 AM - 10:41 AM | Update On The Randomized Head-To-Head Comparison Of In.Pact (Medtronic) And Ranger (Boston Scientific) DCBs For Complex SFA Lesions: 5-Year Results Of The COMPARE RCT: Similar Results With Different Paclitaxel Dosages |
Presenter(s):Dierk Scheinert, MD / Sabine Steiner, MD | |
10:42 AM - 10:47 AM | Update On The BioMimics 3D Spiral Flow Prosthetic Graft From Veryan Medical: Does It Prevent Neointimal Hyperplasia And Improve Patency: 3-Year Results With FemPop Lesions |
Presenter(s):Robert E. Beasley, MD, FSIR, FSCAI | |
10:48 AM - 10:53 AM | One Year Results Of The SPORTS RCT – Comparing DESs (Eluvia – Boston Scientific) Versus Bare Metal Stents (BMSs) Versus DCBs: Which Device Is Best And In What Circumstances |
Presenter(s):Gunnar Tepe, MD | |
10:54 AM - 10:59 AM | Updated 5-Year Results Of The IMPERIAL RCT Head-To-Head Comparison Of The Eluvia DES (Boston Scientific) With The Zilver PTX DES (Cook): Both Are Safe And Effective: What Are The Differences |
Presenter(s):Stefan Mueller-Huelsbeck, MD / William A. Gray, MD / Thomas Zeller, MD | |
11:00 AM - 11:05 AM | New Findings From The DRASTICO Study Comparing DESs To DCBs For FemPop Lesions: 5-Year Results With TASC A/B Lesions Versus TASC C/D Lesions |
Presenter(s):Francesco Liistro, MD | |
11:06 AM - 11:11 AM | Stellarex (Philips) DCBs With Low Dose Paclitaxel Is Safe And Has Higher Patency Rates Than POBA With De Novo Or Recurrent FemPop Lesions At 5 Years In The ILLUMENATE US And European RCTs |
Presenter(s):Sean P. Lyden, MD / Marianne Brodmann, MD / Sahil A. Parikh, MD / William A. Gray, MD | |
11:12 AM - 11:18 AM | Panel Discussion |
NEW INFORMATION ON BTK DCBs AND DESs | |
11:18 AM - 11:23 AM | Why Some BTK DCB Trials Have Not Shown Uniformly Better Results: Technical And Balloon Factors Matter |
Presenter(s):Francesco Liistro, MD | |
11:24 AM - 11:29 AM | When, How And With What Devices Are Endovascular Treatments The Best Way To Treat BTK Disease Causing CLTI |
Presenter(s):Brian G. DeRubertis, MD | |
11:30 AM - 11:35 AM | 5-Year Results From The AcoArt II BTK DCB RCT Show Safety With No Increased Mortality And Improved Patency Versus POBA To Treat BTK Lesions |
Presenter(s):Wei Guo, MD / Francesco Liistro, MD | |
11:36 AM - 11:41 AM | Sirolimus DCBs For Infrapopliteal Interventions: The Cordis/MedAlliance Selution 4BTK IDE Trial Update: Overseas Results Have Been Promising |
Presenter(s):Patrick J. Geraghty, MD / George L. Adams, MD / Michael K.W. Lichtenberg, MD | |
11:42 AM - 11:47 AM | How Does The LIFE BTK Study With Esprit Bioresorbable DES (From Abbott) Change The BEST- CLI Conclusions For BTK Lesions |
Presenter(s):Lawrence A. Garcia, MD | |
11:48 AM - 11:53 AM | Below-The-Ankle Endo Interventions In 2024: Techniques, Devices And Should Balloons Be Drug Coated Or Not |
Presenter(s):Marianne Brodmann, MD | |
11:54 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 26 | |
SESSION 27 SCHEDULE | |
Wednesday
SESSION 27:
PROGRESS IN EXOTIC AND EXTREME NEW TREATMENTS FOR VERY DISTAL LOWER EXTREMITY DISEASE CAUSING ADVANCED CLTI: OPTIONS TO SAVE THE “NO OPTION FOR TREATMENT” LIMB AND THE “DESERT FOOT”
|
|
x | |
1:00 PM - 1:05 PM | Successful Bypasses To Foot Arteries And Their Branches Allowed Limb Salvage In What Were Thought To Be 'No Option For Treatment' CLTI Patients |
Presenter(s):Enrico Ascher, MD / Frank J. Veith, MD | |
1:06 PM - 1:11 PM | What Presently Defines A No Option Or Desert Foot Before Or After Failed Endo Or Open Treatments: Under What Conditions Are Further Extreme Limb Salvage Procedures Possible |
Presenter(s):Peter A. Schneider, MD | |
1:12 PM - 1:17 PM | No Option CLTI Is Often A Misnomer: What Diagnostic And Therapeutic Procedures Can Result In Successful Limb Salvage In Many Of These Patients |
Presenter(s):Hisham Rashid, FRCS, FRCS(Gen) | |
VALUE OF PROSTHETIC (PTFE) TIBIAL BYPASSES | |
1:18 PM - 1:23 PM | Why PTFE Bypasses To Infrapopliteal Arteries Have Been A Controversial Procedure For More Than 40 Years – And Why They Continue To Be |
Presenter(s):Matthew T. Menard, MD | |
1:24 PM - 1:29 PM | Long-Term Multicenter Outcomes Show That Prosthetic (PTFE) Bypasses To Tibial And Peroneal Arteries Are Worthwhile |
Presenter(s):Hasan H. Dosluoglu, MD / Richard F. Neville, MD / Enrico Ascher, MD / Frank J. Veith, MD | |
UPDATE ON FOOT VEIN ARTERIALIZATION FOR CLTI | |
1:30 PM - 1:35 PM | Value Of Open Surgical Vein Arterialization: When And How It Can Be Useful: Technical Tips From The First One To Make It Work |
Presenter(s):Pramook Mutirangura, FRCS (Edinburgh) | |
1:36 PM - 1:41 PM | Why Foot Vein Arterialization Can Save Limbs With Truly No Other Option: What Is The Physiology That Allows Successful Arterialization Into Small Veins And The Capillary Bed: What Is Necessary For This To Occur |
Presenter(s):Roberto Ferraresi, MD | |
1:42 PM - 1:47 PM | Update On The PROMISE Trials And Registry Results In No Option CLTI Patients With Foot Gangrene Shows That Deep Vein Arterialization (DVA) Using The LimFlow Device Can Produce Wound Healing And Limb Salvage: When Does It Work And When Doesn’t It: Are There Drawbacks |
Presenter(s):Daniel G. Clair, MD / Hany M. Zayed, MD / Andrej Schmidt, MD / Daniela Branzan, MD | |
1:48 PM - 1:53 PM | Technical Advances In (DVA) With The LimFlow Device: Improved Access, Better Post Procedural Care And Wound Management Are Essential |
Presenter(s):Anahita Dua, MD, MS, MBA | |
1:54 PM - 1:59 PM | Technical Tips For DVA: The Most Important Part Starts After The Procedure |
Presenter(s):Erwin Blessing, MD | |
2:00 PM - 2:05 PM | Deep Venous Arterialization (DVA): Advantages Of Open Surgical Versus Endovascular Procedures Based On A Single Center Experience |
Presenter(s):Richard F. Neville, MD | |
2:06 PM - 2:11 PM | Novel Uses Of Selective Superficial Venous Arterialization To Achieve Lower Limb Salvage: Techniques, Indications, Precautions And Results |
Presenter(s):Patrick J. Geraghty, MD | |
2:12 PM - 2:17 PM | Hybrid Superficial Venous Arterialization For No Option CLTI: Technical Tips: Causes And Patterns Of Failure - Which Is Common |
Presenter(s):Miguel F. Montero-Baker, MD | |
2:18 PM - 2:24 PM | Panel Discussion |
END OF SESSION 27 | |
SESSION 28 SCHEDULE | |
Wednesday
SESSION 28:
NEW DEVELOPMENTS IN PROSTHETIC GRAFTS; STENT GRAFTS; PERCUTANEOUS ENDOVASCULAR BYPASSES; STENT OCCLUSIONS AND TREATMENT OF IN STENT RESTENOSIS (ISR)
|
|
x | |
NEW CONCEPTS RE PTFE GRAFTS AND STENT-GRAFTS | |
2:25 PM - 2:30 PM | Heparin-Bonded Expanded PTFE Grafts For BTK Bypasses: What Is The Evidence That They Are Better And Are Propaten (Gore) Grafts The Best For Extensive FemPop Disease: Based On An RCT And A Systemic Review And Meta-Analysis |
Presenter(s):Yann Gouëffic, MD, PhD | |
2:31 PM - 2:36 PM | Less Invasive And More Effective Hybrid Method For Restoring Patency To Occluded PTFE Bypasses Using A Fluoroscopically Guided Adherent Clot Remover (From Edwards) |
Presenter(s):Neal S. Cayne, MD / Frank J. Veith, MD | |
2:37 PM - 2:42 PM Power Point Presentation with Synched Audio |
5-Year Results Of Viabahn Stent-Graft For Complex FemPop Lesions: Technical Tips, Advantages And Limitations |
Presenter(s):Osamu Iida, MD, PhD | |
PERCUTANEOUS FEMPOP BYPASSES | |
2:43 PM - 2:48 PM | 3-Year Results With Percutaneous (PQ) Transvenous FemPop PTFE Bypasses Using The Torus 2 Endograft (From Endologix): How Is It Done And Updated Results From The US DETOUR Trial: Does It Have Limitations |
Presenter(s):Sean P. Lyden, MD / Daniel G. Clair, MD / Peter A. Schneider, MD | |
2:49 PM - 2:54 PM | 5-Year Results With Percutaneous Transvenous PTFE FemPop Bypass (PQ From Endologix) The DETOUR 1 TRIAL: Will Open Bypasses Become Obsolete |
Presenter(s):Dainis K. Krievins, MD | |
2:55 PM - 3:00 PM | Percutaneous Extravascular FemPop PTFE Bypasses Without Traversing The Vein: Technique And 6-Year Experience In Patients: Is It More Cost Effective: What Are The Limitations |
Presenter(s):Pierre G. Sarradon, Docteur / Jean Pierre Becquemin, MD, FRCS | |
STENT OCCLUSIONS AND TREATMENT OF IN STENT RESTENOSIS (ISR) | |
3:01 PM - 3:06 PM | Treatment Of SFA In Stent Occlusions: Technique Of Direct Stent Puncture: And Value Of The Excimer Laser To Cross And Treat The Occlusions: How Is It Done And Advantages |
Presenter(s):Craig M. Walker, MD | |
3:07 PM - 3:12 PM | What Are The Best Current Treatment Options For ISR: What Are The Results Including Recurrence Rates |
Presenter(s):Stefan Mueller-Huelsbeck, MD | |
ROLE OF OPEN PTFE BYPASSES IN CLTI | |
3:13 PM - 3:18 PM | In The Endovascular Era, What Is The Current Role Of Open Bypasses In A Limb Salvage Program: What Percentage Of CLTI Patients Will Need One At Some Time In Their Course And What Percentage Of Those Will Require A PTFE Graft |
Presenter(s):Niten Singh, MD | |
3:19 PM - 3:39 PM | Panel Discussion And Break Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 28 | |
SESSION 29 SCHEDULE | |
Wednesday
SESSION 29:
LOWER EXTREMITY TRIALS; GUIDELINES; FOOT PERFUSION EVALUATION METHODS AND VALUE OF ANGIOSOMES
|
|
x | |
3:40 PM - 3:45 PM | An Important Multicenter Propensity Matched Comparison Of Endo Versus Open Infrainguinal Treatment For CLTI Shows That Open Treatment Is Superior And Supports The Main Finding Of BEST-CLI |
Presenter(s):Jean-Baptiste Ricco, MD, PhD | |
3:46 PM - 3:51 PM | How To Reconcile The Different Primary Outcomes And Main Conclusion Of The BEST-CLI And BASIL-2 RCTs |
Presenter(s):Michael S. Conte, MD | |
3:52 PM - 3:57 PM | How The Data From BEST-CLI And BASIL-2 Can Be Combined To Produce Conclusions Superior To Those Of Either Trial Alone |
Presenter(s):Alik Farber, MD, MBA / Andrew W. Bradbury, MD, FRCSEd / Matthew T. Menard, MD / Kenneth Rosenfield, MD | |
3:58 PM - 4:03 PM | New Subanalysis Findings From The BEST-CLI RCT Are Critically Important To The Treatment Of CLTI Patients: Open Surgical Bypass Operations Still Have A Critical Role: Open Versus Endo Treatment Of Infrapopliteal Disease: Does Endo Treatment Burn Bridges |
Presenter(s):Matthew T. Menard, MD / Alik Farber, MD, MBA / Kenneth Rosenfield, MD | |
4:04 PM - 4:09 PM | Findings From BASIL-3, An RCT Comparing Clinical And Cost Effectiveness Of 3 Treatment Modalities For CLTI From FemPop Disease: POBA Versus DCBs Versus DESs |
Presenter(s):Andrew W. Bradbury, MD, FRCSEd | |
METHODS FOR EVALUATING FOOT PERFUSION | |
4:10 PM - 4:15 PM | Foot Perfusion Measurements Are The Best Method To Evaluate Treatment Effectiveness For CLTI: What Methods Are Available And Best |
Presenter(s):Werner Lang, MD | |
4:16 PM - 4:21 PM | How And Why To Measure Foot Perfusion During And After Endo Treatments: Hyperspectral Imaging, O2 Sensors, Etc.: When Is The Angiosome Concept Helpful; When Not |
Presenter(s):Marianne Brodmann, MD | |
4:22 PM - 4:27 PM | New Methods For Evaluating The Significance Of Lower Extremity Arterial Lesions And Foot Perfusion Using Fractional Flow Reserve (FFR) And MRI; How They Work And Their Value In Assessing Therapeutic Success |
Presenter(s):Bijan Modarai, PhD, FRCS | |
4:28 PM - 4:35 PM | Panel Discussion |
END OF SESSION 29 | |
SESSION 30 SCHEDULE | |
Wednesday
SESSION 30:
NEW DEVELOPMENTS IN THE TREATMENT OF INTERMITTENT CLAUDICATION (IC) AND ACUTE LIMB ISCHEMIA (ALI)
|
|
x | |
INTERMITTENT CLAUDICATION (IC) | |
4:36 PM - 4:41 PM | At 2 Years After Endovascular Interventions For IC, Only 32% Of Patients Were Free From Recurrent IC: From A VQI Multicenter Study: What Are The Implications |
Presenter(s):Peter F. Lawrence, MD | |
4:42 PM - 4:47 PM | Decreasing Unnecessary And Potentially Harmful Endovascular Procedures In Patients With IC Which Are Almost Never Justified And Should Not Be Reimbursed |
Presenter(s):Caitlin W. Hicks, MD, MS | |
4:48 PM - 4:53 PM | Under What Circumstances Could Tibial Endo Interventions Possibly Be Justified For IC |
Presenter(s):Sahil A. Parikh, MD | |
4:54 PM - 4:59 PM | When Do Outcomes For Lower Extremity Revascularization Justify Their Use For IC In Patients >80 And >90 |
Presenter(s):Jeffrey J. Siracuse, MD, MBA, FACS | |
5:00 PM - 5:04 PM | Panel Discussion |
ACUTE LIMB ISCHEMIA (ALI) (SEE ALSO SESSION 63) | |
5:04 PM - 5:09 PM | When And Why Is ALI Best Treated By Open Surgery: When Are Endovascular Treatments Best |
Presenter(s):Peter Henke, MD | |
5:10 PM - 5:15 PM | The PROMOTE-ALI Study Shows That Open Surgery Is Still Number One In The Treatment Of ALI |
Presenter(s):Katariina M. Noronen, MD | |
5:16 PM - 5:21 PM | DEBATE: ALI Is Always Best Treated Endovascularly: Why And What Techniques May Be Required |
Presenter(s):Ali Amin, MD, RVT, FACS, FACC | |
5:22 PM - 5:27 PM | DEBATE: When Is Open Surgery Required To Treat ALI: When Is Mechanical Thrombectomy And Thrombo-Aspiration The Best Treatment: When Should Lytics Be Used: Based On A Systematic Review And Meta-Analysis |
Presenter(s):Yann Gouëffic, MD, PhD | |
5:28 PM - 5:33 PM | Characteristics Of All The Commercial Systems For Mechanically Removing Clot To Treat ALI: What Are The Advantages And Disadvantages Of Each |
Presenter(s):Jos C. van den Berg, MD, PhD | |
5:34 PM - 5:39 PM | What Is New With Penumbra Indigo Clot Aspiration Systems: Improved Mechanical Catheter And Computer Based Clot Removal Indigo Systems: Modulated Pulsed Aspiration Technology (Lightning Bolt And Thunder Bolt) For The Treatment Of Acute Arterial Clot: How It Works And Why It Improves Clot Removal In Various Vascular Beds: Is Open Surgery Ever Needed |
Presenter(s):James F. Benenati, MD | |
5:40 PM - 5:45 PM | New Findings From The STRIDE Multicenter Trial: Mechanical Suction Thrombectomy With The Indigo Aspiration System (Penumbra) Had Few Complications And Excellent Limb Salvage: When Was It Contraindicated And When Was Angioplasty, Stenting Or Bypass Necessary |
Presenter(s):Thomas S. Maldonado, MD | |
5:46 PM - 5:51 PM | Endovascular Mechanical Thrombectomy Is Obviating The Need For Thrombolytics In ALI: What Devices Are Available And What Are Their Advantages And Limitations |
Presenter(s):Patrick E. Muck, MD, FACS | |
5:52 PM - 5:57 PM | Time To Perfusion In ALI: Which Is Faster, Lightning Bolt 7 (Penumbra) Or Open Surgical Embolectomy: When Is Open Surgery Necessary In 2024 |
Presenter(s):Sean P. Lyden, MD | |
5:58 PM - 6:05 PM | Panel Discussion End of Program D |
END OF SESSION 30 | |
SESSION 31 SCHEDULE | |
Wednesday
SESSION 31:
ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND RIVAROXABAN
Moderators:Caron B. Rockman, MD / Michael R. Jaff, DO
|
|
x | |
6:40 AM - 6:45 AM | Postop Myocardial Infarctions (MIs) In Vascular Patients: What Are The New Options For Diagnosis, Prevention And Treatment |
Presenter(s):Peter Henke, MD | |
6:46 AM - 6:51 AM | What Is The Best Current Method For Evaluating The Heart In Patients Undergoing Open And Endo Vascular Surgery: When Is A Stress Test An Important Tool |
Presenter(s):David H. Stone, MD | |
6:52 AM - 6:57 AM | New Findings From The VOYAGER PAD And COMPASS RCTs With Low Dose Rivaroxaban (Xarelto [Janssen/J&J]) And Aspirin: How Do These Drugs Lower Major Adverse Limb And Cardiac Event Rates After Lower Extremity Revascularization (Endo And Open) |
Presenter(s):Marianne Brodmann, MD / Sebastian E. Debus, MD, PhD | |
6:58 AM - 7:03 AM | How Does The Morbidity And Pathology Of Adverse Events With Arteriosclerosis Depend On Thrombosis: This Explains The Benefits Of Rivaroxaban And Aspirin Seen In The VOYAGER And COMPASS Trials |
Presenter(s):Anthony J. Comerota, MD, FACS, FACC | |
7:04 AM - 7:09 AM | DEBATE: LDL Cholesterol (LDL-C) Lowering And Statins For Prophylaxis Of Vascular Events Are Dangerous And Not Helpful: What Does The Latest Evidence Show |
Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC, PhD, FACS | |
7:10 AM - 7:15 AM | DEBATE: Not So: Update On LDL-C Lowering With Statins And Other Drugs: They Are Proven To Stabilize And Shrink Plaques And Decrease Morbid Vascular Events: Stopping Statins Increases Patients’ Risk Of MI And Death |
Presenter(s):Ron Waksman, MD | |
7:16 AM - 7:21 AM | The Risk Of Arteriosclerosis And Its Complications Are Increased By LDL Cholesterol (LDL-C) Levels, Elevated Lp(a) And Inflammation: What Are The Best Medical Strategies To Decrease These Parameters: Statins, Adjunctive LDL-C Lowering Drugs Inclisiran, Bempedoic Acid, Ezetimibe, PCSK-9 Inhibitors, Lepodisiran, Colchicine, Olezarsen, Etc.) And Anti-Inflammatories: How They Should Be Administered |
Presenter(s):Richard Bulbulia, MA, MD, FRCS | |
7:22 AM - 7:27 AM | Update On LDL-C Lowering During A Lifetime: How Low To Strive For With Intensive Drug Therapy: How Young To Start If High; How Old To Continue Statins: Why And How Often Should LDL-C Levels Be Measured |
Presenter(s):J. David Spence, MD | |
7:28 AM - 7:33 AM | An Interesting New Anti-Atherosclerosis Vaccine (AtheroVax): A Drug To Produce Lifelong LDL-C Lowering With A Single Gene Modifying Treatment: The Heart-1 Gene-Editing Trial: How Does AtheroVax Work |
Presenter(s):Nicholas Kipshidze, MD, PhD, DSc | |
7:34 AM - 7:42 AM | Panel Discussion |
END OF SESSION 31 | |
SESSION 32 SCHEDULE | |
Wednesday
SESSION 32:
CATHETER BASED TREATMENTS FOR RESISTANT HYPERTENSION; MANAGEMENT OF CARDIAC PROBLEMS, CORONARY DESs, SMOKING AND TRANSFUSION IN VASCULAR SURGERY PATIENTS; PREVENTING VASCULAR AND CARDIAC COMPLICATIONS
Moderators:Ron Waksman, MD / Lindsay Machan, MD
|
|
x | |
UPDATE ON RENAL DENERVATION FOR HYPERTENSION | |
7:42 AM - 7:47 AM | Renal Denervation For Resistant Hypertension Really Works As Shown By RCTs: What Are The Techniques And Devices: When Should They Be Used |
Presenter(s):Eric A. Secemsky, MD, MSc | |
7:48 AM - 7:53 AM | The Role Of Pressure Wires And IVUS In The Assessment Of Renal Artery Stenosis In The Treatment Of Hypertension And Other Conditions |
Presenter(s):Lindsay Machan, MD | |
7:54 AM - 7:59 AM | How And Why Do Thoracic Endografts For TEVAR Negatively Affect The Blood Pressure And The Heart: Can A Compliant Endograft Prevent The Problem: Does This Problem Arise With EVARs |
Presenter(s):Juan C. Parodi, MD | |
OTHER TOPICS RELATED TO VASCULAR DISEASE AND ITS TREATMENT | |
8:00 AM - 8:05 AM | When And To What Level Can Postoperative Anemia Be Tolerated After Major Vascular Surgery: When Should It Be Corrected By Transfusion And Do Cardiac Comorbidities Make A Difference |
Presenter(s):Panos Kougias, MD, MSc | |
8:06 AM - 8:11 AM | New Developments In Methods To Prevent Kidney Damage From Iodinated Contrast Agents |
Presenter(s):Roxana Mehran, MD | |
8:12 AM - 8:17 AM | How Important Is Inflammation As Determined By C-Reactive Protein (CRP) Levels In Predicting Adverse Cardiac Events: What Drugs Can Lower This Risk |
Presenter(s):Ron Waksman, MD | |
8:18 AM - 8:23 AM | When Should Smoking Be Stopped Before AAA Repair; Before Lower Extremity Bypass: At Least 4 Weeks: Why Does The Duration Of Cessation Matter |
Presenter(s):Jeffrey J. Siracuse, MD, MBA, FACS | |
8:24 AM - 8:29 AM | In Patients Undergoing Carotid Endarterectomy (CEA), What Should Best Medical Therapy (BMT) Be: Should Clopidogrel Be Part Of This BMT And Should It Be Continued During The Perioperative Period |
Presenter(s):Timothy M. Sullivan, MD | |
8:30 AM - 8:35 AM | How To Manage Patients With Recent Coronary DESs Who Require Vascular Operations Or Interventions: What To Do About Antiplatelet Medications: How Long To Wait Before Stopping Safely: What To Do With Urgent Or Emergent Cases To Avoid DES Thrombosis |
Presenter(s):Caron B. Rockman, MD | |
8:36 AM - 8:42 AM | Panel Discussion |
8:42 AM - 8:54 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 32 | |
SESSION 33 SCHEDULE | |
Wednesday
SESSION 33:
PROGRESS IN MANAGING ENDOLEAKS: UNDERSTANDING THEIR CONSEQUENCES AND PREDICTING, PREVENTING AND TREATING THEM (FOR IMPORTANT RELATED TALKS SEE SESSION 33 IN OUR 2023 PROGRAM ON OUR WEBSITE VEITHsymposium.org)
|
|
x | |
ALL ENDOLEAKS AFTER EVAR | |
8:54 AM - 8:59 AM | Update On The Optimal Management Of Endoleaks: Key Points From A Systematic Review |
Presenter(s):Bernardo C. Mendes, MD | |
9:00 AM - 9:05 AM | Dynamic CT Scanning – The Gold Standard For Evaluating Endoleaks: Technical Requirements And How To Make It Help In Diagnosis And Treatment |
Presenter(s):Alan B. Lumsden, MD, FACS | |
9:06 AM - 9:11 AM | How To Improve Endoleak Detection And Finding Its Source With Contrast Enhanced Sonography |
Presenter(s):Thanila A. Macedo, MD | |
TYPE 1 ENDOLEAKS | |
9:12 AM - 9:17 AM | Major Systemic Trauma Can Lead To High-Flow (Type 1) Endoleaks In EVAR Patients: Can They Occur With Endografts Fixed By Hooks Or Barbs And What Is The Best Treatment |
Presenter(s):Carlo Setacci, MD | |
9:18 AM - 9:23 AM | Update On Embolization Treatment For Type 1 Endoleaks After EVAR: Indications And Technical Tips To Make It Work Successfully: Contraindications |
Presenter(s):Robert A. Morgan, MD | |
9:24 AM - 9:29 AM | How Can Type I Endoleaks Cause Sac Pressurization (Endotension) Without Contrast Visualization: How To Detect And Treat It: What Else Can Cause Endotension |
Presenter(s):Kenneth Ouriel, MD, MBA | |
9:30 AM - 9:35 AM | How To Treat Type 1 Endoleaks After EVAR: When Cuff, When F/EVAR, When Chimney, When Open Conversion: What About Embolization |
Presenter(s):Matteo Orrico, MD / Nicola Mangialardi, MD | |
9:36 AM - 9:41 AM | Panel Discussion |
TYPE 2 ENDOLEAKS AFTER EVAR | |
9:41 AM - 9:46 AM | Most Type 2 Endoleaks After EVAR Should Be Left Alone Because Treatments Have Poor Results, Have Complications And Do Not Improve Outcomes: What Are The Exceptions |
Presenter(s):Hence J.M. Verhagen, MD, PhD | |
9:47 AM - 9:52 AM | When Should We Reintervene And Keep Reintervening For Persistent Type 2 Endoleaks: What Factors With Persistent Type 2 Endoleaks Are Predictors Of AAA Rupture |
Presenter(s):Naoki Fujimura, MD, PhD | |
9:53 AM - 9:58 AM | When Do Type II Endoleaks Cause Type I Endoleaks After Standard EVAR: How To Best Diagnose And Treat Them: Does One Need Proximal Aortic Control If Treatment Is Open Conversion |
Presenter(s):Randall R. De Martino, MD | |
9:59 AM - 10:04 AM | The Role Of Mural Thrombus In The Development Of Late Type II Endoleaks: How Best To Prevent Them And Treat Them |
Presenter(s):Natzi Sakalihasan, MD, PhD | |
10:05 AM - 10:10 AM | Patients On Anticoagulation Are More Likely To Develop Endoleaks After EVAR: How Does It Influence The Outcome Of Endoleak Treatment And Should It Be Stopped If Possible |
Presenter(s):Faisal Aziz, MD | |
10:11 AM - 10:16 AM | How Can 3D Fusion And ASSIST Guidance (GE) Help In Type 2 Endoleak Treatment By Any Approach: How To Do It |
Presenter(s):Mark W. Mewissen, MD, FSIR, RVT | |
10:17 AM - 10:22 AM | Panel Discussion |
10:23 AM - 10:28 AM | Transcaval Approach For Endoleak Embolization: A Minimally Invasive Hot Needle Approach And Other Technical Tips Including How To Close The Aortic Access Site |
Presenter(s):Sean P. Lyden, MD | |
10:29 AM - 10:34 AM | Transgraft Treatment Of Type 2 Endoleaks After EVAR: When And How To Do It |
Presenter(s):James F. McKinsey, MD | |
10:35 AM - 10:40 AM | The Latest Advances In The Treatment Of Type 2 Endoleaks: A New Technique With The Taurus Device Will Be Better: What Is It And Results |
Presenter(s):Zvonimir Krajcer, MD, FACC | |
10:41 AM - 10:46 AM | Innovative Type 2 Endoleak Obliteration Via Collateral Networks: Technical Tips |
Presenter(s):Palma M. Shaw, MD, MBA, FACS, RPVI, DFSVS | |
10:47 AM - 10:55 AM | An Algorithm For Diagnosing And Treating Challenging Endoleaks After F/B/EVAR For TAAAs |
Presenter(s):Thomas F. Lindsay, MDCM, FRCS | |
10:56 AM - 11:00 AM | Panel Discussion |
END OF SESSION 33 | |
SESSION 34 SCHEDULE | |
Wednesday
SESSION 34:
ISSUES IMPORTANT TO VASCULAR SURGEONS/SPECIALISTS
Moderators:Kim J. Hodgson, MD / Thomas L. Forbes, MD
|
|
x | |
11:00 AM - 11:05 AM | A Tribute To James S. T. Yao, MD, PhD (1932-2023) |
Presenter(s):Jon S. Matsumura, MD | |
11:06 AM - 11:11 AM | How Human Behavior – Even With Vascular Surgeons/Specialists – Is Controlled By Biases And Rationalizations: How To Overcome These And Perform Better |
Presenter(s):Scott L. Stevens, MD | |
ISSUES RE EVIDENCE BASED PRACTICE | |
11:12 AM - 11:17 AM | RCTs Are Too Often Underpowered With Other Serious Flaws: So They Are Misused As Evidence, Negatively Influencing Practice And Innovation In Health Care |
Presenter(s):Frans L. Moll, MD, PhD | |
11:18 AM - 11:23 AM | Why Systematic Reviews, Meta-Analyses And RCTs Can Be Misleading: What To Do About It: Does Current Wisdom Help |
Presenter(s):Janet T. Powell, MD, PhD | |
11:24 AM - 11:29 AM | Answering The Current Big Questions: Vascular Surgeons/Specialists Need To Develop High Quality Evidence To Improve Care: How And Why To Do It |
Presenter(s):Jens Eldrup-Jorgensen, MD | |
ISSUES IMPORTANT TO VASCULAR SURGEONS/SPECIALISTS | |
11:30 AM - 11:35 AM | How Can Vascular Surgeons/Specialists Become Successful Entrepreneurs: What To Do And What Not To Do |
Presenter(s):Jeffrey H. Lawson, MD, PhD | |
11:36 AM - 11:41 AM | The Distracted Surgeon: Lessons Learned From Running Multiple Rooms: Is It Really More Efficient Or A Bad Practice Resulting In Poor Patient Care |
Presenter(s):Patrick A. Stone, MD | |
ISSUES IN VASCULAR TRAINING | |
11:42 AM - 11:47 AM | Optimal New Training Paradigm For Vascular Surgeons: 0+5 Vascular Surgery Residency Followed By 2 Years Of Cardiac Surgery Residency Training: Why Is It Better Than 2 Extra Years Of Laboratory Research |
Presenter(s):Alan B. Lumsden, MD, FACS | |
11:48 AM - 11:53 AM | Obtaining Cardiac Surgery Training After Vascular Surgery Training: I Did It, So It’s Possible: Is It Worthwhile: Advantages And Disadvantages |
Presenter(s):Jennifer L. Perri, MD, MBA | |
11:54 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 34 | |
SESSION 35 SCHEDULE | |
Wednesday
SESSION 35:
RECORDED LIVE CHALLENGING CASES AND INNOVATIVE TECHNIQUES FROM THE PLINIO ROSSI AND LINC COMPONENTS
|
|
x | |
THE PLINIO ROSSI COMPONENT | |
1:00 PM - 1:08 PM | DES Versus DCB+BMS Versus BMS+DCB Versus DCB+DES: The Winner Is: Evaluation Of The Different Treatment Strategies With A Focus On The Now Increasingly Common Combination Of DCB Plus BMS |
Presenter(s):Fabrizio Fanelli, MD, EBIR | |
1:08 PM - 1:16 PM | Uterine Transplantation and Pregnancy: A Star in the Sky |
Presenter(s):Pierfrancesco Veroux, MD | |
1:16 PM - 1:24 PM | The Knickerbocker Technique – an Underutilized and Highly Effective Strategy for False Lumen Management in Chronic Aortic Dissection |
Presenter(s):Andrew Holden, MBChB | |
1:25 PM - 1:30 PM | Panel Discussion |
THE LINC COMPONENT | |
Moderator(s): Dierk Scheinert, MD / Andrej Schmidt, MD / Daniela Branzan, MD | |
1:30 PM - 1:59 PM | PROGRAM TO BE DETERMINED |
END OF SESSION 35 | |
SESSION 36 SCHEDULE | |
Wednesday
SESSION 36:
MORE ISSUES IMPORTANT IN VASCULAR SURGERY: HISTORY, PRACTICE PATTERNS, VALUE OF GUIDELINES AND RCTs, MALPRACTICE, SCIENCE, TRAINING AND HUMAN BEHAVIOR
|
|
x | |
2:00 PM - 2:05 PM Power Point Presentation with Synched Audio |
A Tribute To Hans-Henning Eckstein, MD, PhD (1955-2024) |
Presenter(s):Sebastian E. Debus, MD, PhD | |
VASCULAR HISTORY | |
2:06 PM - 2:11 PM | Einstein And Nissen: A New York Story About An AAA Wrapped In Cellophane |
Presenter(s):Frank J. Criado, MD | |
2:12 PM - 2:17 PM | The SVS Digital History Archive: What Is It, Why It Is Important And Should Vascular Surgeons Contribute To It And Use It |
Presenter(s):Jerry Goldstone, MD, FACS, FRCSEd | |
2:18 PM - 2:23 PM | Multispecialty Vascular Care Departments Or Units Within Institutions Are Best For Patients And Physicians: How Should The Dominant Specialty And Leader Be Chosen: How Should Rewards Be Distributed |
Presenter(s):Barry T. Katzen, MD | |
VASCULAR SURGERY’S ROLE AND RECOGNITION | |
2:24 PM - 2:29 PM | Vascular Surgery's Identity And Role Is Usually In A Subservient Position Within A Heart And Vascular Unit: What Should Be Done To Correct This Inequity In The Interest Of Better Patient Care |
Presenter(s):Timur P. Sarac, MD | |
2:30 PM - 2:35 PM | Vascular Surgery Needs An Independent ABMS Approved Board And Associated RRC To Thrive As A Specialty In The Medical Hierarchy And To Have Its Value Appropriately Recognized |
Presenter(s):Sean P. Lyden, MD | |
2:36 PM - 2:41 PM | The Negative Impact Of Hospital Administrators On Vascular Surgery And Vascular Surgeons' Careers: Why Is It Happening, Why Is It Worse For Vascular Surgeons Than Other Specialists And What Can Be Done To Counteract It |
Presenter(s):Samuel R. Money, MD, MBA | |
2:42 PM - 2:47 PM | The Role Of Women In Vascular Surgery: What Has It Been And Where Is It Going |
Presenter(s):Cynthia K. Shortell, MD | |
2:48 PM - 2:56 PM | Panel Discussion |
ISSUES RE THE CONFLICT BETWEEN ETHICS AND FINANCES | |
2:56 PM - 3:01 PM | Simultaneous Overuse And Undertreatment Of Patients With PAD And CLTI: Why The Problem Exists And What Should Be Done To Fix It |
Presenter(s):Joseph L. Mills, MD | |
3:02 PM - 3:07 PM | Physician And Industry Responsibility In Overuse Of Technology (Atherectomy, CAS, EVAR, Etc.): Especially Important In View Of The Recent Media Spotlight On This Issue |
Presenter(s):Murray L. Shames, MD | |
UNIONIZATION FOR VASCULAR SURGEONS | |
3:08 PM - 3:13 PM | Why Vascular Surgeons Should Unionize: The Pros And Cons |
Presenter(s):Enrico Ascher, MD | |
3:14 PM - 3:19 PM | Racial And Ethnic Disparities In Clinical Trials And The Treatment Of CLTI: What Are The Causes And What Can Be Done About Them |
Presenter(s):Vincent L. Rowe, MD | |
3:20 PM - 3:32 PM | Panel Discussion And Break Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 36 | |
SESSION 37 SCHEDULE | |
Wednesday
SESSION 37:
MORE ISSUE-RELATED TOPICS IMPORTANT TO VASCULAR SURGEONS AND VASCULAR SPECIALISTS; ISSUES RELATED TO OUTPATIENT CENTERS OR OFFICE BASED LABS (OBLs)
|
|
x | |
3:32 PM - 3:37 PM | Vascular Spinoff Revenue In Tertiary Healthcare Systems: Substantially More Downstream Benefits FROM Vascular Surgeons: How To Make Hospital Administrators Appreciate The Value Of Vascular Surgeons And Reward Them Appropriately |
Presenter(s):Joseph V. Lombardi, MD, MBA | |
3:38 PM - 3:43 PM | The Significant Burden Of Iatrogenic Vascular Injury On The Vascular Surgery Workforce At A Tertiary Care Center: What Can And Should Be Done To Offset This Problem |
Presenter(s):Caron B. Rockman, MD | |
3:44 PM - 3:49 PM | Current Medicare Reimbursement For Complex AAAs (F/B/EVAR) Is Inadequate For Physicians And Less Profitable For Hospitals: How Does It Harm Vascular Surgery |
Presenter(s):Samuel R. Money, MD, MBA | |
3:50 PM - 3:55 PM | How And Why Aortic And Lower Extremity Artery Gender Differences Matter In The Treatment Of Vascular Disease: What Can Be Done To Offset This Problem |
Presenter(s):Linda M. Harris, MD | |
3:56 PM - 4:01 PM | The Value Of Telehealth In Vascular Surgery: Reimbursement Issues And When Is It Misleading |
Presenter(s):Misty D. Humphries, MD, MAS | |
ISSUES RELATED TO OUTPATIENT CENTERS AND OBLs | |
4:02 PM - 4:07 PM | The Ever-Changing Reimbursement For Lower Extremity Endovascular Therapies In Hospitals And OBLs: Why It’s Happening And Where Is It Going |
Presenter(s):Sean P. Roddy, MD / Robert M. Zwolak, MD, PhD | |
4:08 PM - 4:13 PM | Limb Preservation Centers: Benefit To Patients, Physicians And Health Care Systems: How To Create One |
Presenter(s):Krishna Jain, MD | |
4:14 PM - 4:19 PM | How Can OBLs Provide Good Vascular Care With Excellent Results, Be Profitable And Still Allow Vascular Surgeons To Only Work From 8 AM To 5 PM |
Presenter(s):Mark A. Mattos, MD | |
4:20 PM - 4:25 PM | How To Make Outpatient Vascular Treatment Facilities (OBLs, ASCs) Safe, Effective And Profitable Without Doing Unjustified Procedures: How Can They Make Uniquely Important Vascular Research Contributions |
Presenter(s):Christopher J. Kwolek, MD, MBA / Enrico Ascher, MD | |
4:26 PM - 4:32 PM | Panel Discussion |
END OF SESSION 37 | |
SESSION 38 SCHEDULE | |
Wednesday
SESSION 38:
UPDATES AND ISSUES IMPORTANT TO ALL VASCULAR SURGEONS AND SPECIALISTS: FUTURE REIMBURSEMENT; IMPROVING VASCULAR CARE QUALITY; FIXING FALSE TESTIMONY; FLAWED PEER REVIEW; FDA IMPROVEMENTS; LEARNING HEALTH SYSTEMS
|
|
x | |
VASCULAR REIMBURSEMENT ISSUES | |
4:32 PM - 4:37 PM | What’s Happening With Vascular Surgeon Reimbursement In 2024 And What Are The Prospects For 2025: For Hospital And OBL Procedures |
Presenter(s):Sean P. Roddy, MD | |
4:38 PM - 4:43 PM | Current Medicare Reimbursement For Ch/EVAR And F/EVAR Is Inadequate: The Situation Is Untenable: How Did We Get There And Can The Problem Be Fixed |
Presenter(s):Clayton J. Brinster, MD | |
4:44 PM - 4:49 PM | Reimbursement For Vascular Procedures Under CMS Is Deeply Flawed And Subject To The Bias Of Others: It Results In Unethical Compensatory Behavior: What Can Be Done About It |
Presenter(s):Sean P. Roddy, MD | |
ISSUES RE QUALITY OF VASCULAR CARE | |
4:50 PM - 4:55 PM | New Developments In And Benefits From VQI Participation: It Will Make For Better Doctors And Vascular Care And It Will Cut Hospital Costs |
Presenter(s):Jens Eldrup-Jorgensen, MD | |
4:56 PM - 5:01 PM | The SVS/ACS Vascular Verification Program (VVP) To Assure Quality Vascular Care In Inpatient And Outpatient Programs: What Is It And How Will It Help Vascular Surgery |
Presenter(s):Anton N. Sidawy, MD, MPH | |
5:02 PM - 5:07 PM | How Can The Insurance Industry Improve The Quality And Appropriateness Of Vascular Care And Help Vascular Surgery Survive In A Competitive World |
Presenter(s):Russell H. Samson, MD, DFSVS, RVT, FACS | |
PUNISHING FALSE TESTIMONY | |
5:08 PM - 5:13 PM | How Do We Hold Physicians Who Provide False Or Misleading Testimony Against Vascular Surgeons Accountable: Has The SVS Committee On This Topic Ever Done Anything To Do What Should Be Done |
Presenter(s):O. William Brown, MD, JD | |
5:14 PM - 5:20 PM | Panel Discussion |
PEER REVIEW RELATED ISSUES | |
5:20 PM - 5:25 PM | Our System Of Peer Reviews Is Flawed: Within Hospitals; Within Journal Reviews: How Might Artificial Intelligence (AI) Improve Them |
Presenter(s):Timothy M. Sullivan, MD | |
5:26 PM - 5:34 PM | What Is An Impact Factor For A Peer Reviewed Journal Or An Article: What Is Plum X And H-Index: How Are They Calculated And Why Are They Important: What Constitutes Plagiarism – It’s Not Simple (8-Minute Presentation) |
Presenter(s):Peter F. Lawrence, MD / Peter Gloviczki, MD | |
FDA RELATED ISSUES | |
5:35 PM - 5:40 PM | I Was From The Government And I'm Here To Help: FDA Resources To Assure Safe And Effective Medical Devices In Vascular Disease: What Is The LEAF Initiative To Assure That Trials Are Appropriate For FDA Approval |
Presenter(s):Robert E. Lee, MD / Philip P. Goodney, MD, MS | |
5:41 PM - 5:46 PM | Why Do IDEs Fail To Get FDA Approval: Updates To The FDA 510 (K) Program And Why They Are Important |
Presenter(s):Valerie M. Merkle, PhD | |
5:47 PM - 5:52 PM | Different Perspectives From Industry And The FDA Regarding The Importance Of Innovation, Engineering And Financial Rewards That Influence Innovation |
Presenter(s):Dorothy B. Abel, BSBME | |
5:53 PM - 5:58 PM | What Is A Learning Health System And Why Should It Matter To Vascular Surgery |
Presenter(s):Charles C. Miller, PhD | |
5:59 PM - 6:05 PM | Panel Discussion End of Program E |
END OF SESSION 38 | |
SESSION 39 SCHEDULE | |
Wednesday
SESSION 39:
MORE TOPICS RELATED TO THE THORACIC AORTA, AORTIC DISSECTIONS, INFLAMMATORY ANEURYSMS AND THEIR TREATMENT
Moderators:Ramon Berguer, MD, PhD / Timothy A. Resch, MD, PhD
|
|
x | |
6:50 AM - 6:55 AM | A Novel Low Profile Stent Graft For The Treatment Of All Thoracic Aortic Segments: What Makes It Unique And Clinical Status |
Presenter(s):Francesco Setacci, MD | |
6:56 AM - 7:01 AM | Options For Left Subclavian Revascularization During TEVAR: Laser Fenestration, Open Bypass, Single Branch Device (Gore), Etc.: Advantages And Limitations Of Each |
Presenter(s):Timothy A. Resch, MD, PhD | |
7:02 AM - 7:07 AM | Challenges And Successes With Endografts In The Treatment Of Ascending Aortic Dissections (TAADs), Penetrating Ulcers And Pseudoaneurysms |
Presenter(s):Rodney A. White, MD | |
7:08 AM - 7:13 AM | DEBATE: The STABILISE Technique To Eliminate The False Lumen And Relaminate The Aorta Will Change The Treatment Of Acute And Subacute TBADs And Will Replace Most False Lumen Occlusion Devices And F/B/EVAR Treatments: How To Do It And Precautions |
Presenter(s):Igor A. Laskowski, MD, PhD / Heepeel Chang, MD | |
7:14 AM - 7:19 AM | DEBATE: Not So Fast! A Multimodular Approach To Treating Acute, Subacute And Chronic TBADs With TAAAs: Who Needs A F/B/EVAR; Who Needs A Candy-Plug Or Other Techniques |
Presenter(s):Tilo Koelbel, MD, PhD / Fiona Rohlffs, MD, PhD | |
7:20 AM - 7:25 AM | Outer/Inner/Upward Branches Or Fenestrations: Strategies For Complex Aortic Repair For Patients With Chronic TBADs: Advantages And Limitations Of Each |
Presenter(s):Bijan Modarai, PhD, FRCS | |
7:26 AM - 7:31 AM | Current Advances In The Treatment For Inflammatory Aneurysms: How Effective Are EVAR And TEVAR |
Presenter(s):Furuzan Numan, MD | |
7:32 AM - 7:37 AM | Update On The Experience With BeGrafts (From Bentley), A Balloon Expandable Covered Stent For Treating Aortic Coarctations, Aneurysms And Midaortic Syndrome: Advantages And Limitations |
Presenter(s):Elchanan Bruckheimer, MBBS | |
7:38 AM - 7:43 AM | Relay Custom Made Endografts (Terumo) For TEVAR, Scalloped, Etc.: When And Why Are They Advantageous And Do They Still Have A Role In View Of Other New Endografts |
Presenter(s):Michael P. Jenkins, MBBS, BSc, MS, FRCS, FEBVS / Mo S. Hamady, MD, FRCR, EBIR, FSIR | |
7:44 AM - 7:51 AM | Panel Discussion |
END OF SESSION 39 | |
SESSION 40 SCHEDULE | |
Wednesday
SESSION 40:
MORE ADVANCES RELATED TO TREATING PATHOLOGY INVOLVING THE ASCENDING AORTA AND THE AORTIC ARCH; AORTIC DISSECTIONS, INTRAMURAL HEMATOMAS (IMHs) AND THEIR TREATMENT
Moderators:Rodney A. White, MD / Tilo Koelbel, MD, PhD
|
|
x | |
7:52 AM - 7:57 AM | Debranching Aortic Arch Branches: When And How To Do It; Technical Tips And How To Avoid Pitfalls |
Presenter(s):Bernardo C. Mendes, MD | |
7:58 AM - 8:03 AM | With TAADs When And How Should The Distal Aorta Be Treated By TEVAR Before Repair Of The Ascending Aorta |
Presenter(s):Ourania Preventza, MD / Joseph S. Coselli, MD | |
8:04 AM - 8:09 AM | With TAADs Why And When Should TEVAR Of The Descending Thoracic Aorta Be Performed Prior To Open Type A Repair: Should The Procedures Be Staged |
Presenter(s):Mazin Foteh, MD | |
8:10 AM - 8:15 AM | Late Results Of Patients With TAADs Treated By Open Repair Of The Ascending Aorta And Arch With A FET And Completed By The STABILISE Technique Distally |
Presenter(s):Jean-Marc Alsac, MD, PhD | |
8:16 AM - 8:21 AM | With Chronic TBADs Laser Assisted Resection Of The Dissection Septum Or Membrane Creates A Single Lumen TEVAR Landing Zone: How Is This Technique Performed And Updated Results |
Presenter(s):Nuno V. Dias, MD, PhD / Bjõrn Sonesson, MD, PhD | |
8:22 AM - 8:27 AM | Panel Discussion |
8:27 AM - 8:32 AM | Updated Experience For Precise TEVAR Placement In Or Near The Arch By Valsalva And PEEP (Munich Valsalva Maneuver): It Is Safe And Effective And Better Than Adenosine, Rapid Pacing And Caval Occlusion: How To Do It And Results |
Presenter(s):Nikolaos Tsilimparis, MD, PhD | |
8:33 AM - 8:38 AM | Updated 5-Year Results From The European Experience With The Novel Nexus Single And Double (Duo) Branched (OTS) Endovascular Devices (From Endospan) For The Treatment Of Zone 0 And 1 Aortic Arch Aneurysms: What Makes This Device Unique |
Presenter(s):Mario L. Lachat, MD | |
8:39 AM - 8:44 AM | Status And Results From The US TRIOMPHE Trial Of The Endospan Nexus Endograft (OTS) For Treating Complex Aortic Arch Lesions Including Chronic Dissections |
Presenter(s):Ross Milner, MD | |
8:45 AM - 8:50 AM | In Situ Fenestration For Endovascular Repair Of Aortic Arch Lesions: Does It Reduce Perioperative Strokes And How To Avoid Cerebral Ischemia During The Procedure |
Presenter(s):Ralf R. Kolvenbach, MD | |
8:51 AM - 8:56 AM | Origins Of Intramural Hematomas (IMHs): Why So Many Prove Benign And Do Well With Medical Treatment: When And How To Treat Them With TEVAR |
Presenter(s):Frank J. Criado, MD | |
8:57 AM - 9:03 AM | Panel Discussion |
9:03 AM - 9:16 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 40 | |
SESSION 41 SCHEDULE | |
Wednesday
SESSION 41:
OPEN AND ENDO TREATMENT OF COMPLEX AAAs (JUXTA, PARA- AND SUPRA-RENAL) AND TAAAs; INTERESTING NEW DEVICES FOR THEIR TREATMENT
Moderators:Christopher J. Kwolek, MD, MBA / Gilbert R. Upchurch, MD
|
|
x | |
COMPLEX AAAs AND TAAAs | |
9:16 AM - 9:21 AM | Does Open Repair Still Remain The Gold Standard For Complex AAA Repair: What The Updated And Good Studies That Bear On This Question Show: It’s Not The Old RCTs (EVAR 1, DREAM And OVER) |
Presenter(s):George Geroulakos, MD, PhD | |
9:22 AM - 9:27 AM | TAAA Repairs For Aneurysms From Dissections And Degenerative Disease Are Best Treated By Combining Open And Endo Techniques: Technical Tips |
Presenter(s):Yamume Tshomba, MD | |
9:28 AM - 9:33 AM | Hybrid Repair Of A TAAA (Proximal Endograft + Distal Open Repair - The Upchurch Procedure): When Is It Indicated; What Are The Advantages And Updated Results |
Presenter(s):Gilbert R. Upchurch, MD / Sal Scali, MD / Dean Arnaoutakis, MD | |
9:34 AM - 9:39 AM | Endovascular Solutions To Effectively Deal With Hostile Neck Anatomy Of AAAs Other Than F/B/EVAR: Why They Should Be Favored |
Presenter(s):Stavros K. Kakkos, MD, PhD | |
9:40 AM - 9:45 AM | French National (Real World) Comparison Of Results Of F/EVAR And Open Repair (ORFEVAR Trial) For The Treatment Of Complex AAA (Juxtarenal, Suprarenal And Type IV TAAAs): Do We Need An RCT |
Presenter(s):Frederic Cochennec, MD, PhD | |
9:46 AM - 9:52 AM | Panel Discussion |
9:52 AM - 9:57 AM | Optimal Surveillance Methods And Timing After F/B/EVAR And EVAR |
Presenter(s):Sara L. Zettervall, MD | |
9:58 AM - 10:03 AM | Secondary Interventions Up To 30 Days Following F/B/EVAR Of Complex AAAs: How Morbid Are They |
Presenter(s):Jonathan R. Boyle, MD, MA (Cantab) FRCS | |
TOPICS RELATED TO INTERESTING NEW DEVICES | |
10:04 AM - 10:09 AM | Shape Memory Polymer Embolization Devices To Treat Gutter Endoleaks After Parallel Grafts: Technique And Results |
Presenter(s):James F. McKinsey, MD | |
10:10 AM - 10:15 AM | Update On The TAMBE Endograft Device (Gore) For Treating Complex AAAs And TAAAs: Current Configuration And Advantages, Technique For Insertion: Now Approved By The FDA |
Presenter(s):Carlos H. Timaran, MD | |
10:16 AM - 10:21 AM | Update On The WeFlow Device For Juxtarenal AAA, TAAA And Arch Repairs: A New Inner Branch And Outer Branch Approach: How Does It Work And Promising Results |
Presenter(s):Wei Guo, MD | |
10:22 AM - 10:27 AM | How To Prevent Patch Aneurysms After Open TAAA Repair With Long Antegrade Grafts: How To Treat Them When They Occur – Endo, Open |
Presenter(s):Manju Kalra, MBBS | |
10:28 AM - 10:33 AM | Use Of FORS Technology (Philips) In The Treatment Of TAAAs: Technical Tips In Its Use: What Are Its Advantages, Limitations And Disadvantages |
Presenter(s):Geert Willem H. Schurink, MD, PhD | |
10:34 AM - 10:40 AM | Panel Discussion |
END OF SESSION 41 | |
SESSION 42 SCHEDULE | |
Wednesday
SESSION 42:
PROGRESS IN TREATING ILIAC ANEURYSMS; ILIAC BRANCHED DEVICES (IBDs); UPDATE ON MULTILAYER FLOW MODULATING (MLFM) AND OTHER BARE STENTS FOR TREATING ANEURYSMS AND DISSECTIONS
|
|
x | |
TREATMENT OF ILIAC ANEURYSMS WITH IBDs OR PARALLEL GRAFTS | |
10:40 AM - 10:45 AM | 15-Year Experience With Iliac Branched Endografts For Aortoiliac Aneurysms: Advantages, Limitations: Long-Term Results Of The Various IBD Devices |
Presenter(s):Giovanni Pratesi, MD | |
10:46 AM - 10:51 AM | 5-Year Outcomes Of The ICEBERG Study Of The Gore IBD (IBE Device) For Revascularizing The Hypogastric Artery With Aortoiliac Aneurysms: Advantages And Limitations |
Presenter(s):Michel Reijnen, MD, PhD | |
10:52 AM - 10:57 AM | 5-Year Outcomes Of The Cook PRESERVE II Study Of The Cook IBD (ZBIS): Why Is It Different From Other IBD Devices: When Is It Contraindicated |
Presenter(s):W. Anthony Lee, MD | |
10:58 AM - 11:03 AM | Advantages And Current Status Of The Artivion IBD Device For Treating Common And Internal Iliac Artery Aneurysms: From The PLIANT II Multicenter Study: When Will This Device Be Available In The US |
Presenter(s):Lee Bouwman, Dr | |
11:04 AM - 11:09 AM | Parallel Endograft Techniques For Treating Common And Internal Iliac Artery Aneurysms: When And Why They Are Better Than IBDs And How To Make Them Work Effectively |
Presenter(s):Armando C. Lobato, MD, PhD | |
11:10 AM - 11:15 AM | Panel Discussion |
UPDATE ON MULTILAYER FLOW MODULATING (MLFM) AND OTHER BARE STENTS | |
11:16 AM - 11:21 AM | Why MLFM Bare Stents Should Be The Treatment Of Choice For Visceral, Peripheral And Iliac Aneurysms: Advantages And Has Rupture Been Universally Prevented: What About For TAAAs |
Presenter(s):Michel C. Henry, MD | |
11:22 AM - 11:27 AM | Treatment Of Aortic Dissections With Multilayer Bare Stents (MLFM) And 9 Years Of Follow Up: When Are They Effective And When Aren’t They |
Presenter(s):Victor S. Costache, MD, PhD / Ivo Petrov, MD, PhD | |
11:28 AM - 11:33 AM | Value Of Multilayer Bare Stents (MLFM – Allay From Intressa) In The Treatment Of TBAD Patients With Or At High Risk Of End Organ Malperfusion: Long-Term Results |
Presenter(s):Claude D. Vaislic, MD | |
11:34 AM - 11:39 AM Power Point Presentation with Synched Audio |
Role Of Bare Metal AMDS Stents From Artivion (Formerly Cryolife/Jotec) For Repair Of Acute Type A Dissections: Indications, Results And Limitations |
Presenter(s):Wilson Y. Szeto, MD | |
11:40 AM - 11:45 AM | Thoraflex Hybrid Graft Rescue When Treatment Of Aortic Dissection In The Arch With Bare Stents (AMDS From Artivion And Allay From Intressa) Fails: What Is The Mechanism Of Failure And What Is The Bailout Procedure |
Presenter(s):Mazin Foteh, MD | |
11:46 AM - 11:51 AM | Aortic Dissection In Pregnancy: Why Is The Mortality So High: Why Is Its Diagnosis Delayed: How Should Its Treatment Differ From Non-Pregnant Patients |
Presenter(s):Richard G.J. Gibbs, FRCS | |
11:52 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 42 | |
SESSION 43 SCHEDULE | |
Wednesday
SESSION 43:
MORE NEW DEVELOPMENTS IN AAA TREATMENT AND STANDARD EVAR: A NEW DEVICE TO SLOW AAA GROWTH; AAA NECK DILATATION AFTER EVAR; VALUE OF LOW PROFILE AAA ENDOGRAFTS; IMPROVED ULTRASOUND SURVEILLANCE AND ALL AAAs ARE NOT TIME BOMBS WAITING TO EXPLODE
Moderators:Michael L. Marin, MD / Stephan Haulon, MD
|
|
x | |
1:00 PM - 1:05 PM | Endovascular Strategies For Repairing Giant Hypogastric Artery Aneurysms (>6 cm): What Special Techniques Are Needed |
Presenter(s):Jacques Busquet, MD | |
1:06 PM - 1:11 PM | Debunking The Lingering Myths Of Asymmetrical Saccular Aneurysms: Are They All Ticking Time Bombs, How Should Their Diameter Be Measured – To Include The Normal Aorta Or Not: Do They Rupture At A Smaller Diameter |
Presenter(s):Frank J. Criado, MD | |
1:12 PM - 1:17 PM | A Direct Comparison Of Major Contemporary EVAR Devices – Looking At Long-Term Efficacy And Patient Survival Using Big Data And Linkage Techniques |
Presenter(s):Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed (ClinEpi) | |
1:18 PM - 1:23 PM | EVAR Patients On Anticoagulation Have Increased Mortality, Endoleaks, Sac Expansion And Reinterventions: From A Meta-Analysis Of >35,000 Patients |
Presenter(s):George A. Antoniou, MD, PhD, MSc, FEBVS | |
1:24 PM - 1:29 PM | Rapid Gate Cannulation During EVAR: A Technical Tip To Make It Quick And Easy |
Presenter(s):Felice Pecoraro, MD | |
1:30 PM - 1:35 PM | Panel Discussion |
1:36 PM - 1:41 PM | An RCT Shows The Advantages Of Inferior Mesenteric Artery (IMA) And Lumbar Embolization: The Next Generation Of EVAR Endografts Must Prevent Endoleaks: How Can It Be Done |
Presenter(s):Dominique Fabre, MD, PhD / Stephan Haulon, MD | |
1:42 PM - 1:47 PM | Value Of Preemptive Embolization Of AAA Side Branches (IMA And Lumbars) Prior To EVAR: Objective Evidence That It Prevents Sac Enlargement |
Presenter(s):Daniela Branzan, MD / Andrej Schmidt, MD | |
1:48 PM - 1:53 PM | How To Minimize Gutter Type 1A Endoleaks With Chimney EVAR (Ch/EVAR): How Does A Standard Protocol Help; How To Treat Them When They Occur |
Presenter(s):David J. Minion, MD | |
1:54 PM - 1:59 PM | DEBATE: Repairs Of Small AAAs (<5.5 cm) Are Justified By Many Evidence Based Reasons: What Are These Reasons And What Are The Downsides |
Presenter(s):Jessica P. Simons, MD, MPH | |
2:00 PM - 2:05 PM | DEBATE: There Is High Level Evidence That Men With AAAs <5.5 cm Should NOT Undergo Elective Repair: AAAs < 6 cm In Men Rarely Rupture: The Thresholds For Repair Of Aortic And Iliac Aneurysms Need To Be Raised |
Presenter(s):Anders Wanhainen, MD, PhD | |
2:06 PM - 2:11 PM | Panel Disccusion |
END OF SESSION 43 | |
SESSION 44 SCHEDULE | |
Wednesday
SESSION 44:
MORE NEW DEVELOPMENTS IN AAAs: WITH HERITABLE AORTIC DISEASE (CONNECTIVE TISSUE GENETIC DISORDERS): HOW DOES THROMBUS LOAD EFFECT PROGNOSIS AFTER EVAR; OTHER RELATED AAA TOPICS
Moderators:Evan C. Lipsitz, MD, MBA / James H... Black, III, MD
|
|
x | |
TREATMENT OF AORTIC ANEURYSMS WITH HERITABLE AORTIC DISEASE AND CONNECTIVE TISSUE DISORDERS | |
2:12 PM - 2:17 PM | In Patients With AAAs From Genetic Aortopathy (Heritable Aortic Disease): Is Active Exercise Beneficial Or Harmful |
Presenter(s):James H... Black, III, MD | |
2:18 PM - 2:23 PM | Results Of Endovascular Graft Aortic Repair In Mixed Connective Tissue Disease (Heritable Aortic Disease) Patients: Is It Time To Change The Guidelines: In What Circumstance Is Endovascular Repair Indicated |
Presenter(s):Sal Scali, MD | |
2:24 PM - 2:29 PM | Reasons To Change From Open To Endovascular Aortic Aneurysm Repair In Patients With Heritable Aortic Disease (Connective Tissue Disorders): When Is Open Repair Mandatory In This Setting; Technical Tips |
Presenter(s):Michael J. Jacobs, MD | |
2:30 PM - 2:35 PM | Value Of F/B/EVAR In The Management Of Failed Open Repairs Of Complex AAAs In Patients With Heritable Aortic Disease: Technical Tips |
Presenter(s):Barend M.E. Mees, MD, PhD, FEBVS / Geert Willem H. Schurink, MD, PhD / Michael J. Jacobs, MD | |
2:36 PM - 2:41 PM | Why Selection Of Bridging Stent-Graft Type Is Vitally Important For F/B/EVAR Treatment Of Complex AAAs In Patients With Heritable Aortic Disease: Which Stent-Graft Is Best |
Presenter(s):Gustavo S. Oderich, MD, FACS / Carlos H. Timaran, MD / Andres Schanzer, MD | |
THE EFFECT OF AAA SAC THROMBUS LOAD | |
2:42 PM - 2:47 PM | DEBATE: Large Flow Luminal Space In An AAA Sac With Minimal Mural Thrombus Is Associated With Adverse Events After EVAR: It Is More Important Than AAA Sac Size: Thrombus May Be Protective |
Presenter(s):Hence J.M. Verhagen, MD, PhD | |
2:48 PM - 2:53 PM | DEBATE: Large Amount Of AAA Sac Thrombus Promotes Morbidity Without Rupture And With Rupture: By What Mechanisms Is Thrombus Harmful And How Can Thrombus Load Be Quantitated |
Presenter(s):David H. Deaton, MD, FACS | |
2:54 PM - 2:59 PM | Update On Technical Tips To Perform SAFE Large Sheath Percutaneous Femoral Access And Closure For Complex AAA EVAR In Obese Or Scarred Groins – Even With Calcified Arteries: It Is Almost Always Possible |
Presenter(s):Barend M.E. Mees, MD, PhD, FEBVS | |
3:00 PM - 3:05 PM | Lessons Learned From The Nellix Experience: Why Sac Sealing Should Still Be Pursued For EVAR, But Not From The Nellix Platform: What Changes Would Make Sac Sealing Devices Work |
Presenter(s):Matt M. Thompson, MD | |
3:06 PM - 3:12 PM | Panel Discussion |
3:12 PM - 3:24 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 44 | |
SESSION 45 SCHEDULE | |
Wednesday
SESSION 45:
MORE HOT AORTIC TOPICS
Moderators:Timothy A.M. Chuter, MD / Peter Gloviczki, MD
|
|
x | |
3:24 PM - 3:29 PM | What's New And What's Wrong With The New SVS Guidelines For Aortic Surgery |
Presenter(s):Michael C. Stoner, MD | |
3:30 PM - 3:35 PM | Aorto-Enteric Fistulas Associated With Infected EVARs Or Open Prosthetic Grafts: What Are The Differences Between Them And What Are The Implications For Treatment |
Presenter(s):Sal Scali, MD | |
3:36 PM - 3:41 PM | Active AAA Sac Management With Polymer Plugs: How To Use Them To Improve Outcomes By Preventing Endoleaks After EVAR: Results From The SHAPE AAA Trial (From Shape Memory) |
Presenter(s):Andrew Holden, MBChB | |
3:42 PM - 3:47 PM | Fenestrated And Branched Graft Treatment Of Failed Open TAAA Repairs |
Presenter(s):Mazin Foteh, MD | |
3:48 PM - 3:53 PM | Aortic Dissection Tear Size And Morphology: Why Is It Important: How Do Bare Stents Prevent Stent-Graft Induced New Entry Tears (SINEs) After Treatment Of Aortic Dissections |
Presenter(s):Shang Loh, MD | |
3:54 PM - 3:59 PM | Panel Discussion |
4:00 PM - 4:05 PM | Coil Embolization To Treat Aortic ‘Blebs’, Entry-Tears And Pseudoaneurysms: How Does It Work, When Is It Indicated, And Results |
Presenter(s):Jos C. van den Berg, MD, PhD | |
4:06 PM - 4:11 PM | Endovascular Treatment In Patients With Connective Tissue Disorders: When Can This Be Considered First Choice Treatment: Technical Tips And Results |
Presenter(s):Piergiorgio Cao, MD, FRCS | |
4:12 PM - 4:17 PM | Endovascular Management For Isolated Abdominal Aortic Dissection: When To Treat Invasively And When Not; What To Do If It Involves The Juxtarenal Aorta: How Does Treatment Differ From That Of AAAs |
Presenter(s):Chang Shu, MD | |
4:18 PM - 4:23 PM | What Modifications Of The Distal Components Of F/EVAR Endografts Help To Avoid Branch Vessel Stent-Graft Compression: Indications And Results |
Presenter(s):Nuno V. Dias, MD, PhD | |
4:24 PM - 4:29 PM | Lipophilic Statins Like Lipitor Increase Risk Of Paraplegia More Than Hydrophilic Statins Like Crestor After B/EVAR For TAAA Repairs: What Is The Mechanism |
Presenter(s):Jade S. Hiramoto, MD | |
4:30 PM - 4:35 PM | Panel Discussion |
END OF SESSION 45 | |
SESSION 46 SCHEDULE | |
Wednesday
SESSION 46:
MORE SHORT HOT NEW TOPICS RELATED TO AORTC DISEASE AND ITS TREATMENT
Moderators:Andres Schanzer, MD / Peter F. Lawrence, MD
|
|
x | |
4:36 PM - 4:41 PM | DEBATE Round 3: The Vast Majority Of Failed EVARs Can Be Treated Endovascularly |
Presenter(s):Ross Milner, MD | |
4:42 PM - 4:47 PM | DEBATE Round 3: Not So: Many Failed EVARs Are Best Repaired By Open Conversion |
Presenter(s):Michel Makaroun, MD | |
4:48 PM - 4:53 PM | Are Low Profile Devices For EVAR And TEVAR Improving Or Worsening Their Outcomes |
Presenter(s):Naoki Fujimura, MD, PhD | |
4:54 PM - 4:59 PM | There Is No Doubt AAA Screening Saves Lives: Do We Need Changes In The Screening Criteria |
Presenter(s):Maarit Venermo, MD, PhD | |
5:00 PM - 5:05 PM | What Is The AS-Score And How Does It Influence SCI Risk After Endovascular TAAA Repair: What Can Be Done To Offset This |
Presenter(s):Tilo Koelbel, MD, PhD | |
5:06 PM - 5:11 PM | What Are The Differences Between The ACC/AHA And The European Guidelines On Ascending Aorta And Arch Disease |
Presenter(s):Ourania Preventza, MD | |
5:12 PM - 5:17 PM | Panel Discussion |
5:18 PM - 5:23 PM | 10 Years Of PMEGs For Complex AAAs: How Do The Results Vary With And Without An IDE, The Extent Of The AAA And With And Without A Prior EVAR |
Presenter(s):Marc L. Schermerhorn, MD | |
5:24 PM - 5:29 PM | With Esophageal Cancer, When Is Prophylactic TEVAR Indicated To Prevent An Aorto-Esophageal Fistula: It Improves Palliation But Does It improve Survival |
Presenter(s):I-Hui Wu, MD, PhD | |
5:30 PM - 5:35 PM | Small Tips And Modifications In Radiation Safety Can Make A Huge Impact On Staff Exposure: What Are They And How Can They Be Enforced |
Presenter(s):Maarit Venermo, MD, PhD | |
5:36 PM - 5:41 PM | Pediatric Abdominal Aortic Aneurysms: What Is Their Etiology And How Should They Be Managed |
Presenter(s):Sherene Shalhub, MD, MPH | |
5:42 PM - 5:47 PM | B/EVAR In Patients With A Narrow Paravisceral Aorta (<2.5 cm) Is Best Performed With Inner Branched Endografts: Technical Tips To Achieve Optimal Results |
Presenter(s):Michele Antonello, MD / Franco Grego, MD | |
5:48 PM - 5:53 PM | ZFEN Versus Treo Endografts As Platforms For PMEG F/EVARs: Which Is Best And When: Technical Considerations, Advantages And Disadvantages |
Presenter(s):Joshua D. Adams, MD | |
5:54 PM - 5:59 PM | When Can Duplex Ultrasound Fully Replace CT Surveillance After EVAR: When Is CT Surveillance Necessary |
Presenter(s):Sal Scali, MD | |
6:00 PM - 6:10 PM | Panel Discussion End of Program F |
END OF SESSION 46 | |
Thursday, November 21, 2024
Print Entire 2024 Program:
|
|
SESSION 47 SCHEDULE | |
Thursday
SESSION 47:
EXCITING NEW OR REDISCOVERED TECHNIQUES, DEVICES, CONCEPTS
|
|
x | |
6:50 AM - 6:55 AM | A Patient-Centric Smartphone App For Monitoring Vascular And Endovascular Procedures: What Does It Measure And How Is It Helpful |
Presenter(s):Todd R. Vogel, MD, MPH | |
6:56 AM - 7:01 AM | A New Robotic Device (From Sentante) To Assist With Endovascular Treatments: It Can Accommodate 3 Devices At Once And Be Operated From A Great Distance |
Presenter(s):Gary M. Ansel, MD | |
7:02 AM - 7:07 AM | Pediatric Vascular And Endovascular Surgery Is A New Subspecialty Within Vascular Surgery: In Pediatric Patients How Important Are Endovascular Techniques, What Modifications Are Needed And Why Most Aortic Lesions Need To Be Treated By Open Surgery |
Presenter(s):Alex Fairman, MD | |
7:08 AM - 7:13 AM | Management Of Pediatric Arterial And Aortic Aneurysms In 2024: Differing Etiologies Necessitating Different Therapeutic Interventions |
Presenter(s):James C. Stanley, MD | |
7:14 AM - 7:19 AM | Update On Remote Monitoring Of Vascular Graft Function And Other Parameters Including Blood Pressure: Where Is It At And Where Is It Going |
Presenter(s):Richard F. Neville, MD | |
7:20 AM - 7:25 AM | Effect Of Increased Hydration And Protein Intake On Lower Extremity Arteriosclerotic Ischemia With Intermittent Claudication And CLTI: What Is The Evidence And The Mechanism: Will It Change The Game And Decrease The Need For Stents And Bypasses |
Presenter(s):Juan C. Parodi, MD / Samuel Fernandez, MD | |
7:26 AM - 7:31 AM | Panel Discussion |
7:32 AM - 7:37 AM | Provider Skill Is Not Appropriately Recognized And Rewarded In The Health Care Value Equation Of Value = Outcome/Cost: Even Within A Specialty All Doctors Are Not Equal: There Are Stars, Superstars And Journeymen: What To Do About It |
Presenter(s):Lars B. Lonn, MD, PhD | |
7:38 AM - 7:43 AM | Can Advances In MRI Eliminate Radiation From AAA Diagnosis, Its Endovascular Treatment And Its Follow Up: The Zero Radiation Project And Where It Stands |
Presenter(s):Kak Khee Yeung, MD, PhD | |
7:44 AM - 7:49 AM | How And Why Do Thoracic Endografts For TEVAR Negatively Affect The Blood Pressure And The Heart: Can A Compliant Endograft Prevent The Problem; How Should It Be Made |
Presenter(s):Juan C. Parodi, MD | |
7:50 AM - 7:55 AM | The Negative Impact On Cardiovascular Hemodynamics: Lessons Of TEVAR, F/EVAR, B/EVAR And EVAR: What Causes The Problem And What Can Be Done To Fix It |
Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC, PhD, FACS | |
7:56 AM - 8:01 AM | Current Status And Future Potential Of Pig To Human Organ Xenografting |
Presenter(s):Robert A. Montgomery, MD, D Phil | |
8:02 AM - 8:07 AM | Panel Discussion |
END OF SESSION 47 | |
SESSION 48 SCHEDULE | |
Thursday
SESSION 48:
PROGRESS IN FENESTRATED AND BRANCHED EVAR (F/B/EVAR) AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED TOPICS
|
|
x | |
8:08 AM - 8:13 AM | Outcomes Of Leaving The Celiac Trunk Without A Stent Or Stent-Graft During 4 Vessel F/EVAR: Why A Stent Is Unnecessary And Can There Be Problems With Wires Across The Celiac Or SMA Orifices |
Presenter(s):Timothy A. Resch, MD, PhD | |
8:14 AM - 8:19 AM | Value Of Parallel Endografts In The Management Of TAAAs And Other Aortoiliac Pathology: Why Do They Fail And How To Make Them Work |
Presenter(s):David J. Minion, MD | |
8:20 AM - 8:25 AM | Complete Aortic Endovascular Repairs For Zones 0-10 Using Parallel Endografts With A Docking Station: How And Why To Make Them Work Effectively Despite Doubts About Parallel Grafts: What Are The Limitations |
Presenter(s):Manish Mehta, MD, MPH | |
8:26 AM - 8:31 AM | DEBATE: Long-Term Results Of F/EVAR For Juxta- And Pararenal AAAs: Data From ARC Show That It Should Be The Procedure Of Choice |
Presenter(s):Andres Schanzer, MD | |
8:32 AM - 8:37 AM | DEBATE: Not So: Other Data Including A Meta-Analysis Indicates That We Still Need An RCT Versus Open Repair To Determine The Best Treatment For Juxta- And Pararenal AAAs |
Presenter(s):Ian Loftus, MD | |
8:38 AM - 8:44 AM | Panel Discussion |
8:45 AM - 8:50 AM | Why Balloon Expandable Bridging Stent-Grafts Are Best For F/B/EVAR: Which One Is Best And Why: A US Perspective: Advantages Of The Gore VBX Stent-Graft |
Presenter(s):Mark A. Farber, MD | |
8:51 AM - 8:56 AM | Which Bridging Covered Stents Or Stent-Grafts Work Best For F/B/EVAR: A European Perspective: Why Renal Artery Bridging Stent-Grafts Are The Achilles Heel In B/EVAR And What To Do About It |
Presenter(s):Martin J. Austermann, MD | |
8:57 AM - 9:02 AM | The Role Of Open Surgery As Both An Adjunct And Bailout For Failed F/B/EVAR Procedures For Complex AAAs: How To Choose Between Endo And Open Repairs As The Primary Procedure |
Presenter(s):Bijan Modarai, PhD, FRCS | |
9:03 AM - 9:08 AM | Aneurysm Rupture During The Interval Of Staged Endovascular TAAA Repairs: How Frequent Is It And What Can Be Done To Prevent It: Optimal Delay For Stage 2 |
Presenter(s):Randall R. De Martino, MD / Bernardo C. Mendes, MD | |
9:09 AM - 9:14 AM | Evolving Roles Of In Situ Laser F/EVAR For TAAA Repairs: Technical Tips And Results |
Presenter(s):Sukgu Han, MD | |
9:15 AM - 9:23 AM | Panel Discussion |
9:23 AM - 9:38 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 48 | |
SESSION 49 SCHEDULE | |
Thursday
SESSION 49:
MORE PROGRESS IN F/B/EVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED TOPICS
|
|
x | |
9:38 AM - 9:43 AM | The Value Of Intraoperative Cone Beam CT During F/B/EVAR: What Defects Can Be Detected That Would Otherwise Be Missed: What Equipment Is Required |
Presenter(s):Nuno V. Dias, MD, PhD | |
9:44 AM - 9:49 AM | Causes Leading To Branch Leaks And Occlusions After F/B/EVAR: What Forces Are Important And What Can Be Done To Prevent Them |
Presenter(s):Thomas L. Forbes, MD | |
9:50 AM - 9:55 AM | Update On Optimal Bridging Stent-Grafts For F/B/EVAR: Advantages And Disadvantages Of The BeGraft, BeGraft Plus (Bentley) And Advanta (iCast – Getinge): Experience With >2,000 Target Vessels |
Presenter(s):Eric L.G. Verhoeven, MD, PhD / Athanasios Katsargyris, MD | |
9:56 AM - 10:01 AM | Percutaneous Axillary And Femoral Access For Various Parts Of Complex Endovascular AAA Repair: How To Do Them Safely And How To Downsize Femoral Sheaths To More Rapidly Restore Lower Extremity Flow: Why Is It Important |
Presenter(s):Darren B. Schneider, MD | |
10:02 AM - 10:07 AM | Prediction Of 1-Year Mortality After Endovascular TAAA Repair: When Should We NOT Offer The Procedure |
Presenter(s):Adam Beck, MD | |
10:08 AM - 10:13 AM | Panel Discussion |
10:14 AM - 10:19 AM | Reasons For And Outcomes Of Open AAA Repair In A High Volume Endovascular Center |
Presenter(s):Athanasios Katsargyris, MD / Eric L.G. Verhoeven, MD, PhD | |
10:20 AM - 10:25 AM | F/EVAR Versus Ch/EVAR For Juxtarenal AAAs: How Do The Results Compare After Up To 8 Years Follow-Up In A Real World Experience |
Presenter(s):Ignacio Escotto, MD | |
10:26 AM - 10:31 AM | Parallel Endografts For Aortoiliac Lesions: The Good, The Bad And The Ugly: A Balanced View |
Presenter(s):Grace J. Wang, MD, MSCE | |
10:32 AM - 10:37 AM | Why Is A Distal AUI The Preferred Approach For ZFEN F/EVAR Treatment Of Failed EVAR Devices: When And How To Do It And Outcomes |
Presenter(s):Martin R. Back, MD | |
10:38 AM - 10:43 AM | With Failed EVAR, When Is F/EVAR The Best Treatment: Tips And Tricks For Performing It Successfully |
Presenter(s):Andres Schanzer, MD | |
10:44 AM - 10:49 AM | Tips For Beginners To Avoid Traps When Starting A F/BEVAR Program: It Is Doable But Not Simple |
Presenter(s):Piotr Myrcha, MD | |
10:50 AM - 10:56 AM | Panel Discussion |
END OF SESSION 49 | |
SESSION 50 SCHEDULE | |
Thursday
SESSION 50:
A TRIBUTE TO OUR MILITARY AND MILITARY PHYSICIANS: SOME MILITARY HISTORY; TREATMENT OF MILITARY AND CIVILIAN VASCULAR INJURIES AND CONTROL OF HEMORRHAGE; UPDATE ON REBOA
Moderators:Todd E. Rasmussen, MD, FACS / Wayne F. Yakes, MD
|
|
x | |
10:56 AM - 11:06 AM | The Battle of Midway: How It Saved The United States And The World |
Presenter(s):Wayne F. Yakes, MD | |
11:07 AM - 11:12 AM | Update On A Vascular Surgeon’s Impressions About The Devastating Ukraine War: What Is Happening With Major Vascular Injuries |
Presenter(s):Andriy O. Nykonenko, MD | |
11:13 AM - 11:18 AM | What Is Happening With Major Vascular Injuries To Civilians During The Ukraine War: Are The Resources And Medical Personnel Adequate: Are The US And Western Europe Doing Enough |
Presenter(s):Yuliia Nahaliuk , MD | |
11:19 AM - 11:24 AM | What Has Been The Impact Of The War In Israel On Health Care And Trauma Management For Its Civilian Population |
Presenter(s):Gabriel Szendro, MD | |
11:25 AM - 11:30 AM | Lessons Learned On Treating Major Military And Civilian Vascular Trauma From The October 7th Attack On Israel And Its Combat Aftermath |
Presenter(s):Samy S. Nitecki, MD | |
11:31 AM - 11:36 AM | How The US Military Pursued A Policy Of Zero Preventable Combat Deaths From Wounds In Iraq And Afghanistan: Leave No One Behind: How It Applies To Civilian Casualties |
Presenter(s):Todd E. Rasmussen, MD, FACS | |
11:37 AM - 11:42 AM | Update On Isolated Limb Perfusion To Enable Traumatically Amputated Limb Reimplantation |
Presenter(s):Zachary M. Arthurs, MD | |
11:43 AM - 11:48 AM | Progress In Resuscitation And Endovascular Trauma Management With Catheter Based Treatments Including REBOA And Other Devices: What Is Partial And Intermittent REBOA And What Is Their Value |
Presenter(s):Tal M. Hoerer, MD, PhD | |
11:49 AM - 11:54 AM | When Is REBOA A Valuable Procedure And When Is It Not: Limitations And Precautions: Does It Have Value In Conditions Other Than Trauma |
Presenter(s):Joseph J. DuBose, MD | |
11:55 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 50 | |
SESSION 51 SCHEDULE | |
Thursday
SESSION 51:
PROGRESS IN THE TREATMENT OF RUPTURED INFRARENAL AAAs, COMPLEX AAAs, TAAAs AND RELATED TOPICS
|
|
x | |
1:00 PM - 1:05 PM | How Can The Turndown Rate For Invasive Treatment Of Ruptured AAAs Be Decreased And Is It Worthwhile |
Presenter(s):Matthew W. Mell, MD, MS | |
1:06 PM - 1:11 PM | Selection Of Patients With Ruptured AAAs For Noninvasive (Comfort) Care Based On Scoring System Or Advanced Age Is Inappropriate And Unfair To Some Patients |
Presenter(s):Isabelle Van Herzeele, MD, PhD | |
1:12 PM - 1:17 PM | Only One-Third Of Ruptured AAA Patients In The 3 RCTs Comparing EVAR With Open Repair Were Randomized: Why Does This And Other Flaws Invalidate The RCT Conclusions: RCTs Can Be Misleading |
Presenter(s):Thomas L. Forbes, MD | |
1:18 PM - 1:23 PM | Long-Term Results Of The AJAX RCT Comparing EVAR With Open Repair For Ruptured AAAs: Despite Its Flaws, EVAR Wins In The End – Especially In Patients >80 |
Presenter(s):Willem Wisselink, MD | |
1:24 PM - 1:29 PM | Reasons Why The Use Of Open Repair Versus EVAR For Ruptured AAAs Still Varies Greatly Even Though EVAR Has Been Proven Superior: Bias Rules |
Presenter(s):Martin Malina, MD, PhD | |
1:30 PM - 1:35 PM | Update On Treating All (100%) Ruptured AAAs, Complex AAAs And Thoracic Aneurysms Endovascularly: A 15-Year Experience Shows This Is The Best Treatment And Lowers The Turndown Rate: What Adjuncts May Be Necessary To Achieve This |
Presenter(s):David T. McGreevy, MD, PhD / Tal M. Hoerer, MD, PhD | |
1:36 PM - 1:41 PM | Aortic Endograft Diameter Sizing With Ruptured Aneurysms: Why Is It Different And How To Do It |
Presenter(s):Zoran Rancic, MD, PhD, EMBA HSG | |
1:42 PM - 1:47 PM | Update On Advances In Treatment Of Abdominal Compartment Syndrome Associated With Ruptured AAAs: When And How To Treat Medically And When And How To Treat With Opening The Abdomen |
Presenter(s):Martin Björck, MD, PhD | |
1:48 PM - 1:53 PM | AAA Rupture After EVAR Behaves Differently From De Novo Rupture: How Should Treatment Be Modified In Patients With Post EVAR Ruptures |
Presenter(s):Piotr Szopinski, MD, PhD | |
1:54 PM - 1:59 PM | Panel Discussion |
END OF SESSION 51 | |
SESSION 52 SCHEDULE | |
Thursday
SESSION 52:
MORE NEW DEVELOPMENTS IN TECHNIQUES OF ENDO TREATMENT OF RUPTURED AAAs, COMPLEX AAAs AND TAAAs; WHAT IS AND SHOULD BE HAPPENING WITH AAA SCREENING
|
|
x | |
CURRENT TECHNIQUES FOR TREATING RUPTURED ANEURYSMS | |
2:00 PM - 2:05 PM | With Ruptured Complex AAAs And TAAAs Parallel Grafts Are The Best Treatment: They Are Simpler, More Effective And Less Costly Than Other Treatments |
Presenter(s):Manish Mehta, MD, MPH | |
2:06 PM - 2:11 PM | In Situ Laser Fenestration For Endovascular Treatment Of Complex Ruptured AAAs: What Equipment Is Needed: When Is It Feasible And Why Is It Better Than Other Treatments: Technical Tips |
Presenter(s):Anders Wanhainen, MD, PhD | |
2:12 PM - 2:17 PM | Physician Modified Endografts (PMEGs) And Off-The-Shelf (OTS) Devices Are Both Options For Urgent/Emergent Treatment Of Ruptured Complex AAAs: Technical Tips |
Presenter(s):Bernardo C. Mendes, MD / Gustavo S. Oderich, MD, FACS | |
2:18 PM - 2:23 PM | Modifications Of The TREO-FIT Endograft (Terumo) For EVAR That Make It Suitable For Physician Modification (PMEGs) For Use In Emergent And Ruptured Juxtarenal AAAs |
Presenter(s):Benjamin W. Starnes, MD | |
2:24 PM - 2:29 PM | Applicability And Results Of Cook t-Branch OTS Endograft In Complex Ruptured AAAs: Advantages And Limitations |
Presenter(s):Ciro Ferrer, MD, PhD / Rocco Giudice, MD | |
2:30 PM - 2:35 PM | New Semibranch Custom-Made Stent-Graft (From Artivion) To Treat Pararenal And Juxtarenal AAAs With Narrow Paravisceral Lumen: Advantages And Limitations |
Presenter(s):Rocco Giudice, MD | |
2:36 PM - 2:41 PM | For Treatment Of Ruptured Complex AAAs A Short Custom Made Single Fenestrated Graft Can Be Used To Revascularize The SMA Followed By A Bifurcated Graft And Laser Fenestration For The Renal Arteries: Technique And Experience |
Presenter(s):Nuno V. Dias, MD, PhD | |
2:42 PM - 2:47 PM | Panel Discussion |
2:48 PM - 2:53 PM | A Transvenous (Transcaval) Approach To Endovascular Repair Of Ruptured Thoracic Aneurysms And TAAAs In Patients With Poor Arterial Access: Technical Tips And Can One Deal With Aortic Bifurcation Lesions |
Presenter(s):Tilo Koelbel, MD, PhD | |
2:54 PM - 2:59 PM | Open Retroperitoneal Aortic Approach For Ruptured AAAs: Technical Tips, Advantages And Limitations: When Is It Better Than EVAR And F/EVAR |
Presenter(s):R. Clement Darling III, MD | |
NEW DEVELOPMENTS IN AAA SCREENING | |
3:00 PM - 3:05 PM | Update On Current Screening For AAAs In The US: Most Ruptured AAAs Occur In Patients Not Being Screened: How Should US PSTF Recommendations Be Changed And How Should Screening Groups Be Expanded |
Presenter(s):Marc L. Schermerhorn, MD / Thomas F.X. O'Donnell, MD | |
3:06 PM - 3:11 PM | New Developments In AAA Screening: Should We Change Who Is Being Screened |
Presenter(s):Jes S. Lindholt, MD | |
3:12 PM - 3:17 PM | The Future Of AAA Screening: The Changing Epidemiology Especially Persistent Declining Prevalence Mandates Changes In Screening Recommendations |
Presenter(s):Anders Wanhainen, MD, PhD | |
3:18 PM - 3:24 PM | Technical Tips To Deploy F/EVAR Endografts Precisely With Tortuous Anatomy: How To Compensate For Endograft Rotation And Still Match Fenestrations To Branch Orifices Perfectly |
Presenter(s):Neal S. Cayne, MD / Bjõrn Sonesson, MD, PhD | |
3:24 PM - 3:36 PM | Panel Discussion And Break Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 52 | |
SESSION 53 SCHEDULE | |
Thursday
SESSION 53:
EXCITING NEW OR UPDATED CONCEPTS, TECHNIQUES AND TREATMENTS
Moderators:Fred A. Weaver, MD, MMM / Matt M. Thompson, MD
|
|
x | |
3:36 PM - 3:41 PM | Update On External Sirolimus Patch Wrap-Arounds For PTFE Graft Anastomoses: Do They Decrease Intimal Hyperplasia And Improve Prosthetic Graft Patency |
Presenter(s):Sriram S. Iyer, MD, FACC | |
3:42 PM - 3:47 PM | Implantable Carotid Stent-Like Device To Stimulate The Carotid Sinus Nerve (Of Hering) And Treat Intractable CHF And Hypertension (The Barostim System): Current Clinical Status |
Presenter(s):Fred A. Weaver, MD, MMM / John F. Eidt, MD / Miguel Manzur, MD | |
3:48 PM - 3:53 PM | Reducing Fiber And Lint Contamination During Endovascular And Surgical Procedures: Why Is It Important And How To Prevent it |
Presenter(s):John R. Laird, MD | |
3:54 PM - 3:59 PM | Value Of Prostate Artery Embolization For BPH: Indications, Technique And Results |
Presenter(s):Lars B. Lonn, MD, PhD | |
4:00 PM - 4:05 PM | Peripheral Embolization With TEVAR And EVAR Procedures: How Widespread And Important Is It And An Update On Devices To Prevent It |
Presenter(s):Ralf R. Kolvenbach, MD | |
4:06 PM - 4:11 PM | Cancer Incidence After Lower Extremity Bypass Surgery: How Does It Affect Long-Term Outcome In Patients With CLTI: Why The Relationship With Cancer Exists |
Presenter(s):Dittmar Boeckler, MD | |
4:12 PM - 4:17 PM | Special Technical Tips For The Management Of Pediatric Vascular Trauma And Emergencies: Evolving Endovascular Strategies, Expanded Device Availability, And How To Deal With Spasm |
Presenter(s):Dawn M. Coleman, MD, FACS | |
4:18 PM - 4:23 PM | Visceral Arterial Compression Syndromes And Their Relationship To Genetic Disorders: Current Optimal Diagnosis And Treatment |
Presenter(s):Prof. Dr. Med Wilhelm Sandmann, MD | |
4:24 PM - 4:29 PM | High Resolution Infrared Thermography To Detect Vascular Pathology: How Does It Work And How Does It Help |
Presenter(s):Ivo Petrov, MD, PhD | |
4:30 PM - 4:37 PM | Panel Discussion |
END OF SESSION 53 | |
SESSION 54 SCHEDULE | |
Thursday
SESSION 54:
PROGRESS IN RADIATION SAFETY AND MORE NEW CONCEPTS, DEVICES AND TECHNIQUES
Moderators:Lindsay Machan, MD / Jacob Cynamon, MD, FACR, FSIR
|
|
x | |
4:38 PM - 4:43 PM | Intravascular Lithotripsy (From Shockwave): A New Valuable Tool To Facilitate Access For Large Sheaths In F/BEVAR |
Presenter(s):Eric L.G. Verhoeven, MD, PhD / Athanasios Katsargyris, MD | |
WHAT’S NEW IN RADIATION SAFETY | |
4:44 PM - 4:49 PM | The Occupational Hazards Of The Pregnant Surgeon: What Modifications In Practice And Techniques Are Necessary To Avoid Or Minimize Them |
Presenter(s):Venita R. Chandra, MD | |
4:50 PM - 4:55 PM | Myths And Facts Regarding Radiation Protection And Safety: Imperfections In Protection From Leaded Glasses, Caps, Gloves And Light Weight Leaded Gowns |
Presenter(s):Lindsay Machan, MD | |
4:56 PM - 5:01 PM | Improved Radiation Protection With The Protego System: What Is It, How Does It Work; Experience And Results With Operators, Staff And Patients |
Presenter(s):Venkatesh G. Ramaiah, MD | |
NEW CONCEPTS, ETC. | |
5:02 PM - 5:07 PM | Endovascular Options For The Control Of Submassive And Massive Hemoptysis: It Is Lifesaving: When And How To Do It: Coils Are Required |
Presenter(s):Jacob Cynamon, MD, FACR, FSIR | |
5:08 PM - 5:13 PM | What’s New In Gene And Stem Cell Therapy For No Option CLTI In 2024: Are There Technologies And Trials That Hold Promise – Like BioGenCell |
Presenter(s):Richard J. Powell, MD / Yael Porat, PhD | |
5:14 PM - 5:19 PM | Panel Discussion |
5:20 PM - 5:25 PM | The Aortyx Aortic Patch: A More Compliant Way Than TEVAR To Seal Aortic Defects With TBADs And Other Lesions: A New Endovascular Approach: How Does It Work: Improved Delivery System And Progress To Date |
Presenter(s):Vicente Riambau, MD, PhD | |
5:26 PM - 5:31 PM | Disseminated Fungal Infections Of The Vascular System: Why Are They Important And How Should They Be Diagnosed And Treated |
Presenter(s):Sateesh C. Babu, MD | |
5:32 PM - 5:37 PM | Endovascular Emergency Treatment Of Carotid Blowout From Head And Neck Cancer Or Carotid Patch Infections: Planning, Preparation And Technical Tips Are Essential |
Presenter(s):Michael B. Silva, Jr., MD | |
5:38 PM - 5:43 PM | Gore Excluder Iliac Branch Endoprosthesis (IBE) Extension Into The Gluteal Artery To Treat Hypogastric Aneurysms: Technique And Mid-Term Results |
Presenter(s):Mark W. Mewissen, MD, FSIR, RVT | |
5:44 PM - 5:49 PM | Best Bridging Stent Selection For The Gore Excluder Iliac Branch Endoprosthesis (IBE): What Works And What Doesn’t |
Presenter(s):Steven Maximus, MD / Gustavo S. Oderich, MD, FACS | |
5:50 PM - 6:00 PM | Panel Discussion End of Program G |
END OF SESSION 54 | |
SESSION 55 SCHEDULE | |
Thursday
SESSION 55:
NEW OR IMPROVED DEVICES FOR INFRARENAL AAA REPAIR WITH STANDARD EVAR
|
|
x | |
7:00 AM - 7:05 AM | Updated Results From The AFX 2-LIVE European Registry: An Experience With The Outcomes Of >500 AFX EVAR Cases: Benefits, Complications, Conversions And Technical Considerations |
Presenter(s):Francesco Speziale, MD | |
7:06 AM - 7:11 AM | Current Status Of The AFX 2 Endograft (From Endologix) For EVAR: Is Increased Surveillance Indicated |
Presenter(s):Robert W. Chang, MD | |
7:12 AM - 7:17 AM | Are We Overtreating AAAs: The Current Diameter Thresholds For AAA Repair (5.5 cm For Men; 5.0 cm For Women) Are No Longer Relevant: Based On New Scrutiny Of Old Trials And A Meta-Analysis Of AAA Rupture Risk |
Presenter(s):Timothy A. Resch, MD, PhD | |
7:18 AM - 7:23 AM | Mid-Term Results Of The Alto (Ovation) Low Profile Endograft (From Endologix): Advantages And Current Role In Treating AAAs |
Presenter(s):Gianmarco de Donato, MD | |
7:24 AM - 7:29 AM | Comparison Of Excluder Versus Endurant Endografts For EVAR: Which Graft Is Best And In What Circumstances: From A Multicenter Propensity Score Matched Study |
Presenter(s):Naoki Fujimura, MD, PhD | |
7:30 AM - 7:35 AM | Panel Discussion |
7:36 AM - 7:41 AM | Gore Conformable Excluder For EVAR: Advantages And Indications: From The European EXCeL Registry |
Presenter(s):Marc R.H.M. van Sambeek, MD, PhD | |
7:42 AM - 7:47 AM | How To Optimize Infrarenal Aortic Neck Sealing With Short Or Angulated Necks (>60-90 Degrees) Without Placing Branches In The Renals: The Unique Features Of The Gore Excluder Conformable AAA Endograft: >1 Year Results |
Presenter(s):Robert Y. Rhee, MD | |
7:48 AM - 7:53 AM | New Polymer Filled Low Profile Endograft Device With O-Ring Sealing: Advantages, How Does It Work And Why Is It Better In Patients With Complex Proximal Neck Anatomy |
Presenter(s):Piotr Szopinski, MD, PhD | |
7:54 AM - 7:59 AM | 10-Year Results With The Gore Excluder Endograft For EVAR Show Its Durability: From The GREAT Registry |
Presenter(s):Eric L.G. Verhoeven, MD, PhD / Athanasios Katsargyris, MD | |
8:00 AM - 8:05 AM | Mid-Term Results Of EVAR With Endoanchors In Patients With Hostile Neck Anatomy: Do They Work Better When Used Prophylactically Or Therapeutically: Do They Work Equally Well With All Endografts |
Presenter(s):Apostolos K. Tassiopoulos, MD | |
8:06 AM - 8:11 AM | Panel Discussion |
END OF SESSION 55 | |
SESSION 56 SCHEDULE | |
Thursday
SESSION 56:
NEW OR UPDATED DEVICES FOR STANDARD EVAR OR F/B/EVAR
Moderators:Christopher J. Kwolek, MD, MBA / Margaret Tracci, MD, JD
|
|
x | |
STANDARD EVAR DEVICES | |
8:12 AM - 8:17 AM | Five-Year Results And Advantages Of The TREO (Terumo) Endograft For Standard EVARs: Status In The US |
Presenter(s):Matthew J. Eagleton, MD | |
8:18 AM - 8:23 AM | Real World Outcomes With The TREO Endograft (Terumo Aortic): Results From The European TIGER Registry |
Presenter(s):Vicente Riambau, MD, PhD | |
8:24 AM - 8:29 AM | Status Of The Low Profile Alto Endograft (From Endologix) With More Proximal Polymer Sealing Rings For Standard EVAR: Up To 5-Year Results Show Its Advantages: Status Of The JAGUAR RCT Comparing It With Standard EVAR Endografts |
Presenter(s):Sean P. Lyden, MD / Christopher J. Kwolek, MD, MBA / Andrew Holden, MBChB | |
8:30 AM - 8:35 AM | AFX 2 Anatomically Fixed (On The Aortic Bifurcation) Endografts For AAA Repair: The LEOPARD RCT 5-Year Results Show It Has Similar Outcomes To Other Widely Used Proximally Fixed Endografts |
Presenter(s):Christopher J. Kwolek, MD, MBA | |
F/B/EVAR TOPICS FOR COMPLEX AAAs | |
8:36 AM - 8:41 AM | Comparison Of Various Fenestrated Endografts From Cook, Terumo, Etc.: Advantages And Limitations Of Each |
Presenter(s):Sonia Ronchey, MD, PhD | |
8:42 AM - 8:47 AM | Real World Evaluation Of The OTS Pre-Cannulated Inner Branched Endograft (E-nside From Artivion) For Pararenal Aortic Aneurysms: Advantages And Limitations |
Presenter(s):Theodosios Bisdas, MD / Lee Bouwman, Dr | |
8:48 AM - 8:53 AM | One-Year Outcomes Of The Fenestrated Anaconda (Terumo Aortic) Endograft For Treating Complex AAAs From The GLOBAL FACT Study: What Makes This Endograft Different: Advantages And Limitations |
Presenter(s):Clark J. Zeebregts, MD, PhD | |
8:54 AM - 8:59 AM | Retrospective Analysis Of Laser In Situ Fenestration Of All Endografts: What Does The LIFE Registry Show |
Presenter(s):Jonathan Bath, MD | |
9:00 AM - 9:06 AM | Panel Discussion |
9:06 AM - 9:19 AM | Break - Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 56 | |
SESSION 57 SCHEDULE | |
Thursday
SESSION 57:
NEW OR IMPROVED DEVICES FOR THORACOABDOMINAL ANEURYSM (TAAA) REPAIRS AND THORACIC AORTIC LESION REPAIRS (TEVAR)
Moderators:Ross Milner, MD / Carlos H. Timaran, MD
|
|
x | |
IMPROVED DEVICES FOR TAAA REPAIRS | |
9:20 AM - 9:25 AM | Progress With A New Hybrid Device (Thoracoflo From Terumo Aortic) For TAAA Repair: How It Works, Clinical Experience And Advantages |
Presenter(s):Sebastian E. Debus, MD, PhD / Sabine H. Wipper, MD, PhD / Randy D. Moore, MD | |
9:26 AM - 9:31 AM | Value Of Endo TAAA Repair In Patients With Connective Tissue Disorders: Which Device Or Devices Are Best And Why |
Presenter(s):Gustavo S. Oderich, MD, FACS | |
9:32 AM - 9:37 AM | Comparison Of The Cook t-Branch OTS Endograft Device With The E-nside (Artivion) Multibranched Device For Juxta- And Pararenal AAAs And TAAAs: Advantages And Limitations Of Each |
Presenter(s):Matteo Orrico, MD / Nicola Mangialardi, MD | |
9:38 AM - 9:43 AM | Optimizing Endovascular Treatment Of TAAAs With The Cook OTS t-Branch Endograft: Technical Tips And Contraindications |
Presenter(s):Marcelo Ferreira, MD | |
9:44 AM - 9:49 AM | Current Status And Results With Manifold Branched Grafts For TAAA Repairs: What Are They: What Are Their Limitations And Why Haven’t They Been Commercialized |
Presenter(s):Murray L. Shames, MD / Patrick W. Kelly, MD | |
9:50 AM - 9:55 AM | Treatment Of Narrow True Lumen In Chronic Aortic Dissection Using i-BEVAR E-nside OTS Endograft With Inner Branches (From Artivion): How Does IVUS Help |
Presenter(s):Giovanni Tinelli, MD, PhD / Dittmar Boeckler, MD | |
9:56 AM - 10:01 AM | Twinbranch – A New Approach: Evolution Of The Colt Manifold Device For TAAA Repairs To An Inner Branched Technology |
Presenter(s):Piotr Szopinski, MD, PhD | |
10:02 AM - 10:07 AM | Panel Discussion |
IMPROVED DEVICES FOR TEVAR | |
10:08 AM - 10:13 AM | Low Profile Devices For TEVAR And B/EVAR: Disadvantages And Advantages Based On A 10-Year Experience With Matched Patients |
Presenter(s):Giovanni B. Torsello, MD | |
10:14 AM - 10:19 AM | Current US Status And Results With The RelayPro NBS Endograft For TEVAR: Advantages And Limitations |
Presenter(s):Frank R. Arko, MD | |
10:20 AM - 10:25 AM | Details Of A Novel Low Profile Stent Graft For The TEVAR Treatment Of All Thoracic Aortic Segments: What Makes It Unique And Clinical Status |
Presenter(s):Francesco Setacci, MD | |
10:26 AM - 10:31 AM | Hybrid Repair Of Arch And Descending Aorta Lesions With The Thoraflex Device And RelayPro TEVAR Device: Technical Tips And Clinical Experience |
Presenter(s):Francis Caputo, MD | |
10:32 AM - 10:37 AM | Real World, Long-Term Results With Cook Zenith Alpha Thoracic Low-Profile Endograft: What Have We Learned |
Presenter(s):Germano C.G. Melissano, MD / Roberto L.V. Chiesa, MD | |
10:38 AM - 10:43 AM | The New Cook Custom Single Branch Endograft For TEVAR Of Lesions Close To Or Involving The LSA: Advantages And Results |
Presenter(s):Tilo Koelbel, MD, PhD | |
10:44 AM - 10:49 AM | Status Of And When And How To Use The Gore Conformable CTAG Endograft With Variable Angulation Control Optimally: Advantages And Limitations |
Presenter(s):Sukgu Han, MD | |
10:50 AM - 11:00 AM | Panel Discussion |
END OF SESSION 57 | |
SESSION 58 SCHEDULE | |
Thursday
SESSION 58:
NEW OR IMPROVED DEVICES FOR THE ASCENDING AORTA, THE AORTIC ARCH OR NEAR THE ARCH AND TAAAs (SEE ALSO SESSIONS 1, 2, 3 AND 40 FOR RELATED TOPICS)
Moderators:Rodney A. White, MD / Weiguo Fu, MD
|
|
x | |
11:00 AM - 11:05 AM | Current Status And Results With Terumo Ascending Aorta Endograft: What Makes It Different And What Lesions Can It Treat |
Presenter(s):Vicente Riambau, MD, PhD / Afshin Assadian, MD / Mo S. Hamady, MD, FRCR, EBIR, FSIR | |
11:06 AM - 11:11 AM | Current Status In The US Of The Relay Branch Investigational Device (Terumo Aortic) For Endo Repair Of Aortic Arch Lesions: How Many Branches Can And Should Be Revascularized: Advantages And Limitations |
Presenter(s):Luis A. Sanchez, MD / Eric E. Roselli, MD | |
11:12 AM - 11:17 AM | Aortic Arch Endovascular Repairs: Which Device Is Best For Degenerative Aneurysms And For Dissection: Technical Tips |
Presenter(s):Javairiah Fatima, MD | |
11:18 AM - 11:23 AM | Update On Fenestrated Endovascular Aortic Repair Plus Chimney Graft For TAAA Repairs: The FEVAR/Ch Technique: When And How Is It Beneficial |
Presenter(s):Ross Milner, MD | |
11:24 AM - 11:29 AM | Changes In The Aortic Valve And Aortic Morphometrics After Ascending Aorta And Arch Endograft Placement: Why Are They Important And How Can They Be Avoided |
Presenter(s):Jean Bismuth, MD / Ross Milner, MD | |
11:30 AM - 11:35 AM | How To Manage Dissected Supra Aortic Trunks During Arch Branch Endovascular Repair |
Presenter(s):Stephan Haulon, MD | |
11:36 AM - 11:41 AM | Preloaded Fenestrated Endografts With A Modified Biport Handle (From Cook): A Way To Make F/EVAR Easier: Results From An International Multicenter Study |
Presenter(s):Nikolaos Tsilimparis, MD, PhD | |
11:42 AM - 11:47 AM | What Devices Are Best For Enabling Laser Fenestration For The Endo Treatment Of Arch Lesions: Is The Laser Hole In The Main Graft Made From Below Or Above: How Is The Brain Perfused After The Aortic Graft Is Deployed And Before The Hole Is Made |
Presenter(s):Jean M. Panneton, MD | |
11:48 AM - 11:53 AM | How To Accommodate For Main Endograft Length Discrepancy And Avoid Errant Coverage Of The Supra Aortic Trunks During Emergency Repair Of Ascending Aortic Lesions Coverage |
Presenter(s):Gustavo S. Oderich, MD, FACS / Steven Maximus, MD | |
11:54 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 58 | |
SESSION 59 SCHEDULE | |
Thursday
SESSION 59:
NEW OR UPDATED INFORMATION ON RE-ENTRY DEVICES, LOWER EXTREMITY PROSTHETIC GRAFTS (SEE ALSO SESSION 28) AND MANAGEMENT OF PERIGRAFT SEROMAS
Moderators:Samuel R. Money, MD, MBA / Patrick J. Lamparello, MD
|
|
x | |
A NEW LOOK AT RE-ENTRY DEVICES | |
1:00 PM - 1:05 PM | Pros And Cons Of Re-Entry Devices In Treating CTOs: Why, Where And When To Use Them: Are They Worth The Cost And Have Other Techniques Like Retrograde Access Largely Replaced Them |
Presenter(s):Maria A. Ruffino, MD, EBIR, FCIRSE | |
1:06 PM - 1:11 PM | Re-Entry Devices Are Currently Almost Never Necessary: Techniques To Treat Lower Extremity Lesions Successfully Without Them: When Might They Be Needed |
Presenter(s):Ali Amin, MD, RVT, FACS, FACC | |
PROSTHETIC GRAFTS | |
1:12 PM - 1:17 PM | Final 5-Year Results Of The ZILVERPASS RCT Comparing Prosthetic PTFE Bypasses With Zilver PTX (Cook) Stents To Treat Long FemPop Lesions: Clinical And Financial Results And Their Implications |
Presenter(s):Michel J. Bosiers, MD / Marc Bosiers, MD | |
1:18 PM - 1:23 PM | PTFE Bypasses To Infrapopliteal Targets Can Be Worthwhile For Limb Salvage In Patients With End Stage CLTI: When Is This So And Technical Tips To Make Them Work |
Presenter(s):Matthew T. Menard, MD | |
1:24 PM - 1:29 PM | Heparin Coated (Propaten) PTFE Grafts (Gore) Versus Autologous Vein Grafts For Bypasses To Targets Above And Below The Knee: The Heparin Coated Grafts Are Better And Worth The Cost: Based On A Propensity Matched Analysis |
Presenter(s):David J. Dexter, MD | |
1:30 PM - 1:35 PM | Which Patients With CLTI Should Be Treated Primarily With A Heparin Bonded PTFE Graft And Why: How Can An Amputation-Free Survival Score Be Helpful |
Presenter(s):Carlo Pratesi, MD / Giovanni Pratesi, MD | |
1:36 PM - 1:41 PM | Update On Novel Supramolecular Polymer Technology To Create Endogenous Tissue With Host Collagen And Endothelium Compatible With Flowing Blood: 2-Year Clinical Results Of The aXess Graft (From Xeltis) |
Presenter(s):Frans L. Moll, MD, PhD | |
1:42 PM - 1:47 PM | Perigraft Seromas After PTFE Lower Extremity And Aortic Arterial Grafts: Frequency, Etiology, When Do They Need To Be Treated And How |
Presenter(s):Jae S. Cho, MD | |
1:48 PM - 1:54 PM | Panel Discussion |
END OF SESSION 59 | |
SESSION 60 SCHEDULE | |
Thursday
SESSION 60:
NEW OR IMPROVED ENDOVASCULAR DEVICES FOR LOWER EXTREMITY TREATMENTS: ATHERECTOMY, STENTS, ACCESSORIES, ETC. (SEE ALSO SESSIONS 23-27)
Moderators:Maciej L. Dryjski, MD, PhD / Sateesh C. Babu, MD
|
|
x | |
ATHERECTOMY RELATED TOPICS | |
1:54 PM - 1:59 PM | A Balanced View Of The Value Of Atherectomy For Treatment Of Lower Extremity Lesions: Has It Been Overutilized And Why: When Can It Be Helpful And Which Device Is Best |
Presenter(s):John R. Laird, MD | |
2:00 PM - 2:05 PM | Atherectomy: When Is It The Best Vessel Prep: What Are Its Complications: How To Prevent And Treat Them: Which Device Is Best |
Presenter(s):Theodosios Bisdas, MD | |
2:06 PM - 2:11 PM | The Value Of Directional Atherectomy Followed By DCBs For Long Calcified FemPop Lesions As Demonstrated By The Results Of The REALITY Trial |
Presenter(s):Brian G. DeRubertis, MD | |
2:12 PM - 2:17 PM | Update On Orbital And Laser Atherectomy: Indications, Advantages And Precautions With Above And Below Knee De Novo Lesions And ISR |
Presenter(s):Craig M. Walker, MD | |
2:18 PM - 2:23 PM | A New More Complex Device For Treating Calcified Arterial Lesions With Lithotripsy (From BOLT Medical): How Does It Work And Advantages |
Presenter(s):Marianne Brodmann, MD | |
2:24 PM - 2:30 PM | Panel Discussion |
ANCILLARY TECHNIQUES AND RELATED TOPICS | |
2:30 PM - 2:35 PM | An Update On The Soundbite Technology For Traversing And Treating Calcified Arterial Lesions: How Does It Work, Advantages, And Clinical Experience |
Presenter(s):Marianne Brodmann, MD | |
2:36 PM - 2:41 PM | How Do The Results Of Invasive Treatment Of FemPop Disease Differ In Women And Minorities: The ELEGANCE Global Registry Of Such Treatment With Eluvia DESs And Ranger DCBs Shows How |
Presenter(s):Eric A. Secemsky, MD, MSc / Lee Kirksey, MD | |
NEW INFORMATION ON STENTS AND COVERED STENTS | |
2:42 PM - 2:47 PM Power Point Presentation with Synched Audio |
5-Year Results With The VBX Covered Stent For Aortoiliac Disease: Patency Rates, Advantages And Cost Effectiveness |
Presenter(s):Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed (ClinEpi) | |
2:48 PM - 2:53 PM | Updated Value Of The Supera VMI Stent (Vasculomimetic Stent- From Abbott) For Common Femoral Artery (CFA) Occlusive Lesions: Better Than Endarterectomy: 4-Year Results And Status Of The SUPERSURG RCT (Versus Open Surgery) |
Presenter(s):Yann Gouëffic, MD, PhD / Koen R. Deloose, MD | |
2:54 PM - 2:59 PM | Advantages Of Supera VMI Stent For Complex FemPop Occlusive Lesions: Technical Tips: They Work Even In The Subintimal Position |
Presenter(s):Erwin Blessing, MD | |
3:00 PM - 3:06 PM | Panel Discussion |
3:06 PM - 3:18 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 60 | |
SESSION 61 SCHEDULE | |
Thursday
SESSION 61:
NEW OR IMPROVED ENDOVASCULAR DEVICE COMBINATIONS FOR LOWER EXTREMITY TREATMENTS: ANGIOPLASTY BALLOON IMPROVEMENTS
Moderators:John R. Laird, MD / Timothy A.M. Chuter, MD
|
|
x | |
3:18 PM - 3:23 PM | High-Pressure Non-Compliant Balloons For BTK Arterial Lesion Treatment: When And Why They Work Better And Other Technical Tips: Who Makes Them |
Presenter(s):Steven Kum, MD | |
3:24 PM - 3:29 PM | Update On The Temporary Stent Assisted DCB Angioplasty In BTK Lesions With The Spur Spiked Stent System (Reflow Medical): The DEEPER OUS Trial |
Presenter(s):Michael K.W. Lichtenberg, MD / Thomas Zeller, MD | |
3:30 PM - 3:35 PM | Update On The TOBA Trials Of The Tack Device (From Philips): Indications, Advantages In Improving Outcomes And Limitations |
Presenter(s):Patrick J. Geraghty, MD | |
3:36 PM - 3:41 PM | The Serranator® Balloon Catheter (From Cagent Vascular) For Vessel Prep In BTK Arteries: It Makes Microserrations, Prevents Dissections, Lessens Elastic Recoil With PTA: Current Status |
Presenter(s):Steven Kum, MD / Andrew Holden, MBChB | |
3:42 PM - 3:47 PM | Intravascular Lithotripsy (From Shockwave) In BTK Arteries: Updated Data And New Technologies |
Presenter(s):Andrew Holden, MBChB | |
3:48 PM - 3:53 PM | IVUS Studies Before And After PTAs With The Ultrascore Scoring Balloons (From BD) Show The Benefits Of Such Balloons And How They Work |
Presenter(s):Robert E. Beasley, MD, FSIR, FSCAI | |
3:54 PM - 3:59 PM | Progress In Developing A Curved Angioplasty Balloon: How It Works And Why It’s Important: When Will It Be Available |
Presenter(s):Timothy A.M. Chuter, MD | |
4:00 PM - 4:05 PM | Unfavorable Balloon (Candy) Wrap Can Cause Dissections With Angioplasty: What Is The Mechanism: How Can It Be Recognized And Dissection Avoided: When Does Dissection Have To Be Treated And When Not |
Presenter(s):Jos C. van den Berg, MD, PhD | |
4:06 PM - 4:12 PM | Panel Discussion |
END OF SESSION 61 | |
SESSION 62 SCHEDULE | |
Thursday
SESSION 62:
NEW OR IMPROVED DEVICES AND TECHNIQUES TO PREVENT OR TREAT ENDOLEAKS OR DEVICE MIGRATION: ENDOANCHORS, ETC.
Moderators:William D. Jordan Jr., MD / David H. Deaton, MD, FACS
|
|
x | |
4:12 PM - 4:17 PM | New Findings From The ANCHOR Study Support The Prophylactic Use Of Heli-FX Endoanchor (Medtronic) Fixation: Use Of Its Variable Curve Sheath As A Rescue Tool To Fix Poorly Deployed Endografts |
Presenter(s):William D. Jordan Jr., MD | |
4:18 PM - 4:23 PM | 5-Year Results Of Endoanchors In The Global ANCHOR Registry To Treat Complications With Focus On Preventing And Treating Type IA Endoleaks: Can Virtual Techniques Predict The Need For Endoanchors |
Presenter(s):Jean-Paul de Vries, MD, PhD | |
4:24 PM - 4:29 PM | Endoanchors Improve Seal Zones And Outcomes With Fenestrated Endografts: When And Where Should They Be Used And Technical Tips |
Presenter(s):Shadi J. Abu-Halimah, MD | |
4:30 PM - 4:35 PM | Prophylactic Endoanchors In TEVAR For Complex Anatomy Decrease Endoleaks And Reintervention Rates: Indications And Technical Tips For Their Use |
Presenter(s):Jean M. Panneton, MD | |
4:36 PM - 4:41 PM | Novelrad Percutaneous Endovascular Suturing Device: How Does It Work And Clinical Experience |
Presenter(s):Elchanan Bruckheimer, MBBS | |
4:42 PM - 4:47 PM | Update On The VESTECK Catheter Based Endosuturing Technology For EVAR And TEVAR Fixation: How Does It Work; How Is It Different From Endoanchors And Successful Clinical Results |
Presenter(s):Dainis K. Krievins, MD / Sean P. Lyden, MD / David H. Deaton, MD, FACS | |
4:48 PM - 4:54 PM | Panel Discussion |
END OF SESSION 62 | |
SESSION 63 SCHEDULE | |
Thursday
SESSION 63:
NEW OR IMPROVED ENDOVASCULAR DEVICES FOR CLOT REMOVAL OR EMBOLIZATION (SEE ALSO SESSION 30)
Moderators:James F. Benenati, MD / Frank R. Arko, MD
|
|
x | |
CLOT REMOVING DEVICES | |
4:54 PM - 4:59 PM | Endovascular Arterial Thrombo-Embolectomy Devices: What's The Difference Between Them: Jeti, Penumbra, AngioJet, Pounce, Etc.: What's Coming Down The Road |
Presenter(s):Loay S. Kabbani, MD, MHSA | |
5:00 PM - 5:05 PM | Newer Pharmacomechanical Endovascular Clot Removal Systems: When And Why Is Each Device Best To Use: When Is Open Surgery Needed |
Presenter(s):Guillermo A. Escobar, MD | |
5:06 PM - 5:11 PM | Different Options For Thrombosuction Treatment In ALI: Which Device For Which Case And When To Go For Open Surgery |
Presenter(s):Athanasios Katsargyris, MD | |
5:12 PM - 5:17 PM | Endovascular Hydrodynamic Thrombectomy Of Occluded Visceral Vessels/Stents: Device Description And Clinical Experience |
Presenter(s):Marco V. Usai, MD | |
5:18 PM - 5:23 PM | Rotarex Device Is A Treatment For Subacute Or Chronic Lower Extremity Thrombosed Bypasses Or Stents: How And When Does It Work And When Does It Not |
Presenter(s):Animesh Rathore, MD | |
5:24 PM - 5:29 PM | Panel Discussion |
ENDOVASCULAR OCCLUSIVE DEVICES | |
5:30 PM - 5:35 PM | Embolization Device Selection: The Pros And Cons Of Liquid Agents Versus Coils, Or Plugs |
Presenter(s):Frank R. Arko, MD | |
5:36 PM - 5:41 PM | How Can Shape Memory Polymer Plug Embolization Devices Be Used To Improve Results After TEVAR For Degenerative Aneurysms And TBADs By False Lumen Obliteration |
Presenter(s):Virendra I. Patel, MD, MPH | |
5:42 PM - 5:47 PM | Fibered And Non-Fibered Coil Embolism Technology: Which Type Of Coils Are Best For Different Indications |
Presenter(s):James F. Benenati, MD | |
5:48 PM - 5:53 PM | Indications And Outcomes Of The Impede Embolization Plug (From Shape Memory) For Treatment Of Peripheral And Visceral Artery Lesions: What Makes It Unique |
Presenter(s):Robert A. Morgan, MD | |
5:54 PM - 5:59 PM | Panel Discussion End of Program H |
END OF SESSION 63 | |
SESSION 64 SCHEDULE | |
Thursday
SESSION 64:
VENOUS CLINICAL EXAMINATION AND HEMODYNAMICS
|
|
x | |
7:00 AM - 7:04 AM | Introduction To Veins At VEITH |
Presenter(s):Jose I. Almeida, MD, FACS, RPVI, RVT | |
7:05 AM - 7:10 AM | Overview Of Lymphatic Anatomy, And Physiology |
Presenter(s):Thomas F. O'Donnell, Jr., MD | |
7:11 AM - 7:16 AM | Inflammatory Pathways In Chronic Venous Disease |
Presenter(s):Joseph D. Raffetto, MD | |
7:17 AM - 7:22 AM | Genetics And Venous Disease |
Presenter(s):Sarah Onida, MD, PhD | |
7:23 AM - 7:28 AM | Different Types Of Venous Reflux Identified In 100 Consecutive Patients And Their C Classification And Percentage |
Presenter(s):Ayman Fakhry, MD | |
7:29 AM - 7:34 AM | We Should Revise The Definition Of Venous Reflux: What Other Modality Should We Consider |
Presenter(s):Fedor Lurie, MD, PhD | |
7:35 AM - 7:40 AM | Factors Impacting Venous Return |
Presenter(s):Jose I. Almeida, MD, FACS, RPVI, RVT | |
7:41 AM - 7:46 AM | Venous Thermography And Its Clinical Use |
Presenter(s):Dale Maharaj, MD | |
7:47 AM - 7:52 AM | Panel Discussion |
END OF SESSION 64 | |
SESSION 65 SCHEDULE | |
Thursday
SESSION 65:
VENOUS GUIDELINES, IMPORTANT PAPERS AND REIMBURSEMENT
Moderators:Ruth L. Bush, MD, MPH / Armando Mansilha, MD, PhD, FEBVS
|
|
x | |
7:53 AM - 7:58 AM | Are Venous Maps Standard Of Care: What Should They Include |
Presenter(s):Jan M. Sloves, RVT | |
7:59 AM - 8:04 AM | SVS, AVF, AVLS Varicose Vein Guidelines |
Presenter(s):Peter Gloviczki, MD | |
8:05 AM - 8:10 AM | A Comparison Of The Revised SVS/AVF/ASVL/ESVS Clinical Practice Guidelines In The Management Of Varicose Veins: Contact And Agree II Analysis |
Presenter(s):Thomas F. O'Donnell, Jr., MD | |
8:11 AM - 8:16 AM | Summary Of Important Venous And Lymphatic Articles – International Angiology |
Presenter(s):Armando Mansilha, MD, PhD, FEBVS | |
8:17 AM - 8:22 AM | Summary Of Important Venous And Lymphatic Articles – Journal of Phlebology Editor’s Choice |
Presenter(s):Alun H. Davies, MA, DM, DSc, FRCS, FLSW, FMedSci, FEBVS | |
8:23 AM - 8:28 AM | Summary Of Important Venous And Lymphatic Articles – Journal of Vascular Surgery Venous and Lymphatic Disorders – Editor’s Choice |
Presenter(s):Ruth L. Bush, MD, MPH | |
8:29 AM - 8:34 AM | Primary Venous Insufficiency Increases Risk Of Deep Vein Thrombosis |
Presenter(s):Maxim Shaydakov, MD, PhD | |
8:35 AM - 8:40 AM | Compression: Does It Work: What Data Do You Have To Support |
Presenter(s):William A. Marston, MD | |
8:41 AM - 8:46 AM | Sclerotherapy Of Lower Limb – Consensus Document UIP |
Presenter(s):Oscar Bottini, MD | |
8:47 AM - 8:52 AM | Panel Discussion |
END OF SESSION 65 | |
SESSION 66 SCHEDULE | |
Thursday
SESSION 66:
SUPERFICIAL VEIN TREATMENT STRATEGIES I
Moderators:Kursat A. Bozkurt, MD / Sergio Gianesini, MD, PhD, FACS
|
|
x | |
8:53 AM - 8:58 AM | The Length Of Treated Great Saphenous Vein As A Marker Of Post-Procedural Improvement In Clinical And Patient Reported Outcomes |
Presenter(s):Windsor Ting, MD | |
8:59 AM - 9:04 AM | Update On Fovelass – Society Of French Phlebology Study: RCT Comparing Foam And EVLA In SSV Incompetence |
Presenter(s):Claudine M. Hamel-Desnos, MD | |
9:05 AM - 9:10 AM | What Do You Treat First In C2s With Reflux Of The GSV, SSV, And Vein Of Giacomini |
Presenter(s):Jean Luc Gerard, MD | |
9:11 AM - 9:16 AM | Saphenous Sparing: Why And Instructions For Users |
Presenter(s):Sergio Gianesini, MD, PhD, FACS | |
9:17 AM - 9:22 AM | Thermal Saphenous Vein Recanalization: Risk Factors |
Presenter(s):Ruth L. Bush, MD, MPH | |
9:23 AM - 9:28 AM | Ultrasound Aspects Of The Vein Over Time After Foam Sclerotherapy, And Clinical Consequences |
Presenter(s):Claudine M. Hamel-Desnos, MD | |
9:29 AM - 9:34 AM | Thrombus Extension After Cyanoacrylate Closure Versus Endovenous Glue Induced Thrombosis: What Is The Difference |
Presenter(s):Nuttawut Sermsathanasawadi, MD, PhD | |
9:35 AM - 9:40 AM | Synchronous Trial 12 Months Follow-Up Data (Simultaneous AASV Treatment For Patients Undergoing GSV Ablation) |
Presenter(s):Tobias Hirsch, MD | |
9:41 AM - 9:46 AM | Effects Of Truncal Ablation On Pregnancy |
Presenter(s):Kursat A. Bozkurt, MD | |
9:47 AM - 9:52 AM | Saphenous Ablation On Direct Oral Anticoagulants: Safe, Effective And Durable |
Presenter(s):Glenn Jacobowitz, MD | |
9:53 AM - 9:58 AM | Panel Discussion |
END OF SESSION 66 | |
SESSION 67 SCHEDULE | |
Thursday
SESSION 67:
SUPERFICIAL VEIN TREATMENT STRATEGIES II
|
|
x | |
9:59 AM - 10:04 AM | Decision Making In Saphenous Ablation: What To Use And When |
Presenter(s):Steve Elias, MD | |
10:05 AM - 10:10 AM | Diameters Of The Great Saphenous Vein In Phlebological Practice In France: Report Of The DIAGRAVES Study By The French Society of Phlebology |
Presenter(s):Matthieu M.J. Josnin, MD | |
10:11 AM - 10:16 AM | Non-Compounded Polidocanol 1% Endovenous Microfoam (Varithena) Or Thermal Ablation: A Network Meta-Analysis |
Presenter(s):Lowell S. Kabnick, MD, FACS, FAVLS, DFAVF | |
10:17 AM - 10:22 AM | The Persistent Sciatic Vein |
Presenter(s):Julianne Stoughton, MD, FACS | |
10:23 AM - 10:28 AM | SVT Treatment During Pregnancy: Treatment Choices |
Presenter(s):Kathleen J. Ozsvath, MD | |
10:29 AM - 10:34 AM | Would Treatment Of The Whole Length Of The GSV Reduce Recurrence And Reinterventions |
Presenter(s):Alun H. Davies, MA, DM, DSc, FRCS, FLSW, FMedSci, FEBVS | |
10:35 AM - 10:40 AM | Thermal Versus Nonthermal: Is It Time To Stop The FIRE |
Presenter(s):Sergio Gianesini, MD, PhD, FACS | |
10:41 AM - 10:46 AM | African American Patient Outcomes After Saphenous Ablation For Advanced Venous Disease |
Presenter(s):Faisal Aziz, MD | |
10:47 AM - 10:52 AM | The Use Of Simultaneous Foam Sclerotherapy And Thermal Treatment In Varicose Vein Treatment: Why |
Presenter(s):Tobias Hirsch, MD | |
10:53 AM - 10:58 AM | Complications Of Endovenous Thermal Ablation Of The GSV |
Presenter(s):Dale Maharaj, MD | |
10:59 AM - 11:04 AM | Panel Discussion |
END OF SESSION 67 | |
SESSION 68 SCHEDULE | |
Thursday
SESSION 68:
SUPERFICIAL VEIN TREATMENT STRATEGIES III
Moderators:Manj S. Gohel, MD, FRCS, FEBVS / Houman Jalaie, MD, PhD
|
|
x | |
11:05 AM - 11:10 AM | When Is It OK To Ablate The Truncal Leg Veins With Chronic Iliofemoral Outflow Obstruction |
Presenter(s):Houman Jalaie, MD, PhD | |
11:11 AM - 11:16 AM | SVT Medical Management In 2024: Is There A Role For Surgical Intervention And When |
Presenter(s):Manj S. Gohel, MD, FRCS, FEBVS | |
11:17 AM - 11:22 AM | Management Of Labial And Vulvar Veins |
Presenter(s):Julianne Stoughton, MD, FACS | |
11:23 AM - 11:28 AM | VEINS – An International Platform Trial Collaboration |
Presenter(s):Sarah Onida, MD, PhD | |
11:29 AM - 11:34 AM | What You Should Know About Klippel-Trenaunay Syndrome |
Presenter(s):Byung-Boong Lee, MD | |
11:35 AM - 11:40 AM | Treatment And Pitfalls: Lateral Marginal Vein |
Presenter(s):Peter Gloviczki, MD | |
11:41 AM - 11:46 AM | Overview Of Multicenter Venclose Study And Early Results |
Presenter(s):Erin H. Murphy, MD | |
11:47 AM - 11:52 AM | Great Saphenous Vein Crossectomy: Why |
Presenter(s):Ayman Fakhry, MD | |
11:53 AM - 11:58 AM | What Is Maven: Is There Any Data |
Presenter(s):Jeffrey G. Carr, MD | |
11:59 AM - 12:04 PM | Does Vein Stenting Reduce Great And Small Saphenous Venous Reflux |
Presenter(s):Natalie A. Marks, MD, RPVI, RVT, FSVM | |
12:05 PM - 12:10 PM | Safety And Efficacy Of Endovenous Ablation In Patients With A History Of Deep Venous Thrombosis |
Presenter(s):Mikel Sadek, MD | |
12:11 PM - 12:16 PM | Value And Limitations Of Postoperative Duplex Scans After Endovenous Thermal Ablation |
Presenter(s):Natalie A. Marks, MD, RPVI, RVT, FSVM | |
12:17 PM - 12:22 PM | VEINRESET: US Multicenter HIFU Trial: 6-Month Results |
Presenter(s):Steve Elias, MD | |
12:23 PM - 12:28 PM | Panel Discussion |
12:28 PM - 1:00 PM | Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 68 | |
SESSION 69 SCHEDULE | |
Thursday
SESSION 69:
SUPERFICIAL VEIN TREATMENT STRATEGIES IV
|
|
x | |
1:01 PM - 1:06 PM | Cyanoacrylate And The Small Saphenous Vein: How To Treat The Various Anatomy |
Presenter(s):Janna Bentley, MD | |
1:07 PM - 1:12 PM | Lack Of Symptom Improvement: Why |
Presenter(s):Jeffrey G. Carr, MD | |
1:13 PM - 1:18 PM | Is There Any Evidence For Compression |
Presenter(s):William A. Marston, MD | |
1:19 PM - 1:24 PM | New Superficial Venous Devices: Pre FDA Approval |
Presenter(s):Lowell S. Kabnick, MD, FACS, FAVLS, DFAVF | |
1:25 PM - 1:30 PM | Forecast For Venous Reimbursement 2025 |
Presenter(s):John Blebea, MD, MBA | |
1:31 PM - 1:36 PM | Factors Associated With Recanalization And Reintervention Following Below Knee Polidocanol Endovenous Microfoam |
Presenter(s):Natalie A. Marks, MD, RPVI, RVT, FSVM | |
1:37 PM - 1:42 PM | Which Saphenous Vein Recanalization Should Be Treated And By What Method: Evidence Based |
Presenter(s):Jose I. Almeida, MD, FACS, RPVI, RVT | |
1:43 PM - 1:48 PM | Varithena Meta-Analysis “RELOADED”, The Living Approach |
Presenter(s):Lowell S. Kabnick, MD, FACS, FAVLS, DFAVF | |
1:49 PM - 1:54 PM | Accessory Veins And Their Impact On Recurrence |
Presenter(s):Kerstin S. Schick, MD | |
1:55 PM - 2:00 PM | Deviation Operation In Patients With Deep Venous Reflux And CVI: First Clinical Results |
Presenter(s):Sebastian E. Debus, MD, PhD | |
2:01 PM - 2:06 PM | Do You Need To Treat Venous Tributaries: Pros And Cons |
Presenter(s):Kerstin S. Schick, MD | |
2:07 PM - 2:12 PM | Venous VQI: Ten Years Of Improving Venous Outcomes And Quality |
Presenter(s):Marc A. Passman, MD | |
2:13 PM - 2:18 PM | Panel Discussion |
END OF SESSION 69 | |
SESSION 70 SCHEDULE | |
Thursday
SESSION 70:
SUPERFICIAL VEIN TREATMENT STRATEGIES V
Moderators:Victor M. Canata, MD, PhD / Kasuo Miyake, MD, PhD
|
|
x | |
2:19 PM - 2:24 PM | Venous Lesions Of The Face |
Presenter(s):Kasuo Miyake, MD, PhD | |
2:25 PM - 2:30 PM | Truncal Vein Treatment For Chronic Venous Disease: Is Varithena Endovenous Ablation Or Physician Compounded Foam The Answer |
Presenter(s):Edward G. Mackay, MD | |
2:31 PM - 2:36 PM | Physician Compounded Foam For Truncal Vein Disease: When And Where |
Presenter(s):Matthieu M.J. Josnin, MD | |
2:37 PM - 2:42 PM | Varithena®VLU Registry: Update On The Effects Of Polidocanol Endovenous Microfoam On Wound Healing And Recurrence |
Presenter(s):Raghu Kolluri, MD | |
2:43 PM - 2:48 PM | Phlebectomy Versus Sclerotherapy: Which Is Superior When Considering Efficacy, Complications, And Aesthetics |
Presenter(s):Alun H. Davies, MA, DM, DSc, FRCS, FLSW, FMedSci, FEBVS | |
2:49 PM - 2:54 PM | Ultrasound Guided Foam Sclerotherapy For Reticular Venous Plexus: Systematization Of The Technique |
Presenter(s):Alvaro Orrego, MD, FACS | |
2:55 PM - 3:00 PM | Tips And Tricks Of Sclerotherapy: What Makes It Easier And Successful |
Presenter(s):Victor M. Canata, MD, PhD | |
3:01 PM - 3:06 PM | How To Avoid Complications From Sclerotherapy |
Presenter(s):Jean Luc Gerard, MD | |
3:07 PM - 3:12 PM | Comparison Of Laser And Chemical Sclerosant Versus Sclerosant |
Presenter(s):Kasuo Miyake, MD, PhD | |
3:13 PM - 3:18 PM | Quick Case 1: Ask The Panel Or Audience What Would You Do (Cosmetic) |
Presenter(s):Edward G. Mackay, MD | |
3:19 PM - 3:24 PM | Quick Case 2: Ask The Panel Or Audience What Would You Do (Cosmetic) |
Presenter(s):Janna Bentley, MD | |
3:25 PM - 3:30 PM | Panel Discussion |
END OF SESSION 70 | |
SESSION 71 SCHEDULE | |
Thursday
SESSION 71:
SUPERFICIAL VEIN TREATMENT STRATEGIES VI
Moderators:Kathleen D. Gibson, MD / Sarah Onida, MD, PhD
|
|
x | |
3:31 PM - 3:36 PM | Global Epidemiology Of Chronic Venous Disease: A Systematic Review With Pooled Prevalence Analysis |
Presenter(s):Sarah Onida, MD, PhD | |
3:37 PM - 3:42 PM | When Evaluating Superficial Disease, When Do You Look For Deep Venous Obstruction |
Presenter(s):Gloria Salazar, MD | |
3:43 PM - 3:48 PM | Not All C2 Disease Should Be Treated: An Algorithm To Predict Severity |
Presenter(s):Mikel Sadek, MD | |
3:49 PM - 3:54 PM | Ablative Risks Prior And After Flying: What Do You Tell Your Patients |
Presenter(s):Sarah Onida, MD, PhD | |
3:55 PM - 4:00 PM | Body Mass Index And CEAP Clinical Severity Score |
Presenter(s):Oscar Bottini, MD | |
4:01 PM - 4:06 PM | How Do We Assess Quality Of Life After Venous Interventions: Patient-Reported Outcomes For Chronic Venous Insufficiency |
Presenter(s):Kathleen D. Gibson, MD | |
4:07 PM - 4:12 PM | Optimal Thromboprophylaxis And Post-Op Duplex Imaging Following Superficial Venous Procedures: Evidence Based |
Presenter(s):Andrea T. Obi, MD | |
4:13 PM - 4:18 PM | Mechanical Chemically Assisted Ablation Of Varicose Veins For Venous Insufficiency: American Vein And Lymphatic Society Position Statement |
Presenter(s):John Blebea, MD, MBA | |
4:19 PM - 4:24 PM | Radiofrequency Ablation Versus Polidocanol Endovenous Microfoam Ablation Of Large Diameter Saphenous And Tributary Veins |
Presenter(s):Juan Carlos Jimenez, MD, MBA | |
4:25 PM - 4:30 PM | Outcome Of Early CAC And Compression Therapy In Healing Of VLU |
Presenter(s):Nuttawut Sermsathanasawadi, MD, PhD | |
4:31 PM - 4:36 PM | Randomized Clinical Trial Comparing Cyanoacrylate Glue Closure With Surgical Striping: 30D And 6M Outcomes |
Presenter(s):Manj S. Gohel, MD, FRCS, FEBVS | |
4:37 PM - 4:42 PM | How To Avoid Complications Of The Small Saphenous Vein |
Presenter(s):Jean Luc Gerard, MD | |
4:43 PM - 4:48 PM | Mechanical Occlusion Segmental Chemical Ablation (MOSCA): Animal Study With Wavella Device |
Presenter(s):Steve Elias, MD | |
4:49 PM - 5:04 PM | Panel Discussion |
END OF SESSION 71 | |
SESSION 72 SCHEDULE | |
Thursday
SESSION 72:
LIPEDEMA, LYMPHEDEMA, PHLEBOLYMPHEDEMA
Moderators:Raghu Kolluri, MD / Ayman Fakhry, MD
|
|
x | |
5:05 PM - 5:10 PM | Lower Extremity Edema Workup |
Presenter(s):Maxim Shaydakov, MD, PhD | |
5:11 PM - 5:16 PM | What Is Lipedema And The Current Management |
Presenter(s):Steven M. Dean, DO | |
5:17 PM - 5:22 PM | Risks And Contraindications Of Medical Compression Treatment – A Critical Reappraisal: An International Consensus Statement |
Presenter(s):Tomasz Urbanek, MD | |
5:23 PM - 5:28 PM | Venolymphatic Edema And Its Treatment Options |
Presenter(s):Raghu Kolluri, MD | |
5:29 PM - 5:34 PM | Are Lymphedema, Lipedema, And Edema Related |
Presenter(s):Steven M. Dean, DO | |
5:35 PM - 5:40 PM | Role Of Hydrotherapy In Lymphedema Treatment |
Presenter(s):Ayman Fakhry, MD | |
5:41 PM - 5:46 PM | Update On Pharmacological Treatment For Lymphedema |
Presenter(s):Monika L. Gloviczki, MD, PhD | |
5:47 PM - 5:52 PM | Panel Discussion |
END OF SESSION 72 | |
SESSION 73 SCHEDULE | |
x | |
5:53 PM - 5:58 PM | Turkish Glue And Perforating Veins In VLU Patients |
Presenter(s):Kursat A. Bozkurt, MD | |
5:59 PM - 6:04 PM | Factors That Influence Venous Leg Ulcer Healing And Recurrence Rate After Endovenous Ablation Of Truncal Veins |
Presenter(s):Nuttawut Sermsathanasawadi, MD, PhD | |
6:05 PM - 6:10 PM | Review Of Current Evidence For Topical Treatment For Venous Leg Ulcers |
Presenter(s):Yuri Casseres, MD | |
6:11 PM - 6:16 PM | Why Venous Leg Ulcers Have Difficulty Healing |
Presenter(s):Joseph D. Raffetto, MD | |
6:17 PM - 6:22 PM | Role Of Superficial Venous Therapies In Improving Venous Ulcer Healing: Choice Of Techniques And Use Of Adjunctive Strategies |
Presenter(s):Sung Yup Kim, MD | |
6:23 PM - 6:28 PM | Venous Ulcers: The Contributions Of Deep, Perforator, And Superficial Procedures On Wound Healing |
Presenter(s):Peter F. Lawrence, MD | |
6:29 PM - 6:34 PM | Skin Substitutes To Promote Venous Leg Ulcer Healing: What Is The Evidence |
Presenter(s):Yuri Casseres, MD | |
6:35 PM - 6:40 PM | Compression, Oxygen, And Humidification: Does It Improve Wound Healing |
Presenter(s):Anil P. Hingorani, MD | |
6:41 PM - 6:46 PM | Update On Pharmacological Treatment For Venous Ulcers |
Presenter(s):Monika L. Gloviczki, MD, PhD | |
6:47 PM - 6:52 PM | Panel Discussion End of Program I |
END OF SESSION 73 | |
SESSION 74 SCHEDULE | |
Thursday
SESSION 74:
ADVANCES IN STROKE AND THE NEXT FRONTIER
Moderators:Allan L. Brook, MD / Joshua A. Hirsch, MD
|
|
x | |
7:30 AM - 7:40 AM | Introduction |
Presenter(s):Allan L. Brook, MD | |
7:41 AM - 7:48 AM | Evidence Of Acute Stroke Care And What Gaps Are Left To Fill |
Presenter(s):Dan Antoniello, MD | |
7:49 AM - 7:56 AM | Stroke Imaging Triage: Pearls And Nuances Of Daily Practice |
Presenter(s):Raj Gupta, MD | |
7:57 AM - 8:04 AM | Should ELVO Patients Go Directly To The Angio Suite |
Presenter(s):Eytan Raz, MD | |
8:05 AM - 8:12 AM | Next Generation Thrombectomy Devices And How They Impact Clinical Outcomes |
Presenter(s):David Fiorella, MD, PhD | |
8:13 AM - 8:20 AM Power Point Presentation with Synched Audio |
Tandem Occlusions: Should We Stent – Above, Below, Both, Or Neither |
Presenter(s):Adnan H. Siddiqui, MD, PhD | |
8:21 AM - 8:28 AM | Direct Carotid Access: Is It Time For This Time Saving Approach |
Presenter(s):Ajay K. Wakhloo, MD, PhD, FAHA, FSNIS | |
8:29 AM - 8:36 AM | Imaging Pearls That Save Time |
Presenter(s):Lawrence N. Tanenbaum, MD | |
8:37 AM - 8:44 AM | Aspirations In Aspiration Thrombectomy |
Presenter(s):James Milburn, MD | |
8:45 AM - 8:52 AM | Distal/Middle Intracranial Occlusion Can Lead To Significant Morbidity: Should They Be Treated |
Presenter(s):Charles Esenwa, MD, MS | |
END OF SESSION 74 | |
SESSION 75 SCHEDULE | |
Thursday
SESSION 75:
INTRACRANIAL HEMORRHAGE, VESSEL WALL IMAGING AND NEW DEVELOPMENTS
Moderators:Deepak Khatri, MD / David Gordon, MD
|
|
x | |
8:53 AM - 9:00 AM | Radial And Ulnar Anatomy/Access; Complication Management |
Presenter(s):Sudhakar R. Satti, MD | |
9:01 AM - 9:08 AM | Literature That Has Changed Over The Last Year And How It Has Changed Our Practice |
Presenter(s):Chirag D. Gandhi, MD | |
9:09 AM - 9:16 AM | INTRASACCULAR DEVICES: For SAH, Or Only Elective Cases |
Presenter(s):Ansaar T. Rai, MD | |
9:17 AM - 9:24 AM | A Neiman Fellow Analyzes How The No Surprises Act Interests With MT 4 ELVO Stroke |
Presenter(s):Joshua A. Hirsch, MD | |
9:25 AM - 9:32 AM | Is There Any Imaging To Distinguish Intracranial Athero Versus Embolic Thrombus |
Presenter(s):Richard L. Zampolin, MD | |
END OF SESSION 75 | |
SESSION 76 SCHEDULE | |
Thursday
SESSION 76:
CAROTID AND CEREBRAL ANEURYSMS LATER TRENDS AND POTPOURRI
Moderators:Reade A. De Leacy, MBBS / Amichai J. Erdfarb, MD
|
|
x | |
9:33 AM - 9:40 AM | Robots Are A Bust In The Brain, Or Are We Waiting For Next Generation Devices And Insights |
Presenter(s):Aquilla S. Turk, DO | |
9:41 AM - 9:48 AM | Intracranial Aneurysm Literature: What Has ARISEn |
Presenter(s):David S. Liebeskind, MD | |
9:49 AM - 9:56 AM | Basilar Artery Thrombectomy: Planning For Efficient Revascularization |
Presenter(s):Maksim Shapiro, MD | |
9:57 AM - 10:04 AM | SDH And MMA Embolization: What Is The Standard Of Care |
Presenter(s):Adam S. Arthur, MD | |
10:05 AM - 10:12 AM | MMA Embolization: Does The Embolic Material Really Matter And Why |
Presenter(s):J Mocco, MD, MS | |
END OF SESSION 76 | |
SESSION 77 SCHEDULE | |
Thursday
SESSION 77:
PEDIATRIC STROKE AND LESSONS TO BE LEARNED IN UNIQUE CEREBROVASCULAR ARENAS
Moderators:Allan L. Brook, MD / Peter K. Nelson, MD
|
|
x | |
10:13 AM - 10:20 AM | Pediatric Stroke, And Are Endovascular Methods The Same As For Adults |
10:21 AM - 10:28 AM | Great Pediatric Neurointerventional Cases |
Presenter(s):Amanda Baker, MD | |
10:29 AM - 10:36 AM | 70 Years Of NI Practice: My Most Interesting Case Pearls For All To Enjoy |
Presenter(s):Peter K. Nelson, MD | |
10:37 AM - 10:44 AM | Dural Sinus Stenosis: Is There A Standard Of Care |
Presenter(s):Athos Patsalides, MD, MPH | |
10:45 AM - 10:52 AM | Carotid Blowout: Evidence And Treatment Options |
Presenter(s):Guilherme Dabus, MD | |
10:53 AM - 11:00 AM | Artificial Intelligence: Relevance In Stroke And How It Will Impact Our Lives |
Presenter(s):Allan L. Brook, MD | |
END OF SESSION 77 | |
SESSION 78 SCHEDULE | |
Thursday
SESSION 78:
CAROTID ARTERY THERAPY STARS AND LATEST TRENDS
Moderators:Thomas G. Brott, MD / Don Heck, MD
|
|
x | |
11:01 AM - 11:08 AM | Carotid Artery Disease: New Trials And Best Literature 2023 |
Presenter(s):Thomas G. Brott, MD | |
11:09 AM - 11:16 AM | TCAR Is Better Than True Percutaneous Carotid Stenting: Myth Or Reality |
Presenter(s):Peter A. Schneider, MD | |
11:17 AM - 11:24 AM | CAS Versus TCAR Versus CEA: They Cannot Be Equal And Why |
Presenter(s):Don Heck, MD | |
11:25 AM - 11:32 AM | CEA Done Through A Microincision Versus TCAR: Why Do So Few Perform This |
Presenter(s):Enrico Ascher, MD | |
11:33 AM - 11:40 AM | Latest Stenting Technology For The Carotid Artery: Does It Match The Evidence |
Presenter(s):Michele Antonello, MD | |
11:41 AM - 11:56 AM Power Point Presentation with Synched Audio |
Encore: Why Does Everybody Outside Of Australia Overtreat Carotids (15-Minute Presentation) |
Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
11:57 AM - 12:15 PM | Panel Discussion End Of Program J |
END OF SESSION 78 | |
Friday, November 22, 2024
Print Entire 2024 Program:
|
|
SESSION 79 SCHEDULE | |
Friday
SESSION 79:
PROGRESS IN THE PREVENTION AND TREATMENT OF SPINAL CORD ISCHEMIA (SCI) ASSOCIATED WITH THE TREATMENT OF THORACIC, THORACOABDOMINAL AND COMPLEX ABDOMINAL ANEURYSMS
|
|
x | |
6:40 AM - 6:45 AM | New Experimental Work In Avoiding SCI After TAAA Repair: How Can A Sheep Model Of TEVAR Be Helpful |
Presenter(s):Hamdy Awad, MD | |
6:46 AM - 6:51 AM | With Complex AAAs And Type IV TAAAs, The Incidence Of SCI Is 3 Times Greater With Endovascular Repairs Than Open Repairs: Why Is This A Controversial Finding And How Can It Be So |
Presenter(s):George Geroulakos, MD, PhD | |
6:52 AM - 6:57 AM | Prediction Of Spinal Cord Ischemia With AI After Aortic Procedures: Combinations Of Anatomic Features Accurately Predict Risk |
Presenter(s):Kak Khee Yeung, MD, PhD | |
6:58 AM - 7:03 AM | What Is The Muenster Strategy To Avoid SCI After F/B/EVAR For TAAA: What Is The Proof That It Works |
Presenter(s):Martin J. Austermann, MD | |
7:04 AM - 7:09 AM | How To Use Motor Evoked Potentials (MEPs) To Decrease The Incidence Of SCI After Open And Endo TAAA Repairs: What Else Is Important |
Presenter(s):James H... Black, III, MD | |
7:10 AM - 7:15 AM | Role Of Direct Segmental Artery Revascularization To Prevent SCI After Endovascular TAAA Repairs: When And How To Do It |
Presenter(s):Sukgu Han, MD | |
7:16 AM - 7:21 AM | Current Strategies To Minimize SCI With TAAA Repairs (Endo And Open) By Improving The Intraspinal Collateral Arterial Network: Status Of Intercostal Embolization As Preconditioning To Prevent Ischemia (MIS2ACE): Progress Of The PAPA-ARTIS RCT |
Presenter(s):Christian D. Etz, MD, PhD | |
7:22 AM - 7:27 AM | Extensive Single Center Clinical Experience With Intercostal Coil Embolization (MIS2ACE) To Prevent SCI With Endovascular TAAA Repair: How And When To Do It: Why We Still Need An RCT |
Presenter(s):Daniela Branzan, MD / Andrej Schmidt, MD | |
7:28 AM - 7:33 AM | Why Cerebrospinal Fluid (CSF) Drainage To Decrease SCI With TAAA Repair Is Not A Benign Procedure: When To Use It And When Not |
Presenter(s):Gustavo S. Oderich, MD, FACS | |
7:34 AM - 7:39 AM | Prevention Of SCI After Endovascular TAAA Repairs: Lessons Learned From The US Aortic Research Consortium (ARC) |
Presenter(s):Adam Beck, MD / Mark A. Farber, MD / Andres Schanzer, MD | |
7:40 AM - 7:45 AM | Shifts In Prevention Protocols For SCI During Open And Endovascular TAAA Repairs: What Is Agreed On And What Remains Controversial |
Presenter(s):Germano C.G. Melissano, MD / Roberto L.V. Chiesa, MD | |
7:46 AM - 7:54 AM | Panel Discussion |
END OF SESSION 79 | |
SESSION 80 SCHEDULE | |
Friday
SESSION 80:
NEW DEVELOPMENTS IN THE TREATMENT OF CAROTID STENOSIS: UPDATE ON MESH COVERED STENTS AND TCAR (TRANSCERVICAL CAROTID ARTERY REVASCULARIZATION)
|
|
x | |
7:54 AM - 7:59 AM | Carotid Webs: An Important Etiology Of Devastating Strokes Especially In Young Women: How Should They Be Diagnosed And Treated |
Presenter(s):Bruce A. Perler, MD, MBA | |
MESH COVERED STENTS | |
8:00 AM - 8:05 AM | Long-Term Results Of Micromesh Stents Show Their Value In Carotid Artery Stenting (CAS): Are There Limitations: Do The Differences In The 3 Micromesh Stents Matter |
Presenter(s):Max Amor, MD / D. Christopher Metzger, MD | |
8:06 AM - 8:11 AM Power Point Presentation with Synched Audio |
When You Can Do All, How To Decide Between CEA, TCAR And TFCAS: Will Mesh Covered Stents Like CGuard Make A Difference |
Presenter(s):Adnan H. Siddiqui, MD, PhD / L. Nelson Hopkins, MD | |
8:12 AM - 8:17 AM | Outcome Of TCAR Combined With A Mesh-Covered Stent (CGuard From InspireMD): The Best Of All Worlds: What Is The Proof |
Presenter(s):Ralf R. Kolvenbach, MD | |
8:18 AM - 8:23 AM | Update On All Trial Results With CGuard And CGuard Prime MicroMesh Covered Stents (InspireMD): Are They Making A Difference And Limitations With Transfemoral/Transradial CAS: Evidence Summary And Long-Term Outcomes |
Presenter(s):Piotr Musialek, MD, DPhil / D. Christopher Metzger, MD / Stefan Mueller-Huelsbeck, MD | |
8:24 AM - 8:29 AM | US Studies And Status Of The CGuard And CGuard Prime MicroMesh Stents: Can They Be Used In TCAR And Are They Making A Difference |
Presenter(s):Patrick J. Geraghty, MD | |
8:30 AM - 8:35 AM | Latest Real-World Results Of >2,000 Patients Treated With The Roadsaver (Terumo) Dual-Layer Micromesh Carotid Stent |
Presenter(s):Stefan Mueller-Huelsbeck, MD | |
8:36 AM - 8:42 AM | Panel Discussion |
TCAR RELATED TOPICS | |
8:42 AM - 8:47 AM | Update On Comparative Performance And Risks Of TCAR, Transfemoral CAS (TFCAS) And CEA With > 50K TCAR, 25K TFCAS, And 100K CEA: This Population Based Study Shows That CEA Is Better Than TCAR Which Is Better Than TFCAS |
Presenter(s):Marc L. Schermerhorn, MD / Mahmoud B. Malas, MD, MHS | |
8:48 AM - 8:53 AM | Is TCAR Ready To Replace CEA: What About The Clinical Results To Date: What About The Impact Of Clever Marketing: How Will We Find Out |
Presenter(s):Bruce A. Perler, MD, MBA | |
8:54 AM - 8:59 AM | DEBATE: CEA Versus TCAR In A Single Center Propensity Matched Study: The Outcomes Of The Two Treatments Are Comparable At 30 Days But TCAR Has A Higher Mortality At 2 Years |
Presenter(s):Ali F. AbuRahma, MD / Zach AbuRahma, DO | |
9:00 AM - 9:05 AM | DEBATE: Not So: TCAR Like TFCAS Has Durable Effectiveness Without Increased Mortality At 2 Years And Beyond |
Presenter(s):Sumaira Macdonald, MD, PhD | |
9:06 AM - 9:11 AM | Favorable 30-Day Results Of TCAR In Good Risk Symptomatic And Asymptomatic Patients: Late Breaking Trial Results From ROADSTER 3 Shows That The Stroke, Death And MI Rates Are Lower Than In High Risk Patients |
Presenter(s):Marc L. Schermerhorn, MD | |
9:12 AM - 9:17 AM | TCAR Is Safe In Recently Symptomatic Patients And Those With Contralateral Carotid Occlusions: Why TCAR Should Be The Procedure Of Choice In These Conditions |
Presenter(s):Peter A. Schneider, MD | |
9:18 AM - 9:23 AM | Panel Discussion |
9:24 AM - 9:34 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 80 | |
SESSION 81 SCHEDULE | |
Friday
SESSION 81:
MORE CAROTID HOT TOPICS RELATED TO TCAR, CAS AND EFFECTS OF INTERVENTIONS ON COGNITIVE FUNCTION
|
|
x | |
9:35 AM - 9:40 AM | Comparative Cost Effectiveness Of TCAR, CEA, TFCAS: CEA Is More Cost Effective Than TCAR And TCAR Is More Cost Effective Than TFCAS |
Presenter(s):Mohammad H. Eslami, MD, MPH | |
9:41 AM - 9:46 AM | Intracranial Angiography During TCAR: Why It Can Be Valuable And How To Do It In View Of Flow Reversal |
Presenter(s):Peter L. Faries, MD, FACS | |
9:47 AM - 9:52 AM | Best Device Selection For CAS: What Stent Type And Design, What Type Of Cerebral Protection, What Approach And Delivery System: A Review Of The Evidence |
Presenter(s):Carlo Setacci, MD / Francesco Setacci, MD | |
9:53 AM - 9:58 AM | Comparison Of SVS Versus ESVS Carotid Guidelines For Treatment Of Asymptomatic Carotid Artery Stenosis: What Is Known For Sure And What Remains Controversial |
Presenter(s):Ali F. AbuRahma, MD | |
9:59 AM - 10:04 AM | Management Of Anticoagulants And Antiplatelet Therapy In TCAR Patients |
Presenter(s):Michael C. Stoner, MD | |
CAROTID STENOSIS AND COGNITIVE FUNCTION | |
10:05 AM - 10:10 AM | Preservation Of Cognition: The New Role For Carotid Artery Interventions For Asymptomatic Disease: Will CREST 2 Confirm Or Deny Its Importance: Findings To Date |
Presenter(s):Wesley S. Moore, MD / Brajesh K. Lal, MD / Thomas G. Brott, MD | |
10:11 AM - 10:16 AM | DEBATE: Carotid Intervention Improves Cognitive Function Of Patients With Severe Asymptomatic Carotid Stenosis (ACS): What About In Octogenarians: Should More Or Fewer ACS Patients Undergo Invasive Treatment |
Presenter(s):Wei Zhou, MD | |
10:17 AM - 10:22 AM Power Point Presentation with Synched Audio |
DEBATE: Not So Fast: There Is Still Great Doubt That Eliminating ACS Improves Cognitive Function: It Should Not Be A Reason For Treating More ACS Patients |
Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
10:23 AM - 10:30 AM | Panel Discussion |
END OF SESSION 81 | |
SESSION 82 SCHEDULE | |
Friday
SESSION 82:
MORE CAROTID RELATED NEW DEVELOPMENT TOPICS RELATED TO TCAR, CAS AND CEA, NEW DEVICES, MESH COVERED STENTS, MINI-INCISION CEA, SIGNIFICANCE OF DW MRI DEFECTS, TIMING OF TREATMENT, MEDICAL TREATMENT AND DEALING WITH DISTAL (HIGH) CAROTID LESIONS
|
|
x | |
10:30 AM - 10:35 AM Power Point Presentation with Synched Audio |
Transradial CAS Using Novel Low-Profile Double-Mesh Stents (Roadsaver, Terumo): Results And Technical Tips |
Presenter(s):Andrea Kahlberg, MD | |
10:36 AM - 10:41 AM | Selecting Patients For Carotid Intervention Is Getting Harder: Candidates Are Older (And Sicker), Anatomic Imaging Is Not Standardized, Medical Therapy Is Improving, More Options For Intervention Exist And Cries For Non-Operative Management Are Getting Louder: Is Consensus Even Possible |
Presenter(s):Reese A. Wain, MD | |
SIGNIFICANCE OF SMALL DW MRI DEFECTS AFTER CEA/CAS | |
10:42 AM - 10:47 AM | DEBATE: Silent DWI MRI Brain Lesions (Small Infarcts) After CEA/CAS Don’t Matter |
Presenter(s):Thomas G. Brott, MD | |
10:48 AM - 10:53 AM | DEBATE: Not So: Silent Brain Infarcts (DW MRI Defects) After CEA/CAS Really Matter And Affect Cognitive Changes: The Size And Number Of DW MRI Defects Are Critical |
Presenter(s):Wei Zhou, MD | |
10:54 AM - 10:59 AM | Value Of Lithotripsy (Shockwave) For CAS In Heavily Calcified Lesions: How To Do It Safely And Technical Tips: Limitations And Precautions |
Presenter(s):Max Amor, MD | |
11:00 AM - 11:05 AM | Minimal Incision CEA (MICE) Versus TCAR: Technical Tips For MICE, Cost Effectiveness, Advantages And Limitations Of Both |
Presenter(s):Enrico Ascher, MD | |
11:06 AM - 11:11 AM | For Symptomatic Carotid Stenosis Invasive Treatment (TFCAS, CEA, TCAR) On Weekends Is More Risky: This Is Especially True For TFCAS Which Probably Should Not Be Performed On Weekends |
Presenter(s):Heepeel Chang, MD | |
11:12 AM - 11:18 AM | Panel Discussion |
11:18 AM - 11:23 AM | What Is The Best Medical Treatment For Patients With Carotid Stenosis (Asymptomatic And Symptomatic): Can High Risk Plaques Be Made Low Risk And Smaller: All Stroke Patients Should Be On Statins Because They Markedly Decrease Recurrent Stroke And Mortality Rates |
Presenter(s):J. David Spence, MD | |
11:24 AM - 11:29 AM | Technical Tips And Maneuvers To Make Treatment Of High Carotid Lesions Safe And Relatively Simple |
Presenter(s):Richard J. Powell, MD | |
11:30 AM - 11:35 AM | What Are The Real Risk Factors For CEA, TFCAS And TCAR: Why Has CMS Gotten Their Risk Factors Wrong And How Have They Messed Up Their Reimbursement Incentives |
Presenter(s):Mahmoud B. Malas, MD, MHS | |
TIMING OF CAROTID INTERVENTIONS AFTER SYMPTOM ONSET | |
11:36 AM - 11:41 AM | When Is Urgent (Within 48 Hours) CEA Or CAS Fairly Indicated After A Stroke: How Does Use Of tPA Influence Indications And Neurologic Outcomes In This Setting |
Presenter(s):Hernan A. Bazan, MD, DFSVS, FACS | |
11:42 AM - 11:47 AM | When Is It Reasonable To Perform CEA Within 48 Hours After Stroke Symptoms Starts: Under What Conditions And What Precautions Should Be Taken |
Presenter(s):R. Clement Darling III, MD | |
11:48 AM - 11:53 AM | With Crescendo TIAs And Thrombus Overlying A Plaque What Is The Best Invasive Treatment And When Should It Be Performed |
Presenter(s):Domenico Valenti, DMChir, PhD, FRCS, FRCS(Ed), FEBVS | |
11:54 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 82 | |
SESSION 83 SCHEDULE | |
Friday
SESSION 83:
MORE HOT CAROTID AND SUBCLAVIAN TOPICS: UPDATES ON KEY CAROTID RCTs
|
|
x | |
1:00 PM - 1:05 PM | Lipid Management For High Risk Carotid Lesions: Statins, Ezetimibe, PCSK9 And What Else: Should LDL-C Be Monitored |
Presenter(s):Christos D. Liapis, MD | |
UPDATE ON CAROTID RCTs | |
1:06 PM - 1:11 PM | Update On CREST 2: CEA Versus Best Medical Treatment (BMT) And CAS Versus BMT For Asymptomatic Carotid Stenosis (ACS): Recruitment And Findings To Date: Why Not Present The 30-Day And 1-Year Results: If BMT Showed No Difference In Stroke And Death Rates With Those Of CAS Or CEA, Wouldn’t This Remove Justification For Invasive Treatment Of ACS Until A Benefit Was Shown |
Presenter(s):Thomas G. Brott, MD / Brajesh K. Lal, MD | |
1:12 PM - 1:17 PM | Why The Carotid RCTs Fail To Support The Recent CMS Expansion Of Reimbursement For CAS To Treat Asymptomatic Disease (ACS): Do The 5-Year SPACE-2 Results Suggest That Such Expanded Reimbursement Be Delayed Until CREST-2 Data Is In |
Presenter(s):Caitlin W. Hicks, MD, MS | |
1:18 PM - 1:23 PM | Why CREST-2 May Not Provide Any Valid Answers: Because Of Bad Patient Selection In CREST-2, And Because BMT May Not Be Optimal Without GLP-1 Agonists Which Decrease Stroke Rates: What Is The Evidence |
Presenter(s):Sumaira Macdonald, MD, PhD | |
1:24 PM - 1:29 PM | Update On ACST-2: This RCT Found That CEA And CAS For ACS Had Comparable Adverse Event Rates Up To 10 Years And Implied That Both Invasive Treatments Were Superior To Now Obsolete BMT |
Presenter(s):Alison Halliday, MS, FRCS / Richard Bulbulia, MA, MD, FRCS | |
1:30 PM - 1:35 PM | Not So Fast! ACST-2 – Like CREST – Has Flaws That Invalidate Their Conclusions: Invasive Therapies May NOT Be Better Than BMT: What Are These Flaws |
Presenter(s):J. David Spence, MD | |
1:36 PM - 1:41 PM | What Is The Proof That CAS Is Ever Indicated For ACS: The Evidence Does Not Yet Support It |
Presenter(s):Franco Grego, MD | |
1:42 PM - 1:47 PM | Panel Discussion |
1:48 PM - 1:53 PM | Consecutive Monocenter Results With CAS For Asymptomatic Carotid Stenosis (ACS): We Should Not Need An RCT: But Why We Will Still Do |
Presenter(s):Klaus D. Mathias, MD / Anna Zeller, MD | |
1:54 PM - 1:59 PM | The 2nd European Carotid Surgery Trial (ECST-2): What Will It Tell Us About Best Medical Therapy Versus Invasive Therapy And Progress To Date |
Presenter(s):Gert J. de Borst, MD, PhD | |
2:00 PM - 2:05 PM | When A Duplex Scan Detects Subclavian Steal, Symptomatic Or Asymptomatic, What Is The Natural History And How Should It Be Managed |
Presenter(s):Ali F. AbuRahma, MD | |
2:06 PM - 2:11 PM | DEBATE: Completion Imaging After CEA Is Unnecessary And Potentially Harmful |
Presenter(s):Ali F. AbuRahma, MD | |
2:12 PM - 2:17 PM | DEBATE: Not So: Completion Imaging (Angiography Or Duplex) After CEA Is Necessary And Helpful |
Presenter(s):Keith D. Calligaro, MD | |
2:18 PM - 2:23 PM | Panel Discussion |
END OF SESSION 83 | |
SESSION 84 SCHEDULE | |
Friday
SESSION 84:
MORE HOT CAROTID TOPICS: TREATMENT IN 2024 OF RECURRENT CAROTID STENOSIS; STROKES DURING CAROTID TREATMENT; CAROTID NEAR OCCLUSIONS; SILENT CORONARY ISCHEMIA IN CAROTID PATIENTS
|
|
x | |
2:24 PM - 2:29 PM | Most Recurrent Carotid Stenosis Is Benign: When Is Intervention Justified And What Intervention Should Be Used |
Presenter(s):Ashraf Mansour, MD | |
2:30 PM - 2:35 PM | Current Best Treatment For Strokes Apparent During Or Right After CEA, CAS Or TCAR: Best Diagnostic Modalities And Treatments: Who Should Be Involved And What Skills Are Needed |
Presenter(s):Gert J. de Borst, MD, PhD | |
2:36 PM - 2:41 PM | Can TCAR Be Helpful In The Management Of Carotid String Sign Lesions Or Near Occlusions Of The Internal Carotid Artery: When Is Its Use Justified, Advantage And Technical Tips |
Presenter(s):Animesh Rathore, MD | |
2:42 PM - 2:47 PM | Advances In The Diagnosis And Treatment Of Near Total Occlusions And String Signs Of The Internal Carotid Artery (ICA) In Symptomatic And Asymptomatic Patients: How Are They Best Treated: What Do The Current Guidelines Say |
Presenter(s):Christos D. Liapis, MD | |
2:48 PM - 2:53 PM | Optical Coherence Tomography (OCT) Proves CAS Is Rendered Safer Because Mesh Covered Stents Decrease Emboli: The Imaging Evidence And What It Shows About The Interaction Between Stent And Plaque |
Presenter(s):Carlo Setacci, MD / Francesco Setacci, MD | |
2:54 PM - 2:59 PM | Silent Coronary Ischemia As Detected By FF+RCT Is Common In Carotid Stenosis Patients: Coronary Revascularization In Such Patients Decreases Mortality: When Should It Be Done – Before Or After Carotid Treatment |
Presenter(s):Christopher K. Zarins, MD / Dainis K. Krievins, MD | |
3:00 PM - 3:05 PM | Technical Tips To Enable TCAR In Difficult Anatomic Circumstances Including Use Of A Prosthetic Conduit |
Presenter(s):Ashraf Mansour, MD | |
3:06 PM - 3:11 PM | Compared To CEA, TCAR Improves Operating Room (OR) Throughout But Is More Costly: Tips To Improve OR Efficiency |
Presenter(s):Gregg S. Landis, MD | |
3:12 PM - 3:19 PM | Panel Discussion |
3:19 PM - 3:30 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 84 | |
SESSION 85 SCHEDULE | |
Friday
SESSION 85:
UPDATED ENDOVASCULAR CONCEPT AND MORE HOT AND CONTROVERSIAL CAROTID TOPICS
|
|
x | |
3:30 PM - 3:35 PM | Update On Transvenous Liver Biopsies: What Equipment Is Needed And How To Do Them |
Presenter(s):Jacob Cynamon, MD, FACR, FSIR | |
3:36 PM - 3:41 PM | Floating Clot At The Carotid Bifurcation Is A Prime Indication For Flow Reversal Technology During Treatment Of Carotid Stenosis: How Can Flow Reversal Best Be Achieved In This Setting |
Presenter(s):Juan C. Parodi, MD | |
3:42 PM - 3:47 PM | In Stent Stenosis After CAS: How Can It Be Predicted: When Is It Threatening And How Is It Best Managed |
Presenter(s):Jacques Busquet, MD | |
3:48 PM - 3:53 PM | Anatomic And Procedural Correlates Of Intra- And Postoperative Hypotension With CAS: What Should Be Done About It |
Presenter(s):Michael C. Stoner, MD | |
3:54 PM - 3:59 PM | DEBATE: CAS Is The Best Treatment For Young Healthy Patients With High Grade Asymptomatic Carotid Stenosis (ACS) |
Presenter(s):D. Christopher Metzger, MD | |
4:00 PM - 4:05 PM Power Point Presentation with Synched Audio |
DEBATE:Not So: Even Young Patients With A High Grade ACS Should Not Be Treated By CAS Or CEA: BMT Should Suffice: Are There Any Exceptions |
Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
4:06 PM - 4:11 PM | Why We Need An RCT Comparing TCAR With TFCAS, Transradial CAS And Best Medical Treatment For ACS And Symptomatic Carotid Stenosis |
Presenter(s):Michael H. Wholey, MD, MBA | |
4:12 PM - 4:17 PM | New Technical Tips To Make Minimal Incision CEA (MICE) Easier And Better: Can Same Day Discharge Be Safe |
Presenter(s):Robert M. Proczka, MD, PhD | |
4:18 PM - 4:23 PM | Risks And Causes Of Non-Ipsilateral Stroke Complicating CEA And CAS: How To Decrease Them |
Presenter(s):Mark Conrad, MD, MMSc / W. Darrin Clouse, MD | |
4:24 PM - 4:30 PM | Panel Discussion |
END OF SESSION 85 | |
SESSION 86 SCHEDULE | |
Friday
SESSION 86:
NEW CONCEPTS AND NEW DEVELOPMENTS IN PERCUTANEOUS ACCESS CLOSURE AND WOUND CARE
|
|
x | |
PROGRESS IN PERCUTANEOUS ACCESS AND CLOSURE | |
4:30 PM - 4:35 PM | Update On Large Bore Percutaneous Access Closure: Current Status, New Devices, How To Avoid Complications And Where Do We Go From Here |
Presenter(s):Zvonimir Krajcer, MD, FACC | |
4:36 PM - 4:41 PM | Large Bore Percutaneous Arterial Closure: Which Device Is Best: Advantages And Disadvantages Of The Manta Device |
Presenter(s):Michael J. Singh, MD | |
4:42 PM - 4:47 PM | Current Approaches For Large Bore Device Arterial Closure After Percutaneous EVAR And TEVAR: Technical Tips And Causes Of Failure |
Presenter(s):Gianmarco de Donato, MD | |
4:48 PM - 4:53 PM | How To Use Fascial Suture Technique To Control Percutaneous Large Vessel Access: Technical Tips And When To Use |
Presenter(s):Tal M. Hoerer, MD, PhD / Thomas Larzon, MD, PhD | |
4:54 PM - 4:59 PM | Results And Benefits Of The CELT ACD Femoral Arteriotomy Closure Device In The Office-Based Laboratory And Hospital |
Presenter(s):Joseph J. Ricotta II, MD, MS, DFSVS, FACS | |
PROGRESS IN WOUND CARE | |
5:00 PM - 5:05 PM | Update/Review Of Recently Published AHA Guidelines For Treatment Of Diabetic Wounds In The Setting Of PAD |
Presenter(s):Katherine A. Gallagher, MD | |
5:06 PM - 5:11 PM | A Single Device (From AOTI) For Triple Therapy (Local Oxygen, Compression And Humidification) Enhances Healing Of Non-Healing Lower Extremity Wounds And Incisions |
Presenter(s):David J. Dexter, MD | |
5:12 PM - 5:17 PM | New Developments With The TAVITA System To Predict Wound And Amputation Healing And To Monitor The Effectiveness Of Revascularization Procedures: Hyperspectral Imaging Can Non-Invasively Determine Oxygenation And Perfusion: How Does It Work And Results |
Presenter(s):Jan-Willem Elshof, MD | |
5:18 PM - 5:23 PM | Optimal Treatment For Deep Groin Infection After Prosthetic Bypasses From The Common Femoral Artery: How To Save The Graft And The Leg |
Presenter(s):Hosam F. El Sayed, MD | |
5:24 PM - 5:32 PM | Panel Discussion End of Program K |
END OF SESSION 86 | |
SESSION 87 SCHEDULE | |
Friday
SESSION 87:
POPLITEAL DISEASE TOPICS RELATED TO ANEURYSM TREATMENT, ENTRAPMENTS, ADVENTITIAL CYSTIC DISEASE AND TRAUMA
Moderators:Jason T. Lee, MD / Martin Björck, MD, PhD
|
|
x | |
POPLITEAL ANEURYSMS AND THEIR BEST CURRENT TREATMENTS | |
6:52 AM - 6:57 AM | Endovascular Repair For Popliteal Artery Aneurysm: Pitfalls And Complications: When Is Open Surgery Best |
Presenter(s):Irwin V. Mohan, MBBS, MD, FRCS, FEBVS, FRACS | |
6:58 AM - 7:03 AM | Treatment Of Popliteal Aneurysms: When Conservative, When Open, When Endovascular: What Are The Hard Data |
Presenter(s):Martin Björck, MD, PhD | |
7:04 AM - 7:09 AM | Endovascular Versus Open Repair: Why After 20 Years Of Selective Endografting, I Now Favor Open Repair In Most Patients |
Presenter(s):Martin R. Back, MD | |
7:10 AM - 7:15 AM | Outpatient Endovascular Repair Of Popliteal Artery Aneurysms With Bare Metal Stents: It Shouldn’t Work, But Does: What Is The Evidence |
Presenter(s):Sam S. Ahn, MD, FACS, MBA | |
7:16 AM - 7:21 AM | Rescue Procedures For Failed Endovascular Repairs Of Popliteal Aneurysms: Observation May Be Enough: If Not, Hybrid Versus Open Repair: Technical Tips |
Presenter(s):Jose Fernandes e Fernandes, MD, PhD, FRCS (Eng), FACS, FESC, FEBVS | |
ENTRAPMENTS, ADVENTITIAL CYSTIC DISEASE AND TRAUMA | |
7:22 AM - 7:29 AM | Updates On The Diagnosis And Treatment Of Popliteal Entrapments: What Are Their Misleading (Doppelganger) Diagnoses |
Presenter(s):Katherine A. Gallagher, MD | |
7:30 AM - 7:35 AM | Management Of Functional Popliteal Artery Entrapment Syndrome In Athletes: What Is The Pathological Anatomy And What Symptoms Does It Cause: Technique Of Surgical Repair |
Presenter(s):Jason T. Lee, MD | |
7:36 AM - 7:41 AM | Adventitial Cystic Disease Of The Popliteal Artery: Pathogenesis, Symptoms And Optimal Treatment |
Presenter(s):Irwin V. Mohan, MBBS, MD, FRCS, FEBVS, FRACS | |
7:42 AM - 7:47 AM | What Is The Surgical Approach And Best Graft Usage For Popliteal Artery Injury From Posterior Knee Dislocation: How Can Associated Vein Injury Be Detected And What Should Its Treatment Be |
Presenter(s):Charles J. Fox, MD, FACS | |
7:48 AM - 7:56 AM | Panel Discussion |
END OF SESSION 87 | |
SESSION 88 SCHEDULE | |
Friday
SESSION 88:
NEW DEVELOPMENTS IN TREATING ARTERIAL (INCLUDING AORTIC) GRAFT INFECTIONS
Moderators:Keith D. Calligaro, MD / Manju Kalra, MBBS
|
|
x | |
7:56 AM - 8:01 AM | Update On The NAIS Procedure (Deep Vein Reconstruction) For Infected Aortic Grafts: How To Make The Operation Easier And Faster: When Is It Indicated |
Presenter(s):John F. Eidt, MD | |
TREATMENT OF MYCOTIC ANEURYSMS | |
8:02 AM - 8:07 AM | What Is The Best Treatment For Mycotic Aneurysms: Open, Endo, Or Hybrid: When Is EVAR Helpful |
Presenter(s):Yamume Tshomba, MD | |
8:08 AM - 8:13 AM | Rifampin Soaked Endografts To Treat Mycotic AAAs: How To Prepare Them And When To Use Them: Are They Stand-Alone Treatment Or Do They Need Adjunctive Techniques |
Presenter(s):Guillermo A. Escobar, MD | |
TREATMENT OF AORTIC AND ARTERIAL GRAFT AND ENDOGRAFT INFECTIONS | |
8:14 AM - 8:19 AM | For Many Infected Prosthetic Arterial/Aortic Grafts, Endografts And Mycotic Aneurysms Less Than The Current Standard Radical Graft Excisional Treatment Is Best: Details And Examples Of This Less Radical Treatment |
Presenter(s):Martin Malina, MD, PhD | |
8:20 AM - 8:25 AM | Support For The Graft Preservation Concept For Treating Prosthetic Aortic Graft Infections From A European Multicenter Study (VASGRA): All Or Part Of The Infected Graft May Be Preserved: Under What Circumstances |
Presenter(s):Zoran Rancic, MD, PhD, EMBA HSG | |
8:26 AM - 8:31 AM | Optimal Techniques In 2024 For Treating Infected Aortoiliac Prosthetic Grafts And Endografts (Including EVAR, TEVAR, F/B/EVAR): From A Large National Cohort And The GRANDPA Global Registry |
Presenter(s):Anders Wanhainen, MD, PhD | |
8:32 AM - 8:37 AM | Panel Discussion |
8:38 AM - 8:43 AM | With Aortic Graft Infection, How Can Inline (In Situ) Flow Be Reestablished: Indications: What Grafts: Technical Tips: Results |
Presenter(s):Peter F. Lawrence, MD | |
8:44 AM - 8:49 AM | Infected Endografts After EVAR: Etiological Factors, Diagnosis, Treatment: Does The Endograft Always Have To Be Removed |
Presenter(s):Mohammad H. Eslami, MD, MPH | |
8:50 AM - 8:55 AM | The Real Truth About Use Of Cryopreserved Conduits (CryoGraft-Artivion) To Treat Infected Aortic/Arterial Reconstructions: From A Large Single Center Experience: There Are Advantages And Limitations |
Presenter(s):Randall R. De Martino, MD / Manju Kalra, MBBS | |
8:56 AM - 9:01 AM | Update On Surgical Treatment For Infected Thoracic Aortic Grafts And Endografts, With Or Without Aorto-Esophageal Or Aorto-Bronchial Fistulas: Optimal Techniques And Results From A Committed Center |
Presenter(s):Germano C.G. Melissano, MD / Andrea Kahlberg, MD / Roberto L.V. Chiesa, MD | |
9:02 AM - 9:07 AM | TEVAR For The Treatment Of Aorto-Esophageal And Aorto-Bronchial Fistulas: Is It Only A Bridging Procedure Or Is It Ever A Definitive Treatment |
Presenter(s):Markus K. Furrer, MD | |
9:08 AM - 9:13 AM | Treatment Of Infected Aortic Grafts (Endo And Open): Explantation Or Preservation: Technical Tips |
Presenter(s):Javairiah Fatima, MD | |
9:14 AM - 9:20 AM | Panel Discussion |
9:20 AM - 9:34 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 88 | |
SESSION 89 SCHEDULE | |
Friday
SESSION 89:
PROGRESS IN VASCULAR IMAGING AND GUIDANCE FOR ENDOVASCULAR TREATMENTS WITH LESS RADIATION EXPOSURE OR CONTRAST TOXICITY
|
|
x | |
9:34 AM - 9:39 AM | Advantages And Disadvantages Of The Three Main Hybrid OR Suites (GE, Siemens, Philips): How To Pick The Best One For Your Institution |
Presenter(s):Bjoern D. Suckow, MD | |
ADVANCED ENDOVASCULAR GUIDANCE WITH LESS RADIATION | |
9:40 AM - 9:45 AM | 3-Dimensional Advanced Guidance Systems For Endovascular Procedures: How Do The IOPS (Centerline), FORS (Philips), And Cydar (Medtronic) Systems Work And Reduce The Need For Radiation |
Presenter(s):Mark A. Adelman, MD | |
9:46 AM - 9:51 AM | With F/B/EVAR For Complex AAAs, FORS Lumiguide Fiberoptic Guidance (Philips) Reduces Radiation Exposure Compared To Standard Imaging |
Presenter(s):Marc L. Schermerhorn, MD | |
9:52 AM - 9:57 AM | New Developments With The IOPS (Centerline) Guidance System For F/B/EVAR: How Effective Is It Proving To Be: Advantages And Limitations |
Presenter(s):Matthew J. Eagleton, MD | |
9:58 AM - 10:03 AM | What Is Redo Fusion And How Does It Help After Failed Endovascular Complex Aortic Procedures |
Presenter(s):Giovanni Tinelli, MD, PhD | |
10:04 AM - 10:09 AM | Panel Discussion |
DUPLEX AND INTRAVASCULAR ULTRASOUND | |
10:10 AM - 10:15 AM | Duplex Ultrasound Guidance: When Can It Replace Fluoroscopy For Endovascular Procedures: Requirements, Advantages, Limitations: Is Its Use Becoming Widespread |
Presenter(s):Enrico Ascher, MD / Natalie A. Marks, MD, RPVI, RVT, FSVM | |
10:16 AM - 10:21 AM | Intraprocedural Duplex Ultrasound Guidance May Be Better And Cheaper Than IVUS For Most Endovascular Cases: When Is It Not |
Presenter(s):Eric A. Secemsky, MD, MSc | |
EKG-GATED CTA | |
10:22 AM - 10:27 AM | EKG-Gated CTA And Its Added Value For Sizing EVAR And TEVAR Endografts: How It Decrease Failures |
Presenter(s):Frans L. Moll, MD, PhD | |
VASCULAR HOLOGRAPHY | |
10:28 AM - 10:33 AM | Update On The ARCUS System Of Augmented Reality (Derived From A Contrast CT) And Its Value In Vascular And Endovascular Procedures: How Does It Work And Experience To Date |
Presenter(s):Jan M.M. Heyligers, MD, PhD, FEBVS | |
10:34 AM - 10:39 AM | Update On Holographic Guidance Of Endovascular Procedures (With Augmented Reality Goggles And No Screen): How Does It Work And Clinical Experience: What Is Possible And What Is Not |
Presenter(s):Claude Mialhe, MD | |
10:40 AM - 10:48 AM | Panel Discussion |
END OF SESSION 89 | |
SESSION 90 SCHEDULE | |
Friday
SESSION 90:
AUGMENTED REALITY (AR), MIXED REALITY AND ARTIFICIAL INTELLIGENCE (AI): HOW WILL THEY IMPROVE VASCULAR IMAGING AND ENDOVASCULAR DEVICE GUIDANCE WHILE MINIMIZING RADIATION
|
|
x | |
10:49 AM - 12:00 PM | PROGRAM TO BE DETERMINED |
12:00 PM - 1:00 PM | Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 90 | |
SESSION 91 SCHEDULE | |
Friday
SESSION 91:
PRESENTATIONS AND CHALLENGING RECORDED LIVE CASES FROM MÜNSTER, GERMANY
|
|
x | |
1:00 PM - 1:37 PM | PROGRAM TO BE DETERMINED |
END OF SESSION 91 | |
SESSION 92 SCHEDULE | |
Friday
SESSION 92:
NEW DEVELOPMENTS IN THE TREATMENT OF THORACIC OUTLET SYNDROMES (TOSs)
Moderators:Mark A. Adelman, MD / Michael J. Singh, MD
|
|
x | |
1:38 PM - 1:43 PM | For Venous TOS An Anterior Infraclavicular Approach Permits Resection Of The Anterior Third Of The First Rib Which Is Sufficient: Technique, Limitations And Results |
Presenter(s):Keith D. Calligaro, MD / Matthew J. Dougherty, MD | |
1:44 PM - 1:49 PM | Minimal Invasive Transaxillary First Rib Resection Under Local And Regional Anesthesia For TOSs: How To Do It, Limitations And Precautions |
Presenter(s):Francesco Spinelli, MD | |
1:50 PM - 1:55 PM | To Treat Various Forms Of TOSs Resection Of The Middle Third Of The First Rib Is Sufficient: A 30-Year Experience: How To Do It And When Not To |
Presenter(s):Claude D. Vaislic, MD | |
1:56 PM - 2:01 PM | Robotic Approach To Thoracic Outlet Decompression: How To Do It: Limitations And Contraindications |
Presenter(s):Katherine A. Teter, MD | |
2:02 PM - 2:07 PM | Supraclavicular Approach To Arterial And Neurogenic TOSs (Video Presentation) |
Presenter(s):Ramesh K. Tripathi, MD, FRCS, FRACS | |
2:08 PM - 2:13 PM | Botox Injections In The Treatment Of Neurogenic TOS: How Does It Work, When To Do It, How To Do It And Results |
Presenter(s):Jason T. Lee, MD | |
2:14 PM - 2:19 PM | Adolescent Neurogenic And Vascular TOSs: They Are Different And Uniquely Challenging: How To Diagnose Them And How Best To Treat Them In Athletes And Non-Athletes |
Presenter(s):Michael J. Singh, MD | |
2:20 PM - 2:25 PM | Subclavian Artery Aneurysms In Patients With Genetic Arteriopathy: How Should They Be Worked Up And Treated |
Presenter(s):Sherene Shalhub, MD, MPH | |
2:26 PM - 2:32 PM | Panel Discussion |
2:32 PM - 2:42 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 92 | |
SESSION 93 SCHEDULE | |
Friday
SESSION 93:
BEST ANTIPLATELET REGIMENS UPDATE ON RARE VASCULAR DISEASES; NEW DEVELOPMENTS IN ANTIPLATELET AND ANTICOAGULATION REGIMENS AND MEDICAL AND DRUG TREATMENTS
Moderators:Caron B. Rockman, MD / Kellie R. Brown, MD
|
|
x | |
UPDATE ON TREATMENT OF RARE VASCULAR DISEASES | |
2:42 PM - 2:47 PM | Optimal Current Management Of Takayasu's Disease Involving The Supra-Aortic Branches: Technical Details For Open Surgical Management And What Is The Role For Endo Treatment With Bare Or Covered Stents |
Presenter(s):Kellie R. Brown, MD | |
2:48 PM - 2:53 PM | The Present Status Of Buerger’s Disease: Does It Still Exist; How To Diagnose And Treat It |
Presenter(s):Kamphol Laohapensang, MD | |
2:54 PM - 2:59 PM | How To Make Operations For Complications Of Vascular Ehlers Danlos Syndrome Go Well |
Presenter(s):James H... Black, III, MD | |
3:00 PM - 3:05 PM Power Point Presentation with Synched Audio |
Medical Treatment Of Patients With Vascular Ehlers Danlos Syndrome: How Does Celiprolol Treatment Work And How Does It Help |
Presenter(s):Martin Björck, MD, PhD | |
ANTIPLATELET AND ANTICOAGULATION TREATMENT | |
3:06 PM - 3:11 PM | Current Optimal Antiplatelet And Anticoagulation Treatment For Various Vascular Procedures In Various Vascular Beds: What Newer Drugs And DOACs Are Useful And What Is The Optimal Timing Of Treatment |
Presenter(s):Peter Henke, MD | |
3:12 PM - 3:17 PM | Understanding The Barriers To Antiplatelet And Statin Adherence Following Vascular Interventions: What Should Be Done About It |
Presenter(s):Wei Zhou, MD | |
3:18 PM - 3:23 PM | Panel Discussion |
3:24 PM - 3:29 PM | Next Generation Antithrombotic Agents: What’s On The Horizon For Anticoagulant And Antithrombotic Drugs: How Will They Work And How Helpful Will They Be |
Presenter(s):Elliot L. Chaikof, MD, PhD | |
3:30 PM - 3:35 PM | Lowering LDL-C And Controlling Elevated Blood Pressure And Lipoprotein Little A [Lp(a)] Can Lower Cardiovascular Risk 80%: What To Do If Patients Can’t Tolerate A Statin Dose: Ezetimibe (Zetia), A PCSK9 Inhibitor, Inclisiran, Bempedoic Acid (Nexletol), Etc. |
Presenter(s):Richard Bulbulia, MA, MD, FRCS | |
NEW DEVELOPMENTS IN MEDICAL MANAGEMENT | |
3:36 PM - 3:41 PM | What Are The Best Medical Treatments After Carotid, Aortic And Lower Extremity Endovascular And Open Procedures |
Presenter(s):Maciej L. Dryjski, MD, PhD | |
3:42 PM - 3:47 PM | Value And Limitations Of Statins And Non-Statin Lipid Lowering Agents And Other Medical Treatments In Patients With Carotid Artery Stenosis: Should They Be The Same Or Different In Patients Undergoing Invasive Procedures |
Presenter(s):Kosmas I. Paraskevas, MD | |
3:48 PM - 3:52 PM | Panel Discussion |
END OF SESSION 93 | |
SESSION 94 SCHEDULE | |
Friday
SESSION 94:
ADVANCES IN THE ENDO AND OPEN TREATMENT OF VASCULAR TRAUMA
Moderators:Todd E. Rasmussen, MD, FACS / Gilbert R. Upchurch, MD
|
|
x | |
3:52 PM - 3:57 PM | Vascular Injuries After Blunt Abdominal Trauma: Diagnosis And Management: When Endo, When Open Treatment |
Presenter(s):Dittmar Boeckler, MD | |
3:58 PM - 4:03 PM | New Developments In The Endovascular Management Of Vascular Injuries: How Can A Hybrid Suite Be Helpful |
Presenter(s):Ravi R. Rajani, MD | |
UPDATE ON BLUNT THORACIC AORTIC INJURY (BTAI) | |
4:04 PM - 4:09 PM | How To Manage Heparin In TEVAR For BTAI When Head Or Other Injuries Are Also Present: Some, None Or Just Sheath Flushing |
Presenter(s):Charles J. Fox, MD, FACS | |
4:10 PM - 4:15 PM | Outcomes Of BTAI In >1,000 Patients: When Is Observation The Best Treatment; When Is TEVAR Best: When Is It Not: Technical Tips: From The Aortic Trauma Foundation Registry |
Presenter(s):Ali Azizzadeh, MD | |
4:16 PM - 4:21 PM | Acute Thoracic Aortic Pseudo-Coarctation After BTAI: What Is It: How Does It Produce Distal Organ Ischemia: How Should It Be Diagnosed And Treated Emergently By TEVAR: Technical Tips |
Presenter(s):Erica L. Mitchell, MD, MEd | |
4:22 PM - 4:27 PM | Classification Of BTAIs In Adults And Pediatric Patients: The Evidence Shows That Grade I And II Lesions Can Be Treated Conservatively Whereas Grades III And IV Should Be Treated Endovascularly: Recommendations For Graft Sizing In Children |
Presenter(s):Elina Quiroga, MD, MPH | |
4:28 PM - 4:33 PM | Update On The Retrievable Rescue Stent-Graft For Treating Aortic And Vena Cava Injuries: What Is It: How Does It Work And Current Status |
Presenter(s):Bryan W. Tillman, MD, PhD | |
4:34 PM - 4:39 PM | Update On Resuscitative Endovascular Balloon Occlusion Of The Aorta (REBOA): When Is It A Valuable Procedure And When Is It Not: Limitations And Precautions |
Presenter(s):Gilbert R. Upchurch, MD | |
4:40 PM - 4:45 PM | Evolving Techniques In Pediatric Vascular And Endovascular Trauma Surgery: What Special Precautions Are Needed: How To Deal With Arterial Spasm: When And How Can Endovascular Grafts Be Used |
Presenter(s):Michael C. Dalsing, MD | |
4:46 PM - 4:56 PM | Panel Discussion End of Program L |
END OF SESSION 94 | |
SESSION 95 SCHEDULE | |
Friday
SESSION 95:
DEEP VENOUS PHYSIOLOGY AND VENOUS STENT ISSUES
|
|
x | |
7:30 AM - 7:34 AM | Introduction: Deep System |
Presenter(s):Lowell S. Kabnick, MD, FACS, FAVLS, DFAVF | |
7:35 AM - 7:40 AM | Why Do We Call It Venous Hypertension |
Presenter(s):Brajesh K. Lal, MD | |
7:41 AM - 7:46 AM | Appropriate Patient Selection For Iliac Vein Stenting |
Presenter(s):Jose I. Almeida, MD, FACS, RPVI, RVT | |
7:47 AM - 7:52 AM | Is 50% Stenosis The Cutpoint For Stenting |
Presenter(s):Mark H. Meissner, MD | |
7:53 AM - 7:58 AM | Iliocaval Duplex Ultrasound With Image Optimization |
Presenter(s):Jan M. Sloves, RVT | |
7:59 AM - 8:04 AM | Physiologic Assessment Of The Severity Of Iliac Vein Obstruction |
Presenter(s):Fedor Lurie, MD, PhD | |
8:05 AM - 8:10 AM | Approaching The NIVL Patient: How To Ensure Success |
Presenter(s):Mahmood Razavi, MD | |
8:11 AM - 8:16 AM | An Ultrasound Imaging And Computational Fluid Dynamic Protocol To Assess Hemodynamics In Iliac Vein Compression Syndrome |
Presenter(s):C. Alberto Figueroa, PhD | |
8:17 AM - 8:22 AM | Panel Discussion |
END OF SESSION 95 | |
SESSION 96 SCHEDULE | |
Friday
SESSION 96:
VENOUS STENT TRIALS
|
|
x | |
8:23 AM - 8:28 AM | RCT: Venous Stenting Versus Conservative Treatment In Deep Venous Obstruction |
Presenter(s):Houman Jalaie, MD, PhD | |
8:29 AM - 8:34 AM | Early Experience With The Gore Viafort Venous Stent |
Presenter(s):Andrew Holden, MBChB | |
8:35 AM - 8:40 AM | The BEYOND Venous Stent Registry |
Presenter(s):Michael K.W. Lichtenberg, MD | |
8:41 AM - 8:46 AM | Criteria To Predict Mid-Term Outcome After Stenting Of Chronic Iliac Vein Obstructions (PROMISE Trial) |
Presenter(s):Iris Baumgartner, MD | |
8:47 AM - 8:52 AM | Will The BEST Trial Answer The Question On Iliac Stenting |
Presenter(s):Alun H. Davies, MA, DM, DSc, FRCS, FLSW, FMedSci, FEBVS | |
8:53 AM - 8:58 AM | A Look At Long-Term Venous Stent Data: ABRE Study 36-Month Clinical Outcome |
Presenter(s):Stephen A. Black, MD | |
8:59 AM - 9:04 AM | Zilver Vena Stent Trial: 4-Year Outcomes |
Presenter(s):Anthony J. Comerota, MD, FACS, FACC | |
9:05 AM - 9:10 AM | Venovo Venous Registry: 36-Month Data Report From A Real World Registry |
Presenter(s):Michael K.W. Lichtenberg, MD | |
9:11 AM - 9:16 AM | Panel Discussion |
END OF SESSION 96 | |
SESSION 97 SCHEDULE | |
Friday
SESSION 97:
FEMORO-ILIOCAVAL CHRONIC TOTAL OCCLUSIONS, RECANALIZATION TECHNIQUES AND OTHER CONSIDERATIONS
|
|
x | |
9:17 AM - 9:22 AM | Steps To Minimize Complications During Central Venous Recanalization |
Presenter(s):Marcelo Guimaraes, MD, MBA, FSIR | |
9:23 AM - 9:28 AM | Ruptured IVC And Iliac Vein: Now What |
Presenter(s):Jose I. Almeida, MD, FACS, RPVI, RVT | |
9:29 AM - 9:34 AM | Outcomes And Predictors Of Failure Of Iliac Vein Stenting |
Presenter(s):Rabih A. Chaer, MD | |
9:35 AM - 9:40 AM | Preclinical Data On Sirolimus Coated Balloons In Deep Veins: Results From The vSTRIDE Trial |
Presenter(s):Andrea T. Obi, MD | |
9:41 AM - 9:46 AM | Results Of Revcore For Use In Chronic Deep Vein Stent Occlusion |
Presenter(s):Steven D. Abramowitz, MD | |
9:47 AM - 9:52 AM | Hybrid Open And Endovascular Techniques For Complex Iliofemoral Disease |
Presenter(s):Erin H. Murphy, MD | |
9:53 AM - 9:58 AM | Endovascular Brachiocephalic And IVC Bypass Graft Creation: Changing What Is (Im)Possible |
Presenter(s):Marcelo Guimaraes, MD, MBA, FSIR | |
9:59 AM - 10:04 AM | Veins Aren’t Round – Stented Veins Don’t Need To Be Either |
Presenter(s):Lowell S. Kabnick, MD, FACS, FAVLS, DFAVF | |
10:05 AM - 10:10 AM | Panel Discussion |
END OF SESSION 97 | |
SESSION 98 SCHEDULE | |
Friday
SESSION 98:
VENOUS THROMBOSIS SCIENCE AND TREATMENT STRATEGIES
Moderators:Thomas W. Wakefield, MD / Peter Henke, MD
|
|
x | |
10:11 AM - 10:16 AM | Have Venous Trials Changed The Management Of The Ilio-Femoral DVT In 2024 |
Presenter(s):Ali Amin, MD, RVT, FACS, FACC | |
10:17 AM - 10:22 AM | Update Of Post-Thrombotic Syndrome Prevention |
Presenter(s):Tomasz Urbanek, MD | |
10:23 AM - 10:28 AM | Update On Experimental DVT Vein Wall Injury |
Presenter(s):Peter Henke, MD | |
10:29 AM - 10:34 AM | Venous Thromboembolism In The Context Of Chronic Venous Disease |
Presenter(s):Thomas W. Wakefield, MD | |
10:35 AM - 10:40 AM | Inflow Assessment In PTS Patients |
Presenter(s):Jose I. Almeida, MD, FACS, RPVI, RVT | |
10:41 AM - 10:46 AM | Why Do VTE Risk Scores Fail To Prevent VTE |
Presenter(s):Peter Henke, MD | |
10:47 AM - 10:52 AM | Inflammation, Selectins And Venous Thrombosis |
Presenter(s):Thomas W. Wakefield, MD | |
10:53 AM - 10:58 AM | Predictive Modeling For Post-Thrombotic Syndrome In DVT Patients |
Presenter(s):Steven D. Abramowitz, MD | |
10:59 AM - 11:04 AM | Assessing Radiation Exposure To Patients During Recanalization Of Chronic Venous Obstruction |
Presenter(s):Houman Jalaie, MD, PhD | |
11:05 AM - 11:10 AM | Panel Discussion |
END OF SESSION 98 | |
SESSION 99 SCHEDULE | |
Friday
SESSION 99:
THROMBUS REMOVAL THROMBECTOMY DEVICES AND OTHER ISSUES TO CONSIDER
Moderators:Patrick E. Muck, MD, FACS / Constantino Pena, MD
|
|
x | |
11:11 AM - 11:16 AM | P-Max Study: Mechanical Thrombectomy For Iliofemoral DVT With Aspirex – 24-Month Results |
Presenter(s):Michael K.W. Lichtenberg, MD | |
11:17 AM - 11:22 AM | Tips And Tricks With Lightning FLASH For PE And DVT Patients |
Presenter(s):Patrick E. Muck, MD, FACS | |
11:23 AM - 11:28 AM | New Percutaneous Thrombectomy Reperfusion System |
Presenter(s):Patrick E. Muck, MD, FACS | |
11:29 AM - 11:34 AM | CLOUT Registry For The Inari CloTriever |
Presenter(s):David J. Dexter, MD | |
11:35 AM - 11:40 AM | Management Of IVC Thrombus Using Large Bore Mechanical Thrombectomy |
Presenter(s):Constantino Pena, MD | |
11:41 AM - 11:46 AM | Panel Discussion |
END OF SESSION 99 | |
SESSION 100 SCHEDULE | |
Friday
SESSION 100:
VENOUS REFLUX ISSUES AND DEEP VEIN VALVE TECHNOLOGIES
Moderators:Jorge H. Ulloa, MD, FACS / Paul J. Gagne, MD
|
|
x | |
11:47 AM - 11:52 AM | Obstruction Or Reflux: What To Treat First In Venous Ulcers |
Presenter(s):Robert B. McLafferty, MD, MBA | |
11:53 AM - 11:58 AM | When Deep Venous Reflux Repair Is Not Effective: What Next |
Presenter(s):Marzia Lugli, MD | |
11:59 AM - 12:04 PM | Deep Venous Reflux In Patients Undergoing Venous Treatments |
Presenter(s):Mikel Sadek, MD | |
12:05 PM - 12:10 PM | Deep Reflux: What Happens After Concomitant Obstruction Correction |
Presenter(s):Marzia Lugli, MD | |
12:11 PM - 12:16 PM | Deep Vein Valve Devices: What Outcome Measures Should Be Used |
Presenter(s):Fedor Lurie, MD, PhD | |
12:17 PM - 12:22 PM | Long-Term Results Of The SAVVE Trial: A Bioprosthetic Valve |
Presenter(s):David J. Dexter, MD | |
12:23 PM - 12:28 PM | Endovenous Delivery Of New Valve Prosthesis In Humans: The New Trend |
Presenter(s):Jorge H. Ulloa, MD, FACS | |
12:29 PM - 12:34 PM | An Update On The Cook Venous Valve Project |
Presenter(s):Paul J. Gagne, MD | |
12:35 PM - 12:40 PM | Ambulatory Venous Pressure Measurement Via Column Interruption Duration |
Presenter(s):Seshadri Raju, MD | |
12:41 PM - 12:45 PM | Panel Discussion |
12:45 PM - 1:03 PM | Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 100 | |
SESSION 101 SCHEDULE | |
x | |
1:04 PM - 1:09 PM | The Role Of Conservative Pelvic Vein Management |
Presenter(s):Mark H. Meissner, MD | |
1:10 PM - 1:15 PM | Management Of Symptomatic Vulvar Varices With And Without Pelvic Symptoms |
Presenter(s):Steve Elias, MD | |
1:16 PM - 1:21 PM | Pelvic Venous Disease: New Terminology, New Treatment Approach, Still No Level 1 Data |
Presenter(s):Lindsay Machan, MD | |
1:22 PM - 1:27 PM | Ovarian Vein Embolization: Which Patients Benefit |
Presenter(s):Constantino Pena, MD | |
1:28 PM - 1:33 PM | Treatment Algorithm For Left Renal Vein Compression |
Presenter(s):Cynthia K. Shortell, MD | |
1:34 PM - 1:39 PM | Outcomes Of Left Renal Vein Stenting In Patients With Nutcracker Syndrome |
Presenter(s):Rabih A. Chaer, MD | |
1:40 PM - 1:45 PM | Open Surgical And Endovascular Treatment Of Nutcracker Syndrome: Do We Have The Answer Now |
Presenter(s):Manju Kalra, MBBS | |
1:46 PM - 1:51 PM | RCT Of Pelvic Venous Embolization Versus Sham Procedure For Venous Origin Chronic Pelvic Pain In Women |
Presenter(s):Neil M. Khilnani, MD | |
1:52 PM - 1:57 PM | Management Of Combined Iliac Vein Obstruction And Ovarian Reflux |
Presenter(s):Kush R. Desai, MD | |
1:58 PM - 2:03 PM | Panel Discussion |
END OF SESSION 101 | |
SESSION 102 SCHEDULE | |
x | |
2:04 PM - 2:09 PM | Anticoagulation In Childhood, The Role For DOACs |
Presenter(s):Dawn M. Coleman, MD, FACS | |
2:10 PM - 2:15 PM | Management Of Venous Thoracic Outlet Syndrome |
Presenter(s):Chandu Vemuri, MD | |
2:16 PM - 2:21 PM | Which DOAC For What Disease: Review Of Ongoing Trials |
Presenter(s):Andrea T. Obi, MD | |
2:22 PM - 2:27 PM | Hypercoagulable Work Up, Thrombophilia Testing, And Duration Of Anticoagulation |
Presenter(s):Rachel Rosovsky, MD, MPH | |
2:28 PM - 2:33 PM | SVT Treatment Options: DOAC, LMWH, Nothing |
Presenter(s):Steve Elias, MD | |
2:34 PM - 2:39 PM | Update On Reversal Agents For The DOACs |
Presenter(s):Timothy K. Liem, MD, MBA | |
2:40 PM - 2:45 PM | Factor XI Inhibitors: What Are They |
Presenter(s):Alex C. Spyropoulos, MD | |
2:46 PM - 2:51 PM | Panel Discussion |
END OF SESSION 102 | |
SESSION 103 SCHEDULE | |
Friday
SESSION 103:
IVC FILTERS AND MORE ISSUES WITH STENTS
Moderators:William A. Marston, MD / Timothy K. Liem, MD, MBA
|
|
x | |
2:52 PM - 2:57 PM | IVC Filter Retrieval: Basic And Advanced |
Presenter(s):Ripal T. Gandhi, MD, FSVM, FSIR | |
2:58 PM - 3:03 PM | Bertram D. Cohn's Contributions To The Development Of The Original IVC Filter |
Presenter(s):Enrico Ascher, MD | |
3:04 PM - 3:09 PM | What To Do With Fractured Filters And Embolic Filter Fragments |
Presenter(s):Constantino Pena, MD | |
3:10 PM - 3:15 PM | Laser-Assisted IVC Filter Retrieval: When And How |
Presenter(s):Kush R. Desai, MD | |
3:16 PM - 3:21 PM | Denali Filter Experience |
Presenter(s):Eric Hager, MD | |
3:22 PM - 3:27 PM | Surgical Removal Of IVC Filters: Perforation Or Infiltration |
Presenter(s):Timothy K. Liem, MD, MBA | |
3:28 PM - 3:33 PM | Rethinking Filters: The Latest Evidence From The Cook IVC Filter Study |
Presenter(s):Rabih A. Chaer, MD | |
3:34 PM - 3:39 PM | Migration Of Iliac And Renal Vein Stents: T-Stent Might Be A Solution To The Problem |
Presenter(s):Peter Gloviczki, MD | |
3:40 PM - 3:45 PM | Outcome Of Venous Stents In Adolescents, Teenagers, And Pregnancy |
Presenter(s):Mahmood Razavi, MD | |
3:46 PM - 3:51 PM | Acute Iliofemoral DVT In Adolescents And Young Adults And Whether They Should Undergo Stenting For May Thurner At The Time Of DVT Intervention |
Presenter(s):William A. Marston, MD | |
3:52 PM - 3:57 PM | Panel Discussion |
END OF SESSION 103 | |
SESSION 104 SCHEDULE | |
Friday
SESSION 104:
MORE DEEP VENOUS OBSTRUCTION, VENA CAVA, AND STENTS
Moderators:Erin H. Murphy, MD / Efthymios (Makis) Avgerinos, MD
|
|
x | |
3:58 PM - 4:03 PM | IVC Reconstruction Options |
Presenter(s):Erin H. Murphy, MD | |
4:04 PM - 4:09 PM | Tips And Tricks For Optimal Management Of Primary And Secondary IVC Tumors |
Presenter(s):Jill J. Colglazier, MD | |
4:10 PM - 4:15 PM | Stenting Across The IVC Filter Is A Safe And Effective Alternative To Complex Removal |
Presenter(s):Efthymios (Makis) Avgerinos, MD | |
4:16 PM - 4:21 PM | Techniques For Open Removal Of Occluded Open And Closed Cell IVC And Iliofemoral Venous Stents |
Presenter(s):Steven D. Abramowitz, MD | |
4:22 PM - 4:27 PM | Popliteal Venous Aneurysm Repair: How And When To Treat |
Presenter(s):Heron E. Rodriguez, MD | |
4:28 PM - 4:33 PM | Effect Of Venoactive Compounds In Post-Thrombotic Syndrome |
Presenter(s):Monika L. Gloviczki, MD, PhD | |
4:34 PM - 4:39 PM | Does Reducing Venous Hypertension By Ablation Or Venous Stenting “Cure” Edema In Patients With Venous Ulcers |
Presenter(s):Thomas F. O'Donnell, Jr., MD | |
4:40 PM - 4:45 PM | Tips And Tricks When Iliac Vein Stenting And Endovenous Ablation Fail To Heal Venous Ulcers |
Presenter(s):Ramesh K. Tripathi, MD, FRCS, FRACS | |
4:46 PM - 4:51 PM | Getting Out Of A Pinch: A Technique To Remove Frozen Central Venous Catheters |
Presenter(s):Scott L. Stevens, MD | |
4:52 PM - 4:57 PM | Panel Discussion |
END OF SESSION 104 | |
SESSION 105 SCHEDULE | |
Friday
SESSION 105:
MORE IMPORTANT DEEP VENOUS CONCEPTS
Moderators:Arjun Jayaraj, MD / Rabih A. Chaer, MD
|
|
x | |
4:58 PM - 5:03 PM | Thrombolysis For Acute DVT: Guidance From Current Clinical Trials |
Presenter(s):Brian G. DeRubertis, MD | |
5:04 PM - 5:09 PM | Outcomes Of Acute Superior Mesenteric Venous Thrombosis |
Presenter(s):Rabih A. Chaer, MD | |
5:10 PM - 5:15 PM | Measurement Of Edema Using Volumetric Plethysmography |
Presenter(s):Seshadri Raju, MD | |
5:16 PM - 5:21 PM | Open Surgical And Endovascular Treatment Of Superior Vena Cava Syndrome |
Presenter(s):Manju Kalra, MBBS | |
5:22 PM - 5:27 PM | Venous Stent Thrombosis: Insights From The ABRE Study |
Presenter(s):Erin H. Murphy, MD | |
5:28 PM - 5:33 PM | Indications, Technical Aspects, And Outcomes Of Stent Placement In Chronic Iliofemoral Venous Obstruction |
Presenter(s):Maxim Shaydakov, MD, PhD | |
5:34 PM - 5:39 PM | NIVL Management: Highlights From VIVA, AVF, AVLS, SCAI Consensus Statement |
Presenter(s):Kush R. Desai, MD | |
5:40 PM - 5:45 PM | Hemodynamic Consequences After Venous Stenting: An In Vitro Assessment |
Presenter(s):Houman Jalaie, MD, PhD | |
5:46 PM - 5:51 PM | Suprainguinal Lymphatic Disease In Patients Undergoing Stenting For Chronic Iliofemoral Venous Obstruction |
Presenter(s):Arjun Jayaraj, MD | |
5:52 PM - 5:57 PM | Panel Discussion End of Program M |
END OF SESSION 105 | |
Saturday, November 23, 2024
Print Entire 2024 Program:
|
|
SESSION 106 SCHEDULE | |
Saturday
SESSION 106:
MISCELLANEOUS/GENERAL TOPICS AND LOWER EXTREMITY TOPICS TOO IMPORTANT TO MISS
|
|
x | |
6:59 AM - 7:04 AM | Current Status Of An Endovascular First Approach To Lower Extremity Revascularization For CLTI In The Context Of The BEST-CLI Trial: What Are The Exceptions |
Presenter(s):Justin George, MD | |
7:05 AM - 7:10 AM | Radial Access Should Be In The Armamentarium Of Every Vascular Surgeon: Why, When And How To Use It: Equipment Needed And Technical Tips |
Presenter(s):Heron E. Rodriguez, MD | |
7:11 AM - 7:16 AM | Essential Angiographic Skills For Endovascular Surgeons: Must Include Gantry Angle Projections, Image Settings, Contrast Dilution, Injection Pressure And Flow Rates, Frame Rates, Cone Beam CTs, Fusion, Etc. |
Presenter(s):Martin Malina, MD, PhD | |
7:17 AM - 7:22 AM | Severe Iatrogenic Injuries: Etiologies, Locations, Diagnosis And Safe Endo Treatment Techniques: Precautions And Prevention |
Presenter(s):Samy S. Nitecki, MD | |
7:23 AM - 7:28 AM | Novel Wire Fixation Device: How It Works, Where It Can Help And Advantages |
Presenter(s):Patrick E. Muck, MD, FACS | |
7:29 AM - 7:34 AM | Does Hyperbaric Oxygen Therapy Really Work For Ischemic And Nonischemic Wounds In Vascular Patients: Is There Proof And Is It Worth The Cost |
Presenter(s):Robert B. McLafferty, MD, MBA | |
7:35 AM - 7:41 AM | Panel Discussion |
IMPORTANT LOWER EXTREMITY TOPICS | |
7:42 AM - 7:47 AM | With Prograde CFA Punctures, How To Easily Get The Guidewire Down The SFA Rather Than The Deep Femoral |
Presenter(s):Ali Amin, MD, RVT, FACS, FACC | |
7:48 AM - 7:53 AM | Prograde SFA Access Can Be Safe And Effective For Lower Extremity Endo Procedures; When And How To Do It And Obtain Secure Closure |
Presenter(s):Todd Berland, MD / Karan Garg, MD | |
7:54 AM - 7:59 AM | Endovascular Treatment Of CFA Lesions Is Proving Superior To Endarterectomy Because Of Improvements In Technology And Technique And The Complications Of Endarterectomy: How To Do It And When Is Endarterectomy Still Mandatory |
Presenter(s):Martin Malina, MD, PhD | |
8:00 AM - 8:05 AM | Ambulation Physical Therapy For PAD Is Now Covered By Medicare: Why Is It So Poorly Prescribed And What Can Be Done To Enhance Its Use |
Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC | |
8:06 AM - 8:11 AM | Paclitaxel Use In CLTI Patients: Is There Still Any Evidence Of An Increased Amputation Risk |
Presenter(s):Peter A. Schneider, MD | |
8:12 AM - 8:17 AM | Open Treatment First For CLTI In The Era Of BEST-CLI: When Is It Best: It’s Not Just For Patients With Good Ipsilateral Great Saphenous Veins |
Presenter(s):Yana Etkin, MD | |
8:18 AM - 8:26 AM | Panel Discussion |
END OF SESSION 106 | |
SESSION 107 SCHEDULE | |
Saturday
SESSION 107:
MORE LOWER EXTREMITY TOPICS TOO IMPORTANT TO MISS
|
|
x | |
8:26 AM - 8:31 AM | CLTI Nomenclature And Data End-Points Need Refurbishing: A Call To Action For The Next Decade Of Care |
Presenter(s):Miguel F. Montero-Baker, MD | |
8:32 AM - 8:37 AM | Outcomes Of Interventions For PAD In African American Female Patients And Asian Patients: Is It Different And Why: Can Anything Be Done About It |
Presenter(s):Caron B. Rockman, MD | |
8:38 AM - 8:43 AM | The Effect Of Optimal Medical Therapy On Outcomes In Patients With CLTI In The BEST-CLI Trial |
Presenter(s):Vik S. Kashyap, MD | |
8:44 AM - 8:49 AM Power Point Presentation with Synched Audio |
When Is Primary Amputation Ever Appropriate For Patients With CLTI: It’s Much Less Common Than You Think |
Presenter(s):Christopher J. Abularrage, MD | |
8:50 AM - 8:55 AM | Duplex Ultrasound For Diagnosis Of Failing Stents Placed For Arterial Occlusive Disease: Why Is It Important And How Often Should It Be Done After Treatment In Claudicants; In CLTI Patients |
Presenter(s):Keith D. Calligaro, MD | |
8:56 AM - 9:01 AM | Panel Discussion |
9:02 AM - 9:07 AM | Perfusion Imaging With Near-Infrared Spectroscopy (NIRS): How Is It Done And What Is Its Value In Patients Requiring Interventions For Lower Extremity Ischemia |
Presenter(s):Richard F. Neville, MD | |
9:08 AM - 9:13 AM | Can The BEST-CLI Trial Tell Us Whether Saving A Limb Also Prolongs Survival |
Presenter(s):Peter A. Schneider, MD | |
9:14 AM - 9:19 AM | Never Say Never: Endovascular Profundaplasty Is Possible And Effective: How To Do It And Results |
Presenter(s):Pasqualino Sirignano, MD, PhDS / Francesco Speziale, MD | |
9:20 AM - 9:25 AM | Value Of Duplex Gray Scale In Predicting Successful SFA CTO Crossing, Re-Entry And The Need For Distal Access |
Presenter(s):Natalie A. Marks, MD, RPVI, RVT, FSVM / Enrico Ascher, MD | |
9:26 AM - 9:31 AM | Aggressive Interventions Including Atherectomy In Claudicants Leads To More Harm Than Good |
Presenter(s):Dipankar Mukherjee, MD | |
9:32 AM - 9:38 AM | Panel Discussion |
9:38 AM - 9:48 AM | Break – Visit Exhibits And Pavilions (3rd Floor) |
END OF SESSION 107 | |
SESSION 108 SCHEDULE | |
Saturday
SESSION 108:
AORTIC TOPICS TOO IMPORTANT TO MISS AND SPINE EXPOSURE
|
|
x | |
9:48 AM - 9:53 AM | Contemporary Management Of Kommerell’s Diverticulum And Aberrant Subclavian Artery: From The International Vascular Low Frequency Disorders Consortium |
Presenter(s):Peter F. Lawrence, MD / Jonathan Bath, MD | |
9:54 AM - 9:59 AM | Retroperitoneal Bleeding Is A Catastrophic And Poorly Detected Complication Of Groin Access Above The Inguinal Ligament: Early Bird Bioimpedance Monitoring (From Saranas) Can Detect Early Retroperitoneal Access Bleeding: How Does It Work And Results |
Presenter(s):David O'Connor, MD | |
10:00 AM - 10:05 AM | Outcomes Of EVAR In Over 18,000 High-Risk Patients Ineligible For Open Repair: When Is EVAR Justified Over No Intervention In Such Patients: Why Is EVAR 2 No Longer Relevant |
Presenter(s):George A. Antoniou, MD, PhD, MSc, FEBVS | |
10:06 AM - 10:11 AM | Improved System For Evaluating Aortic Neck Anatomy And Suitability For EVAR And Need For F/EVAR |
Presenter(s):David J. Minion, MD | |
SPINE EXPOSURE SURGERY (6-Minute Presentations) | |
10:12 AM - 10:18 AM | Technical Tips And Tools For The Vascular Surgeon To Provide Anterior Exposure For Spine Procedures (6-Minute Presentation) |
Presenter(s):Jeffrey Jim, MD, MPHS | |
10:19 AM - 10:25 AM | Vascular Complications Of Anterior Spine Exposures; How To Avoid Them And How To Treat Them If They Occur (6-Minute Presentation) |
Presenter(s):William P. Robinson, MD | |
10:26 AM - 10:32 AM | Panel Discussion |
END OF SESSION 108 | |
SESSION 109 SCHEDULE | |
Saturday
SESSION 109:
AORTIC AND CAROTID TOPICS TOO IMPORTANT TO MISS
|
|
x | |
TOPICS RELATED TO THE AORTA AND ITS BRANCHES | |
10:32 AM - 10:37 AM | Isolated Mesenteric Artery Dissections Should Be Managed Medically In Most Cases: When Is Open Or Endo Treatment Needed And How To Do It |
Presenter(s):Heron E. Rodriguez, MD | |
10:38 AM - 10:43 AM | Retroperitoneal Exposure Of The Visceral Aorta And Its Branches: It’s Not Simple; Technical Tips |
Presenter(s):R. Clement Darling III, MD | |
10:44 AM - 10:49 AM | Performance Of Newer Generation Endografts (Endologix) Anatomically Fixed On The Aortic Bifurcation For AAA Repair: Long-Term Outcomes In The Medicare Population |
Presenter(s):Mark Conrad, MD, MMSc | |
10:50 AM - 10:55 AM | Fenestrated EVAR Versus Chimney EVAR For Juxtarenal AAAs: When Is One Better Than The Other And What Are The Critical Considerations |
Presenter(s):Piergiorgio Cao, MD, FRCS | |
10:56 AM - 11:01 AM | Balloon Optimized Molding For Better Deployment And Sealing Of Alto (From Endologix) Low Profile Endografts For EVAR: How To Do It And How It Helps Prevent Endoleaks And Migration |
Presenter(s):David J. Minion, MD | |
11:02 AM - 11:07 AM | The Vascular Surgeon’s Role In TAVR Procedures Via The Common Carotid Artery: Pitfalls And Technical Tips |
Presenter(s):Gregg S. Landis, MD | |
11:08 AM - 11:14 AM | Panel Discussion |
CAROTID TOPICS | |
11:14 AM - 11:19 AM | Tips And Tricks For Successful TCAR And When Is CEA And Best Medical Treatment Better Than TCAR |
Presenter(s):Jeffrey Jim, MD, MPHS | |
11:20 AM - 11:25 AM | Techniques For Dealing With Challenging Carotid Lesions: How Does TCAR Facilitate Treatment When Nothing Else Could Work |
Presenter(s):Joseph J. Ricotta II, MD, MS, DFSVS, FACS | |
11:26 AM - 11:31 AM | Shaking Limb Syndrome: What Is Its Symptoms And Why Is It A Good But Uncommon And Overlooked Indication For CEA Or CAS |
Presenter(s):Bruce A. Perler, MD, MBA | |
11:32 AM - 11:37 AM | Carotid Intervention Improves Mood In Depressed Patients With Carotid Stenosis: What Is The Evidence And Should All Depressed Patients With Carotid Disease Undergo Carotid Intervention |
Presenter(s):Wei Zhou, MD | |
11:38 AM - 11:43 AM | Management Of Carotid Infections Including Post CEA With Patches: Outcomes Of Ipsilateral Carotid Bypass In Hostile Necks: Technical Tips |
Presenter(s):Heron E. Rodriguez, MD | |
11:44 AM - 11:49 AM | Eagle Syndrome: Internal Carotid Artery Compression By A Hypertrophic Styloid Process: What Symptoms Does It Cause, How To Diagnose It And How To Fix It |
Presenter(s):Peter F. Lawrence, MD | |
11:50 AM - 11:55 AM | Cerebral Hyperfusion Syndrome After Carotid Interventions: Who Is At Risk; How To Avoid And How To Treat |
Presenter(s):Enrico Ascher, MD | |
11:56 AM - 12:04 PM | Panel Discussion End of Program N VEITHsymposium continues with the A-V Access Program in the Grand Ballroom West, 3rd floor, and the Advances in Vascular Imaging and Diagnosis Program in the Murray Hill Suite on the 2nd floor. |
END OF SESSION 109 | |
SESSION 110 SCHEDULE | |
Saturday
SESSION 110:
IMPORTANT ISSUES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)
Moderators:Larry A. Scher, MD / Anton N. Sidawy, MD, MPH
|
|
x | |
8:00 AM - 8:05 AM | Introduction |
Presenter(s):Larry A. Scher, MD / Anton N. Sidawy, MD, MPH | |
8:06 AM - 8:13 AM | It’s Really All About The Patient! |
Presenter(s):Dori R. Schatell, MS | |
8:14 AM - 8:21 AM | How To Improve The Patient Experience And ‘Ace’ The CMS Patient Experience Surveys |
Presenter(s):Terry Litchfield, MPA | |
8:22 AM - 8:29 AM | What Is The Optimal Time For Access Placement In Patients With Chronic Kidney Disease |
Presenter(s):Charmaine Lok, MD | |
8:30 AM - 8:37 AM | Optimal Start In The Value Based Care World |
Presenter(s):Theodore F. Saad, MD | |
8:38 AM - 8:45 AM | Administrative And System Challenges In Transitioning Chronic Hemodialysis Patients To Dialysis Centers |
Presenter(s):Anthony Meo, RN, MBA | |
8:46 AM - 8:53 AM | The Importance Of Vascular Access Registries In Improving Clinical Outcomes |
Presenter(s):Robert Shahverdyan, MD | |
8:54 AM - 9:04 AM | Panel Discussion |
9:05 AM - 9:12 AM | Update On Access Cannulation: Is There Anything New On The Horizon |
Presenter(s):Deborah Brouwer-Maier, RN, CNN | |
9:13 AM - 9:20 AM | Ultrasound Guided Cannulation For Hemodialysis Access – A Paradigm Shift |
Presenter(s):Vandana D. Niyyar, MD | |
9:21 AM - 9:28 AM | Novel Methods To Predict And Assess AV Fistula Maturation |
Presenter(s):Peter Kotanko, MD | |
9:29 AM - 9:36 AM | Early Follow Up After AV Fistula Creation Improves Access Related Outcomes |
Presenter(s):Yana Etkin, MD | |
9:37 AM - 9:44 AM | Vascular Access Monitoring: Can We Do It Better |
Presenter(s):Charmaine Lok, MD | |
9:45 AM - 9:52 AM | Tips And Techniques For The Use Of Ultrasound In AV Access |
Presenter(s):Robert Shahverdyan, MD | |
9:53 AM - 10:03 AM | Panel Discussion |
10:04 AM - 10:25 AM | Break - Visit Exhibits And Pavilions (3rd Floor) |
END OF SESSION 110 | |
SESSION 111 SCHEDULE | |
Saturday
SESSION 111:
MORE IMPORTANT ISSUES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)
|
|
x | |
10:26 AM - 10:33 AM | Strategies For Development Of A Health Care Network Dialysis Access Program |
Presenter(s):John R. Ross, Sr., MD | |
10:34 AM - 10:41 AM | AV Fistula Maturation: Going Beyond Creation To Successful Cannulation |
Presenter(s):Neghae Mawla, MD, FASDIN | |
10:42 AM - 10:49 AM | Access Surgery In The Breast Cancer Patient |
Presenter(s):Vicki J. Teodorescu, MD | |
10:50 AM - 10:57 AM | Precision Stenting For Central Venous Stenosis |
Presenter(s):Theodore F. Saad, MD | |
10:58 AM - 11:05 AM | Lessons Learned From Three Decades Of Dialysis Access Care |
Presenter(s):Sanford D. Altman, MD | |
11:06 AM - 11:16 AM | Panel Discussion |
END OF SESSION 111 | |
SESSION 112 SCHEDULE | |
Saturday
SESSION 112:
MINISYMPOSIUM: HEMODIALYSIS ACCESS INDUCED DISTAL ISCHEMIA (7-MINUTE TALKS)
Moderators:Larry A. Scher, MD / Yana Etkin, MD
|
|
x | |
11:17 AM - 11:24 AM | Steal Syndrome: More Than A Blood Flow Problem |
Presenter(s):Sal Scali, MD | |
11:25 AM - 11:32 AM | Can We Predict (And Prevent) Steal Syndrome |
Presenter(s):Matthew J. Dougherty, MD | |
11:33 AM - 11:40 AM | Proximalization Should Replace DRIL For Treatment Of HAIDI |
Presenter(s):Homayoun Hashemi, MD, FACS, RVT | |
11:41 AM - 11:48 AM | Contemporary Outcomes Of Distal Radial Artery Ligation For HAIDI |
Presenter(s):Mohamad A. Hussain, MD, PhD | |
11:49 AM - 11:59 AM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break - Mercury Rotunda & Ballroom (3rd Floor) |
END OF SESSION 112 | |
SESSION 113 SCHEDULE | |
Saturday
SESSION 113:
POLITICAL, ECONOMIC AND LEGAL ISSUES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)
Moderators:Larry A. Scher, MD / Anton N. Sidawy, MD, MPH
|
|
x | |
1:00 PM - 1:07 PM | Reimbursement And Regulatory Update In Dialysis Access |
Presenter(s):Terry Litchfield, MPA | |
1:08 PM - 1:15 PM | DEBATE: What Is Optimal For FDA Approval Of Novel Vascular Access Devices: Single Arm Clinical Trials Are Adequate To Support Approval Of Novel Vascular Access Devices |
Presenter(s):Ellen D. Dillavou, MD | |
1:16 PM - 1:23 PM | DEBATE: Regulatory Approval Of Novel Vascular Access Devices: When A Randomized Clinical Study Could Help |
Presenter(s):Robert E. Lee, MD | |
1:24 PM - 1:31 PM | Is Value Based Access Care Finally Ready For Prime Time |
Presenter(s):Evan C. Lipsitz, MD, MBA | |
1:32 PM - 1:39 PM | Expanding Dialysis Innovations And Care Choices: Patients Say ‘If Not Us, Who’; ‘If Not Now, When’ |
Presenter(s):Paul T. Conway | |
1:40 PM - 1:50 PM | Panel Discussion |
END OF SESSION 113 | |
SESSION 114 SCHEDULE | |
Saturday
SESSION 114:
NOVEL TECHNOLOGIES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)
|
|
x | |
1:51 PM - 1:58 PM | Update On The Velocity Percutaneous AV Fistula (Venova Medical) |
Presenter(s):Robert Shahverdyan, MD | |
1:59 PM - 2:06 PM | Use Of Bioengineered Vascular Wrap (SelfWrap) To Improve AV Fistula Outcomes (VenoStent) |
Presenter(s):Ellen D. Dillavou, MD | |
2:07 PM - 2:14 PM | Safety And Efficacy Of HemoWrap Device For Post Cannulation Hemostasis |
Presenter(s):Sundaram Ravikumar, MD | |
2:15 PM - 2:22 PM | InnAVasc Access Graft Prevents Cannulation Injury: Update On The PIVOTAL Clinical Trial |
Presenter(s):Shawn Gage, PA | |
2:23 PM - 2:30 PM | Results Of Wrapsody Arteriovenous Access Efficacy (WAVE) PIVOTAL Trial |
Presenter(s):Mahmood Razavi, MD | |
2:31 PM - 2:38 PM | TBD |
2:39 PM - 2:49 PM | Panel Discussion |
END OF SESSION 114 | |
SESSION 115 SCHEDULE | |
Saturday
SESSION 115:
UPDATE ON CLINICAL CHALLENGES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)
Moderators:Larry A. Scher, MD / Surendra Shenoy, MD, PhD
|
|
x | |
2:50 PM - 2:57 PM | Dear Surgeons: Design Me A Better Access – Observations Of An Interventional Nephrologist |
Presenter(s):Neghae Mawla, MD, FASDIN | |
2:58 PM - 3:05 PM | Creating Autogenous Hemodialysis Access In Children And Adolescents |
Presenter(s):William Jennings, MD | |
3:06 PM - 3:13 PM | Should We Be Performing More Lower Extremity Access Procedures |
Presenter(s):Jeremy Crane, MD | |
3:14 PM - 3:21 PM | Safe And Effective HeRO Graft Placement: Technique And Results |
Presenter(s):Karl A. Illig, MD | |
3:22 PM - 3:29 PM | Treatment Options For Venous Thoracic Outlet Syndrome In Dialysis Patients |
Presenter(s):Mark G. Davies, MD | |
3:30 PM - 3:37 PM | Current Strategies For Selection Of Biologic Versus Prosthetic Grafts For Hemodialysis Access |
Presenter(s):Jesse Garcia, MD | |
3:38 PM - 3:45 PM | Can We Make A Fistula Last Forever |
Presenter(s):Surendra Shenoy, MD, PhD | |
3:46 PM - 3:53 PM | TBD |
3:54 PM - 4:05 PM | Panel Discussion End of Program O |
END OF SESSION 115 | |
SESSION 116 SCHEDULE | |
Saturday
SESSION 116:
MANAGING THE PATIENT WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE (PAD): STRENGTHS AND WEAKNESSES OF THE DIAGNOSTIC TECHNIQUES, WHO NEEDS WHICH TESTS AND WHEN
Moderators:Ann Marie Kupinski, PhD, RVT, FSVU
|
|
x | |
6:50 AM - 7:00 AM | Welcome And Opening Remarks: Navigating The Meeting And Optimizing Your Experience |
Presenter(s):George L. Berdejo, BA, RVT, FSVU | |
PAD is a very complex disease with many available diagnostic modalities. Armed with the right information, a thorough history and physical exam, and the appropriate diagnostic/imaging modality, the patient will be on the right track to getting the help and care he or she needs. How Much is Enough? What Do We Need For Diagnosis, Management And Treatment Of PAD? | |
7:00 AM - 7:08 AM | The History And Physical Examination Matters And Guides The Workup |
Presenter(s):Anahita Dua, MD, MS, MBA | |
7:08 AM - 7:16 AM | Still Important Role Of Physiologic Testing |
Presenter(s):Ann Marie Kupinski, PhD, RVT, FSVU | |
7:16 AM - 7:24 AM | Role Of Duplex Ultrasound In The PAD Workup |
7:24 AM - 7:32 AM | Evolving And Expanding Role Of Pedal Artery Imaging |
Presenter(s):Jill S. Sommerset, BS, RVT, FSVU | |
7:32 AM - 7:40 AM | What About CTA And MRA |
7:40 AM - 7:48 AM | Strategic Use Of Contrast Arteriography |
Presenter(s):John Carson, MD | |
7:48 AM - 8:10 AM | Panel Discussion: Putting It All Together |
END OF SESSION 116 | |
SESSION 117 SCHEDULE | |
Saturday
SESSION 117:
ABDOMINAL IMAGING TIPS AND TRICKS: LESSONS LEARNED FROM CASE STUDY PRESENTATIONS
Moderators:Laurence Needleman, MD
|
|
x | |
8:15 AM - 8:25 AM | Renal Artery Scanning |
Presenter(s):Patrick A. Washko, BS | |
8:25 AM - 8:35 AM | 5 Tips For A Liver Duplex Exam |
Presenter(s):Robert De Jong, RDMS, RVT, FSDMS | |
8:35 AM - 8:45 AM | Mesenteric With Focus On Median Arcuate Ligament Syndrome |
Presenter(s):Phillip J. Bendick, PhD, RVT, FSVU | |
8:45 AM - 8:55 AM | Duplex Surveillance After Complex Aortic Endovascular Repair |
Presenter(s):R. Eugene Zierler, MD, RPVI | |
8:55 AM - 9:05 AM | Bonus Lecture: Who Is The Right Patient For The Renal Artery Duplex Examination |
Presenter(s):Laurence Needleman, MD | |
9:05 AM - 9:15 AM | Panel Discussion |
9:15 AM - 9:45 AM | Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 117 | |
SESSION 118 SCHEDULE | |
Saturday
SESSION 118:
CEREBROVASCULAR
Moderators:TBD
|
|
x | |
9:45 AM - 9:55 AM | Evolution And Review Of Carotid Duplex Criteria: From Strandness To IAC Consensus |
Presenter(s):R. Eugene Zierler, MD, RPVI | |
9:55 AM - 10:05 AM | Review Of IAC Consensus Criteria: How To Transition And Incorporate It Into Your Practice |
Presenter(s):Heather L. Gornik, MD | |
10:00 AM - 10:15 AM | The Role Of Alternative Imaging For Carotid Disease; What’s Best And When is It Necessary |
10:15 AM - 10:25 AM | Panel Discussion |
END OF SESSION 118 | |
SESSION 119 SCHEDULE | |
Saturday
SESSION 119:
PRACTICE ENHANCEMENTS AND PHILISOPHICAL ISSUES I
Moderators:George L. Berdejo, BA, RVT, FSVU
|
|
x | |
10:25 AM - 10:35 AM | Variability Of Practice Patterns From A Survey Of International Vascular Specialists: Lessons Learned And How We Can Be More Value Added |
Presenter(s):Jill S. Sommerset, BS, RVT, FSVU | |
10:35 AM - 10:45 AM | How To Recruit, Train, And Retain Vascular Sonographers |
Presenter(s):George L. Berdejo, BA, RVT, FSVU | |
10:45 AM - 10:55 AM | State Of Vascular Ultrasound Education And Training |
Presenter(s):Traci B. Fox, EdD, RDMS, RVT, FSVU | |
10:55 AM - 11:05 AM | Is There A Role For Advanced Practice Vascular Sonography |
Presenter(s):Joseph P. Hughes, MBA, RVT, RVS, RPhS, NVS, FSVU | |
11:05 AM - 11:15 AM | Sonographer Burnout: How Real Is This And How Can It Be Addressed |
Presenter(s):Aubrey J. Rybyinski, BS, RDMS, RVT, FSDMS | |
11:15 AM - 11:25 AM | What’s Happening With The Workforce: Is The Projected Sonographer Shortage Real, How Can It Be Addressed |
Presenter(s):Traci B. Fox, EdD, RDMS, RVT, FSVU | |
11:25 AM - 11:40 AM | Panel Discussion |
11:40 AM - 11:50 AM | Lunch Break - South Corridor, 2nd Floor |
END OF SESSION 119 | |
SESSION 120 SCHEDULE | |
Saturday
SESSION 120:
TECHNICAL SKILLS LAB
Moderators:Fernando Amador, RVT / Richard Dubin, AAS-DMS, RVT, RDMS
|
|
x | |
(This session will allow you to visit with recognized experts in the field in an informal setting with opportunity for “hands-on” time and conversation to glean technical tips in various areas of vascular ultrasound and physiologic testing.) | |
11:50 AM - 12:40 PM | Station 1: Pedal Artery Imaging |
11:50 AM - 12:40 PM | Station 2: Carotid Artery Imaging |
11:50 AM - 12:40 PM | Station 3: Transcranial Duplex |
11:50 AM - 12:40 PM | Station 4: Venous Reflux Testing |
11:50 AM - 12:40 PM | Station 5: Renal Artery Imaging |
11:50 AM - 12:40 PM | Station 6: Physiologic Test |
11:50 AM - 12:40 PM | Station 7: Hemodialysis Access |
11:50 AM - 12:40 PM | Station 8: Iliocaval Imaging |
12:40 PM - 12:50 PM | Transition To Plenary Sessions (Murray Hill Suites, 2nd Floor) |
END OF SESSION 120 | |
SESSION 121 SCHEDULE | |
x | |
12:50 PM - 1:50 PM | Panel Discussion: Interpreting With The Masters |
Panelist(s): Phillip J. Bendick, PhD, RVT, FSVU / David L. Dawson, MD / Anahita Dua, MD, MS, MBA / Heather L. Gornik, MD / Ann Marie Kupinski, PhD, RVT, FSVU / Leslie M. Scoutt, MD / R. Eugene Zierler, MD, RPVI | |
END OF SESSION 121 | |
SESSION 122 SCHEDULE | |
Saturday
SESSION 122:
WHAT THE VASCULAR SPECIALIST SHOULD EXPECT FROM A WELL-DONE VASCULAR ULTRASOUND EVALUATION
Moderators:David L. Dawson, MD
|
|
x | |
1:50 PM - 2:00 PM | The Lower Extremity Arterial Mapping |
Presenter(s):Jill S. Sommerset, BS, RVT, FSVU | |
2:00 PM - 2:10 PM | The Lower Extremity Vein Evaluation For Reflux |
Presenter(s):Nicos Labropoulos, BSc (Med), PhD, DIC, RVT | |
2:10 PM - 2:20 PM | The Ilio-Caval Evaluation In Chronic Venous Insufficiency |
Presenter(s):Jan M. Sloves, RVT | |
END OF SESSION 122 | |
SESSION 123 SCHEDULE | |
Saturday
SESSION 123:
VENOUS IMAGING: TESTING FOR CHRONIC VENOUS INSUFFICIENCY, LEG REFLUX AND PELVIC VEIN DISORDERS
Moderators:Nicos Labropoulos, BSc (Med), PhD, DIC, RVT
|
|
x | |
2:20 PM - 2:30 PM | Clinical Evaluation Of The Swollen Leg: It’s Not Just Reflux And DVT |
Presenter(s):Steven M. Dean, DO | |
2:30 PM - 2:40 PM | The Anterior Saphenous Vein: Anatomic And Clinical Considerations For The Vascular Sonographer |
Presenter(s):Nicos Labropoulos, BSc (Med), PhD, DIC, RVT | |
2:40 PM - 2:50 PM | The Role Of Duplex Ultrasound In The Evaluation Of The Post Thrombotic Syndrome |
Presenter(s):Jan M. Sloves, RVT | |
2:50 PM - 3:00 PM | Evaluation For Pelvic Vein Reflux |
Presenter(s):Nicos Labropoulos, BSc (Med), PhD, DIC, RVT | |
3:00 PM - 3:10 PM | Duplex Ultrasound Follow-up After Interventions: When, How Often, What To Look For |
Presenter(s):Neil M. Khilnani, MD | |
3:10 PM - 3:20 PM | Panel Discussion (Combined Sessions 122 And 123) |
3:20 PM - 3:45 PM | Break |
END OF SESSION 123 | |
SESSION 124 SCHEDULE | |
Saturday
SESSION 124:
THE EVOLVING HEALTHCARE ENVIRONMENT: IMPACT ON PAYMENT, POLICY, LAB MANAGEMENT AND SVU UPDATES
|
|
x | |
3:45 PM - 3:53 PM | Current Critical Issues For The Vascular Professional |
Presenter(s):Anne M. Jones, RN, BSN, RVT, RDMS, FSVU, FSDMS | |
3:53 PM - 4:01 PM | SVU Updates, Where Are We With The Strategic Plan, And Highlights Of The 2024 SVU Annual Conference |
Presenter(s):Josh D. Lee, MBA | |
4:01 PM - 4:09 PM | Update On The Status Of The Journal of Vascular Ultrasound (JVU) |
Presenter(s):David L. Dawson, MD | |
4:09 PM - 4:17 PM | Reimbursement Updates: Is There Any Good News |
Presenter(s):Joseph P. Hughes, MBA, RVT, RVS, RPhS, NVS, FSVU | |
4:17 PM - 4:30 PM | Panel Discussion |
END OF SESSION 124 | |
SESSION 125 SCHEDULE | |
Saturday
SESSION 125:
HEMODIALYSIS ACCESS, CURVEBALLS AND CONTROVERSIES
|
|
x | |
4:30 PM - 4:40 PM | What Do I Do When I Find Non-Vascular Pathology On My Vascular Ultrasound Study |
Presenter(s):Patrick A. Washko, BS | |
4:40 PM - 4:50 PM | Evaluation Of Cold Sensitivity And Vasospasm |
Presenter(s):Steven M. Dean, DO | |
4:50 PM - 5:00 PM | Utility Of The Toe-Brachial Index |
Presenter(s):William N. Del Valle, RVT | |
5:00 PM - 5:10 PM | Current Applications For Contrast Enhanced Ultrasound In The Vascular Laboratory |
5:10 PM - 5:20 PM | 'Volume Flow: Is This A Wild Goose Chase' |
Presenter(s):Ann Marie Kupinski, PhD, RVT, FSVU | |
5:20 PM - 5:30 PM | Noninvasive Evaluation Of Arterial Steal After Dialysis Access |
5:30 PM - 5:45 PM | Panel Discussion End of Program P |
END OF SESSION 125 | |